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The production of blood cells, or ‘Hematopoiesis’ is a complex series of events resulting 
in the formation of all blood lineages. This involves self-renewal of pluripotent stem cells 
in the bone marrow followed by proliferation and differentiation of these hematopoietic 
stem cells towards mature blood cells. All hematopoietic cells have distinct tasks. ‘Red’ 
blood cells or erythrocytes are required for oxygen transport from the lungs to the vital 
organs of the body, while platelets play an important role in the wound healing process. 
‘White’ blood cells belonging to the myeloid and lymphoid lineages all play a critical role 
in host defence mechanisms, and wound repair, although within these lineages every cell 
type has its own specific function. Lymphocytes are mainly involved in specific immune 
responses in the so-called adaptive immune system. The myeloid lineage regulates the so-
called innate immune response. Here immune cells recognize pathogens by virtue of 
pattern recognition, and this part of the immune system does not have the capacity to 
adapt to a changing immunological environment. Innate immunity is regulated by white 
blood cells such as monocytes and granulocytes, as well as bystander cells such as stromal 
cells. Monocytes are intermediate cells that are distributed through the blood and can 
terminally differentiate into specialized macrophages within tissue microenvironments. 
Furthermore, macrophages play important roles in both degradation of invading pathogens 
by phagocytosis, and in removing dead cells without inducing an inflammatory process. In 
addition, monocytes can differentiate into dendritic cells which are professional antigen 
processing cells (APC). Granulocytes can be subdivided into three different populations: 
neutrophils, eosinophils, and basophils  all playing an important role in immunity against 
bacterial and parasitic infections. These cells are also involved in the pathogenesis of 
many chronic inflammatory responses such as allergic responses by causing tissue 
damage through aberrantly controlled the production of toxic oxygen metabolites and 
release of their granular content consisting of cytotoxic proteins (see chapter 1y). There is 
a cross-talk between the adaptive and innate immune system, which is clearly 
demonstrated by the secretion of cytokines by adaptive immune cells (lymphocytes) that 
can regulate the survival, proliferation, and differentiation of the innate immune cells 
(granulocytes). Taken together, all these different hematopoietic cells play essential roles 
in protecting the body from external pathogens and are required for maintaining 
homeostasis. Aberrant regulation of hematopoiesis can lead to the development of severe 
clinical conditions ranging from severe immune deficiencies to myeloproliferative 
diseases such as leukemia. Acute Myeloid Leukemia (AML) is, for example, 
characterized by a block in myeloid differentiation, resulting in increased levels of 
immature myeloid cells. In order to develop novel therapies against illnesses caused by 
aberrant regulation of hematopoiesis it is necessary to understand the regulatory 
mechanisms underlying these processes. 
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1. The onset of hematopoiesis during embryogenesis  
 
1.1. Primitive hematopoiesis 
During early embryogenesis, two separate waves of hematopoiesis are observed, 
‘primitive’ and ‘definitive’ hematopoiesis (Figure 1). Whereas primitive hematopoiesis 
occurs during early embryogenesis and gives rise to immature blood cells, definitive 
hematopoiesis, at a later stage, gives rise to the mature blood cells.  The onset of primitive 
hematopoiesis occurs within the blood islands of the extra-embryonal yolk sac, 15 days 
post coitum, in human. The yolk sac is formed by extension of ectodermal and 
endodermal epithelium underlaid with mesoderm. Aggregation of these mesodermal cells 
results in angionenic clusters or blood islands, which leads  to the formation of blood 
vessels 1. During primitive hematopoiesis, nucleated erythrocytes are predominantly 
formed expressing fetal specific isoforms of hemoglobin. In addition, development of 
monocytes and megakaryocytes have been observed in the yolk sac 2-4. Besides primitive 
hematopoietic cells, endothelial cells are generated in the yolk sac. These endothelial cells 
share a number of transcription factors with the hematopoietic progenitors, suggesting that 
these cells might derive from a common progenitor 5; 6. Evidence for the existence of a 
common progenitor, which is called a hemangioblast, derives from studies demonstrating 
that Vascular Endothelial Growth Factor (VEGF) responsive precursors can develop to 
both endothelial cells as well as to hematopoietic lineages 6; 7. Although evidence supports 
the hypothesis that hemangioblasts indeed exist, other studies suggest that primitive 
hematopoietic stem cells can be generated by mature endothelial cells 8; 9. 
 
1.2. Definitive hematopoiesis 
Independently of primitive hematopoiesis, definitive hematopoiesis occurs in the A(orta) 
G(onad) M(esonephros) region. The AGM region is an anterior lateral region in the 
embryo that contributes to the formation of the aorta, gonads and mesonephros, and is 
formed by mesoderm. The onset of defininitive hematopoiesis is between 30 to 37 days 
post coitum in man when hematopoietic cells are found adhering to the ventral wall of the 
dorsal aorta 9-11. Endothelial cells in the vascular wall of the dorsal aorta have been 
proposed to be progenitors for these hematopoietic stem cells 12; 13. Subsequently, 
hematopoietic cells are located in the urogenital ridge of the AGM region. In the AGM 
region of the embryo, hematopoietic stem cells predominantly proliferate, after which 
they migrate to fetal liver and spleen where differentiation continues. Upon migration of 
these embryonic hematopoietic stem cells out of the AGM region, the fetal liver becomes 
the predominant site for hematopoiesis during embryogenesis. 
 
1.3. Regulation of hematopoiesis during embryogenesis 
Embryonic hematopoietic stem cells express several transcription factors including, 
SCL/Tal (stem cell leukemia hematopoietic transcription factor), and GATA-2. These 
transcription factors play an important role in both primitive and definitive hematopoiesis. 
Both primitive hematopoiesis in the yolk sac and definitive hematopoiesis in fetal liver 
and spleen are completely disturbed in GATA-2 deficient embryos. Most GATA-2 
deficient embryos die during early embryogenesis of severe anemia. The role of GATA-2 
in definitive hematopoiesis was observed by injection of GATA-2 -/- embryonic stem 
cells  
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into wild-type blastocysts. In the chimeric embryos no GATA-2 -/- hematopoietic cells 
could be detected in the fetal liver 14, demonstrating that GATA-2 is also required for 
definitive hematopoiesis.  
 
Figure1. Hematopoiesis during granulopoiesis. Primitive hematopoiesis during embryogenesis occurs in the 
yolk sac, whereas definitive hematopoiesis initially occurs in the AGM region from which hematopoietic  
progenitors migrate to the fetal liver to induce terminal maturation. (A) Schematic representation of the location 
of the major sites of hematopoiesis during embryogenesis, (B) and the proposed interactions between primitive 
and definitive hematopoiesis. 
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Similar to GATA-2, SCL/Tal also plays a critical role in hematopoiesis during 
embryogenesis. SCL homozygous null mice die during early embryogenesis lacking 
primitive hematopoietic cells 15. Definitive hematopoiesis is also completely disturbed in 
these mice 16. Other transcription factors, however, are specifically required for definitive 
hematopoiesis such that primitive hematopoiesis can still occur in their absence. One 
such factor is the acute myeloid leukemia 1 gene (AML-1), which forms heterodimers 
with the core binding factor (CBFb), and acts as the DNA binding subunit of this dimeric 
complex. AML-1 is found frequently mutated in patients with acute myeloid leukemia, 
and loss of this gene results in complete absence of all hematopoietic lineages during 
murine embryogenesis 17. 
 
1.4. The origin of true hematopoietic stem cells  
After defining two different waves of hematopoiesis during embryogenesis, the question 
arises as to whether true hematopoietic stem cells originate exclusively from the AGM 
region of the embryo or already during primitive hematopoiesis in the yolk sac? 
Primitive hematopoietic stem cells derived from the yolk sac are capable of reconstituting 
the T lymphocyte population in lethally irradiated mice 18, suggesting that the yolk sac 
could be the source of true HSCs. However, other studies have demonstrated that only 
HSCs deriving from the AGM region can repopulate the entire hematopoietic system in 
lethally irradiated mice 19. These studies in combination with the temporal appearance of 
the HSCs in the AGM region suggest that definitive hematopoiesis is autonomously 
initiated in the AGM region 20; 21. 
Other studies, however, argue that highly proliferative potential colony forming cells 
which are exclusively located in the yolk sac during primitive hematopoiesis are capable 
of migration into the circulation of the embryo 22. Furthermore, stem cells derived from 
the yolk sac, upon culture on AGM stromal cells, can function as definitive hematopoietic 
stem cells 23. Taken together, these data suggest that the fate of primitive hematopoietic 
stem cells in the yolk sac is determined by the environment, and upon migration into 
another environment such as the AGM region, the fate of these cells can alter towards 
definitive hematopoiesis. 
 
2. Early adult hematopoietic stem cells 
 
2.1. Characterizing hematopoietic stem cells 
During embryogenesis, the fetal liver is the predominant site for definitive hematopoiesis, 
however, shortly after birth, this shifts from the fetal liver to the bone marrow of the 
trabecular bone. Only a very small fraction of bone marrow cells are responsible for the 
high turnover of the hematopoietic cell pool. For example, in a 70 kg adult, it is estimated 
that approximately 1 trillion cells are formed each day. Approximately 0.01 % of the 
nucleated cells in the bone marrow are the progenitors which are responsible for this cell 
production, and only roughly 5% are in cycle at any time.  
Hematopoietic stem cells (HSCs) are defined as cells which can both self-renew and 
differentiate towards all blood lineages. This HSC pool can be divided into two different 
sub-populations based on their functionality, long-term reconstituting HSCs (LT-HSCs) 
and short-term reconstituting HSCs (ST-HSCs). Both LT-HSC and ST-HSC have the 
capability to self-renew and to generate all hematopoietic lineages. However, the LT-HSC  
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has this capability throughout life, whereas ST-HSCs can only do this for a short period of 
time (8-10 weeks). HSCs are also characterized by the presence or absence of several 
surface markers (Figure 2). For example, the cell surface sialomucin-like adhesion 
molecule CD34 is expressed on early hematopoietic cells and is generally used as a 
marker for HSCs. CD34 positive cells are capable of initiating both short-term 24 and 
long-term hematopoiesis 25 and allow the differentiation of all blood lineages 26. CD34 
expression is high in HSCs and is down-regulated upon differentiation towards more 
mature blood cells 27; 28. Although CD34 is generally used as a marker for HSCs and used 
to isolate HSCs from bone marrow and cord blood, its role in hematopoiesis is largely 
unknown. CD34 has been suggested to play a role in the homing process of HSCs to the 
bone marrow 29. In addition to the expression of CD34 on HSCs and hematopoietic 
progenitors, CD34 expression has also been described on vascular endothelium 30; 31, and 
some fibroblasts 32; 33, suggesting a function outside hematopoiesis. 
 
Figure 2. Hematopoietic stem cells. LT-HSCs have the ability to induce long-term reconstitution of the 
hematopoietic system, whereas ST-HSCs can only do this for a short period of time. Both populations of 
hematopoietic stem cells are characterized by the expression of several surface markers such as CD34+ and 
CD38-, although CD34- CD38- cells appear to be even more immature.  An important feature of HSCs is their 
ability to undergo self-renewal. This process is both positively and negatively regulated by a variety of signaling  
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pathways. Important regulators of self-renewal, such as HoxB4, Notch1, and Fas are depicted in this schematic 
model. A large population of HSCs are quiescent and out of cycle. P21Waf/CIP1 inhibits the entrance of HSCs into 
cell cycle.   
 
The human HSC population is also characterized by the complete absence of lineage 
specific markers (lin-), and by the absence of CD38 (CD38-). Although both CD34+CD38+ 
as well as CD34+CD38- cells are capable of engrafting host bone marrow after 
transplantation, only long-term engraftment has been observed with CD34+CD38- cells 34. 
This indicates that the more primitive HSCs reside in the CD34+CD38- fraction.  Another 
marker for HSCs is the VEGF receptor 2 (KDR). It has been demonstrated that in 
CD34+KDR- cell populations, the self-renewal capacity is completely inhibited 35. 
Furthermore, HSCs are characterised by high expression levels of CD90 36, and CD133 37 
and lower expression levels of  CD117. 
Although HSCs are generally characterized as CD34+ cells, HSCs in the CD34-CD38-  
fraction can also posses long-term, reconstituting potential. In contrast to CD34+CD38- 
cells, these cells do not have the capability to initiate short-term hematopoiesis 38; 39. 
Furthermore, CD34-CD38- HSCs can give rise to CD34+ CD38- HSCs 40; 41, suggesting 
that CD34- cells are more primitive HSCs compared to CD34+ cells.  
 
2.2. Maintainance of the hematopoietic stem cell pool 
 
2.2.1. Quiescent, slowly cycling HSCs 
The cell cycle consists of four different phases, the S (synthesis)-phase, M (mitosis)-phase 
separated by two interphases G1 and G2. In addition to these four phases there is also a 
G0 phase representing quiescent cells which are not in cell cycle, including terminally 
differentiated cells. Progress through cell cycle is regulated at several restriction points by 
Cyclins and Cyclin Dependent Kinases (CDKs). The majority of the hematopoietic stem 
cell population is in G0 phase of the cell cycle. This population can be divided into two 
different sub-populations of cells, based  
on their ability to respond to cytokines, termed cytokine responsive and cytokine non-
responsive cells. HSCs in G0 phase appear to exhibit the highest stem cell repopulating 
activity 42; 43, and it seems necessary to preserve a large part of the HSC population by 
staying in this phase. It has been demonstrated that every HSC divides not more than once 
every 57 days, on average 44; 45,  
suggesting the existence of a long-term quiescent, slowly cycling hematopoietic stem cell 
pool. Although similar results were reported studying primates, the suggestion was made 
that mice enter the cell cycle at a higher frequency  46. Surprisingly, despite the existence 
of a quiescent stem cell pool, mRNAs for Cyclin D2 and D3 are expressed in the fraction 
of early CD34+ Lin- HSCs 44. 
The most important candidate for maintaining the HSCs in a G0 phase are the cyclin-
dependent-kinase inhibitors p27kip1 47 and p21WAF1/CIP. In p21WAF1/CIP (-/-)  knockout mice, 
increased stem cell cycling has been demonstrated, suggesting that p21WAF1/CIP could 
indeed play a role in keeping the HSCs quiescent 47. p21WAF1/CIP is uniformly expressed in 
the 1% CD34+ Lin- HSCs which are cytokine-non-responsive. In contrast, p21WAF1/CIP is 
only expressed in a minority of the entire CD34+ Lin- cell population 48. Autologous 
expression of TGFb might cause the high level of p21WAF1/CIP in early HSCs 49; 50. TGFb is 
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capable of increasing transcription of p21WAF1/CIP in CD34+ cells 51 and inhibits 
proliferation in CD34+ lineage-negative cells 52 (Figure 3).  
In cytokine responsive lineage-negative HSCs, inhibition of entrance into the cell cycle by 
p21WAF1/CIP might be overcome by cytokines and activation of specific transcription 
factors to promote self-renewal of HSCs (see below). 
 
2.2.2. Self-renewal 
An important characteristic of an HSC is the ability to undergo self-renewal (Figure 2). 
The population of hematopoietic stem cells maintains a steady state level throughout adult 
life. During each cell division a decision has to be made resulting in either self-renewal or 
differentiation, which can result in either a symmetric division or an asymmetric division 
resulting in two daughter cells with different cell fates. Although the transcriptional 
regulation of self-renewal is still incompletely understood several transcription factors 
have been suggested to play a role in this process, including HoxB4, a member of the 
homeobox gene family. Although it has been demonstrated  that members of the 
homeobox gene family play an important role in establishing the anterior-posterior axis 
during embryogenesis, their precise role in hematopoiesis is unclear. It has been 
demonstrated that several members of the homeobox gene family are expressed and 
regulated during hematopoietic differentiation, and ectopic expression of HoxB4 in 
murine bone marrow cells resulted in extensively enhanced levels of HSCs which retained 
their full lympho-myeloid repopulating potential53.   
Another protein implicated in early hematopoiesis is Notch1, a transmembrane 
glycoprotein receptor, that undergoes proteolytic cleavage upon ligand binding. 
Subsequently, the activated intracellular domain of Notch1 (Nic) translocates to the 
nucleus  54where it binds to other transcription factors such as CSL 55; 56 and regulates 
transcription 57; 58. Notch1 has been demonstrated to play an important role in both 
hematopoietic stem cell self-renewal and cell fate determination. Ectopic expression of 
Notch1 results in increased stem cell numbers due to decreased differentiation and 
enhanced stem cell self-renewal 59. When progenitors initiate a differentiation program, 
Notch1 expression results in commitment preferably towards the lymphoid lineage. 
Recently, has been demonstrated that both Notch1 and HOXB4 are positively regulated 
by the WNT signaling pathway. WNT signaling has been demonstrated to play an 
important role in various events during animal development. Recent studies demonstrated 
that WNT signaling, specifically WNT3a, plays an important role in regulating self-
renewal of HSCs 60 by regulation of both Notch1 and HoxB4 activity 61.  
Tumor Necrosis Factor a and Fas, a member of the TNF receptor family, usually 
sufficient to induce apoptosis, have also been implicated to play an important role in self-
renewal. In contrast to Notch1 and HoxB4, these proteins are thought to negatively 
regulate stem cell self-renewal. Upon  
TNFa stimulation, Fas expression is dramatically increased and cell growth is inhibited, 
without inducing apoptosis. Moreover, long-term and short-term multilineage 
reconstitution are severely disturbed 62. TNFa has also been demonstrated to inhibit the 
multipotent repopulating capacitiy of HSCs independently of induction of apoptosis 63. 
The suggestion that TNFa and Fas negatively regulate self-renewal has also been 
strenghtened by a study demonstrating TNF mediated arrest of the entry into S phase from 
G0 phase of HSCs 64. 
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2.2.3. Regulation of survival in HSCs 
In order to obtain the required numbers of mature hematopoietic cells, an excess of HSCs 
are generated every day. It has been suggested that the maintenance of the equilibrium of 
the stem cell pool is achieved by removing the excess of cells in a process called 
apoptosis, or programmed cell death.  
Apoptosis is a highly regulated process which can be initiated by either the activation of 
death receptors such as Fas or by intracellular signals resulting, for example, from growth 
factor deprivation. An important regulatory step in inducing apoptosis is the leakage of 
cytochrome c from mitochondria. Anti-apoptotic members of the Bcl-2 family, including 
Bcl-2 itself, and Bcl-XL protect the mitochondria from leakage, whereas pro-apoptotic 
members of the Bcl-2 family including Bim, Bax, Bad, and Hrk form pores in the outer 
membrane of  the mitochondria resulting in leakage of cytochrome c which is required to 
promote caspase activation 65. Caspases are involved in cleavage of proteins and the 
induction of DNA laddering 66; 67. Whereas growth factor deprivation tends to require the 
leakage of cytochrome c from the mitochondria, death receptors can bypass the 
mitochondrial pathway by direct activation of caspase 8.  
Although the processes regulating self-renewal of HSCs have been investigated in detail, 
the mechanisms modulating cell survival are largely unknown. Growth factors, such as 
Steel factor (or stem cell factor) have been suggested to play an important role in 
preventing apoptosis in early HSCs. Recently however, studies demonstrated that SCF 
induced surival via c-kit is specific for mice, whereas HSC survival in humans is mediated 
by FLT-3 ligand. This difference between humans and mice is caused by differential 
expression patterns of c-kit (the SCF receptor) and FLT-3 68. In transgenic mice, 
expression levels of an anti-apoptotic protein Bcl-2, have been demonstrated to influence 
to susceptibility of HSCs to apoptosis. Overexpression of Bcl-2 in absence of growth 
factors results in reduced levels of apoptosis and increased cell numbers (407. 
Interestingly, in absence of the exogenous growth factors, cells overexpressing Bcl-2 start 
to differentiate towards more mature blood cells 69 in particular to granulocytes. Ectopic 
expression of Bcl-xl results in erythroid differentiation, suggesting that members of the 
Bcl-2 family also play an important, although as yet undefined, role in restriction of 
lineage choices 70. Although apoptosis is inhibited by Bcl-2, it is not sufficient to 
completely abrogate cell death. In addition, recent evidence suggest that the upregulation 
of Bcl-2 and stimulation with Stem Cell Factor are both required to induce complete 
survival of HSCs 71. Evidence has been published that both Bcl-2 and c-Kit are regulated 
by the transcription factor c-Myb 72-74. Myb has been suggested to play a crucial role in 
several stages of hematopoiesis including self-renewal, proliferation, differentiation, and 
survival. Expression levels of c-Myb are high in proliferating progenitors and are down-
regulated during terminal differentiation to mature blood cells 75; 76. Besides Bcl-2 itself, 
Bcl-XL 77 various pro-apoptotic members of the Bcl-2 family are expressed in HSCs 78; 79, 
suggesting that the balance between these pro- and anti-apoptotic proteins is critical in 
determining the survival of HSCs. 
 
3. Stem cell plasticity 
 
Recent studies suggest that HSCs have the capacity not only to differentiate towards all 
hematopoietic lineages but also to develop towards other cell types, a phenomenon called  
                                                                                                                              Chapter 1 
 19 
 
‘stem cell plasticity’. For example, HSC enriched bone marrow derived cells have been 
demonstrated to generate a variety of other tissues, including skeletal muscle 80, cardiac 
muscle 81, neurons 82 and hepatic cells 83-85. Furthermore, single cell experiments 
demonstrated a differentiation potential of HSCs towards epithelial cells in lung, liver, 
skin, and gastrointestinal tract 86. 
Recently, however, several studies have argued that HSCs are not in fact ‘plastic’ but that 
other cells are responsible for this phenomenon. The bone marrow also consists of other 
stem cell populations besides HSCs 87, including mesenchymal stem cells, termed 
Multipotent Adult Progenitor Cells (MAPC). These cells are capable, at the single cell 
level, of generating mesenchymal and endothelial cells and after transplantation 
hematopoietic lineages can also be formed 88. After purification of HSCs from the bone 
marrow, it cannot be excluded that minor fractions of MAPCs might still be present, 
which could be responsible for the differentiation towards many cell types generated by 
bone marrow cells.  
Interestingly, it has also been recently demonstrated that bone marrow cells can 
spontaneously fuse with, for example, embryonic stem cells, and thereby adopt the 
phenotype of the  recipient cells 89. Similarly, spontaneous fusion of bone marrow cells 
with hepatocytes 90; 90 has been demonstrated, after transplantation, by the presence of 
donor specific as well as recipient specific alleles in the hepatocytes of the recipient mice. 
Cell fusion is a completely different phenomenon which can easily be interpreted as stem 
cell plasticity. Taken together, these studies suggest that HSCs are not as plastic as 
initially thought, and single cell experiments should be performed to exclude that other 
examples of HSC derived bone marrow cells differentiating towards other lineages are not 
a result of cell fusion rather than plasticity. 
Plasticity has also been investigated at the level of committed progenitor cells by 
investigating their ability to trans-differentiate towards other hematopoietic lineages. 
Many studies demonstrate that upon ectopic expression of a receptor or transcription 
factor, differentiation fate of cells can be altered.  
However, only a few studies have provided evidence for a switch between different 
lineages upon extrinsic stimulation. For example, B-cell progenitors (CD19 antigen, DJ 
rearrangement-positive B220- cells) from mice bone marrow develop not only towards 
mature B cells, but can also differentiate towards macrophage-like cells upon stimulation 
with IL-3, IL-6 and GM-CSF 91. A similar switch towards macrophages has been observed 
by culture of purified T-cell progenitors in presence of either thymic stromal cell line 
conditioned medium or a combination of IL-6, IL-7, and M-CSF 92, suggesting that B and 
T cell progenitors may have the capability to differentiate towards myeloid cells upon 
extrinsic stimuli, ex vivo. 
 
4. Myeloid differentiation 
 
4.1. Common myeloid/lymphoid progenitor 
ST-HSCs can differentiate to multipotent progenitor cells, which are themselves capable 
of differentiation towards a subset of the hematopoietic lineages. These multipotent stem 
cells include both the common lymphoid progenitor 93, and common myeloid progenitor 
94. The common lymphoid progenitor (CLP) give rise to B and T lymphocytes as well as 
NK-cells, whereas the common myeloid progenitor (CMP), also known as the CFU- 
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GEMM (colony-forming unit granulocyte/ erythrocyte/ macrophage/ megakaryocyte) can 
differentiate towards the erythroid, megakaryocytic and monocytic and granulocytic 
lineages (Figure 3).  
The expression of the IL-7 receptor a chain is an important characteristic of the CLP 93 
and its progeny, whereas myeloid cells do not express this receptor. An clinical 
determinant of the myeloid lineage is the expression of the FcgRII and FcgRIII  It has 
been demonstrated that CMPs can be characterised as CD34+ FcgRlo IL-7Ra-. Upon 
differentiation, these cells first develop towards either CD34+FcgRhi or CD34-FcgRlo cells, 
which are granulocyte/macrophage progenitors and megakaryocyte/erthrocyte 
progenitors, respectively 94. Although the presence of a CMP is widely accepted, the 
existence of a CLP has been recently questioned. In fetal liver, a common myelolymphoid 
progenitor (CMLP) which can first give rise to bipotent cells, the myeloid/T-cell 
progenitors and the myeloid/B-cell progenitors, and eventually to some mature myeloid 
cells, T lymphocytes, and B lymphocytes has been observed. Erythrocytes, however, were 
not generated by the CMLP but developed from common myeloerythroid progenitors 95. 
Although it is assumed that hematopoiesis differs between fetal liver and mature bone 
marrow, recent evidence suggest that also in mature bone marrow bipotential B 
lymphocyte/macrophage progenitors are present 96. Whereas CMPs are capable of 
differentiating into all myeloid lineages, CMLPs only differentiate towards 
monocyte/macrophages and not to other myeloid cells. These data suggest that the gradual 
restriction in differentiation potential from HSCs towards mature cells via CMPs and 
CLPs might not be entirely accurate.   
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Figure 3. Two models for hematopoiesis. HSCs can differentiate towards both a common myeloid(CMP) and 
common lymphoid progenitor (CLP) (A). The CMP gives rise to all myeloid lineages, whereas the CLP induces 
lymphocyte differentiation. Recently an alternative model has been proposed in which a common 
myeloid/lymphoid progenitor (CMLP) can develop into both lymphocytes and monocytes (B). 
 
4.2. Cytokines and their receptors in myeloid differentiation 
Two different models have been proposed to describe hematopoiesis, a “stochastic” and 
an “inductive” or “instructive” model. In the stochastic model it is assumed that 
progenitor cells are randomly committed towards a certain lineage and cytokine 
stimulation is merely required for their survival and proliferation. In the inductive model 
however, cytokines are thought to specifically determine the outcome of each division and 
determine the cell fate during differentiation.  
In the inductive model, myeloid differentiation is specifically directed by a variety of 
cytokines, including Erythropoietin (EPO), Granulocyte colony-stimulating factor (G-
CSF), Thrombopoietin (TPO), Interleukin-3 (IL-3), Granulocyte-macrophage colony-
stimulating factor (GM-CSF), Macrophage colony-stimulating factor (M-CSF) and 
Interleukin-5 (IL-5). IL-3 and GM-CSF are cytokines regulating proliferation and survival 
during myeloid differentiation of various lineages, whereas EPO, TPO, G-CSF, M-CSF 
and IL-5 are required for final maturation of erythrocytes 97, megakaryocytes 98; 99, 
neutrophils, monocytes 100 and eosinophils 101; 102 respectively (Figure 4). 
Cytokines bind to their cognate receptors and mediate intracellular signal transduction 
pathways leading to modulation of gene expression. Many cytokine receptors consists of 
multiple subunits, one of which is unique and specific for a certain cytokine. The other 
subunit is shared by multiple cytokines. Although cytokines can exhibit a wide variety of 
functions in different cell types and tissues, there is also some redundancy between 
cytokines. The fact that different cytokines exhibit, in part, similar functions can be 
explained by the presence of shared receptor subunits.  
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Figure 4. Cytokines and hematopoiesis. Development of hematopoietic cells is regulated by specific cytokines, 
which are depicted. Cytokines like IL-3 and GM-CSF play a role in regulating hematopoiesis in general, whereas 
IL-5, G-CSF, M-CSF, TPO, and EPO a critical for regulating differentiation of specific lineages 
 
Cytokine receptor families can be subdivided based on their structural motifs. The IL-3, 
GM-CSF and IL-5 cytokine receptors family consist of two subunits; a cytokine specific  
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a-chain, which is responsible for ligand binding, and a common b-chain. The b-chain 
however, is not capable of ligand binding by itself but forms a high affinity receptor upon  
association with the a-chain. The b-chain is thought to mediate intracellular signalling 
through activation of a variety of signal transduction pathways. Another family of 
cytokine receptors is the gp130 family, which consist of a common b-chain called gp130 
and a cytokine specific a-chain. Cytokines mediating their signals via this receptor family 
include IL-6, IL-11, and leukemia inhibitory factor (LIF). IL-6, for example, has been 
implicated to mediate macrophage development in a leukemic cell line. 
A third cytokine receptor family that plays an important role in myelopoiesis is the growth 
hormone receptor family. This family includes receptors for the cytokines G-CSF, EPO, 
and TPO. In contrast to the other cytokine receptor families, these receptors do not consist 
of multiple subunits and do not share a common subunit. These receptors consist of a 
single subunit which dimerises upon ligand binding, and their activation is required for the 
development of many cell types including erythrocytes and megakaryocytes. 
 
4.3. Transcription regulation of myelopoiesis 
 
4.3.1. Signal Transducers and Activators of Transcription 
Hematopoietic cytokines can regulate cell fate via a variety of intracellular signal 
transduction pathways. The JAK-STAT signal transduction pathway is thought to play an 
important role in regulating myeloid differentiation 103, and in the last decade the signaling 
paradigm mediating this pathway has been elucidated in detail 104 (see chapter 2). In short, 
, cytokine induced receptor dimerization results in activation of members of the receptor-
associated Janus kinase family (JAK) or other kinases through cross-phosphorylation. 
Subsequently, tyrosine phosphorylation of the intracellular domains of the dimerized 
receptor occurs, enabling STAT transcription factors to associate with the receptor. 
STATs are subsequently phosphorylated by the receptor-associated JAK kinases. Homo- 
or heterodimers of STATs are formed and after translocation to the nucleus, transcription 
can be regulated via STAT specific DNA binding sites 105. Currently, seven STAT 
proteins have been identified (STAT1, -2, -3, -4, -5a, -5b, -6). Whereas alternative 
splicing of the transcripts results in the formation of three additional STAT proteins (e.g. 
STAT1b, STAT3b, and STAT4b), proteolytic cleavage of STAT5 also results in the 
formation of truncated STAT5 proteins. STATs have been proposed to play an important 
role in various cellular processes by transcriptional regulation of specific target genes. 
Cyclin D2, and p21WAF/CIP1 are all STAT target genes and play a crucial role in regulation 
of the cell cycle, suggesting a role for STATs in proliferation. Anti-apoptotic members of 
the Bcl-2 family including Bcl-Xl, have also been demonstrated to be regulated by 
STATs, suggesting a role for STATs in survival as well. 
Both STAT3 and STAT5 have been demonstrated to play an important role in myeloid 
differentiation. Although STAT3 deficient mice die during early embryogenesis 106, 
specific deletion of STAT3 in mature macrophages and neutrophils by the Cre-LoxP 
recombination method was used to investigate STAT3 mediated effector functions of 
these cells. These mice demonstrated high levels of inflammatory cytokines such as 
TNFa, IL-1, and IFNg and were highly susceptible to endotoxic shock. These results 
suggest that STAT3, in macrophages and neutrophils, plays an important role in 
controlling the anti-inflammatory response. STAT3, also plays an important role in IL-6  
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mediated monocyte differentiation of M1 cells 107and G-CSF mediated neutrophil 
differentiation of LGM-1 cells 108. Ectopic expression of a dominant-negative STAT3 in 
M1 and LGM-1 cells abrogates the growth arrest observed after both IL-6 and G-CSF 
stimulation respectively, and differentiation is blocked. Regulation of proliferation and 
differentiation by STAT3 is thought to be in part mediated by down-regulation of c-Myc. 
This has, for example, been suggested by expression of a dominant-negative STAT3 in 
M1 cells resulting in abrogation of the IL-6 induced repression of c-myc. In addition, 
STAT3 can also act as an inhibitor of differentiation during EPO mediated erythrocyte 
differentiation 108.  
Another member of the STAT family thought to play an important role in myeloid and 
lymphoid differentiation is STAT5. The myelolymphoid repopulating activity in  STAT5-
/- mice was completely disturbed, as demonstrated by decreased numbers of lymphocytes, 
myelocytes, and erythrocytes 109; 110. Furthermore, its role in myeloid differentiation has 
also been investigated in leukemic cell lines. For example, TPO induced megakaryocyte 
differentiation has been demonstrated to be regulated by STAT5 111. A 10 amino acid 
intracellular deletion of the TPO receptor in UT-7 cells, disabling STAT5 activation 
results in a block of megakaryocyte differentiation. Furthermore, TPO mediated 
megakaryocyte differentiation is suggested to be regulated via p21WAF/Cip1, a STAT5 target 
gene. STAT5 has also been implicated to play an important role in G-CSF mediated 
neutrophil differentiation. Dominant-negative STAT5 inhibits both IL-3 dependent 
proliferation 112 as well as G-CSF mediated differentiation in 32D cells 113.    
 
4.3.2. CAAT/Enhancer Binding Proteins 
Members of the CCAAT/Enhancer Binding Protein (C/EBP) family play an important 
role in myeloid differentiation. The family of C/EBPs consist of six distinct members, 
including C/EBPa,-b,-g,-d,-e, and –z. C/EBPs contain three different domains, a 
carboxy-terminal leucine zipper domain, a DNA binding domain and an N-terminal 
transactivation domain 114. Homo- and hetero-dimerisation, via a leucine zipper domain, is 
required for transcriptional activation via C/EBP consensus sequences. C/EBPg and 
C/EBPz, however, function as dominant-negative regulators of transcription, because they 
lack the N-terminal transactivation domain and have a mutated DNA binding domain 
respectively. Except for C/EBPe, members of the C/EBP family are highly expressed in a 
variety of cell types. C/EBPa?was the first characterized member of the C/EBP family, and 
was found to be expressed in adipocytes and hepatocytes 115; 116. Examination of C/EBPa 
knockout mice demonstrated that C/EBPa plays a critical role in both adipocyte and 
hepatocyte development 117. Expression levels of members of the C/EBP family are also 
differentially regulated throughout myeloid differentiation. C/EBPa, for example, is 
upregulated during early myelopoiesis, and is down-regulated during terminal 
monocyte/macrophage differentiation 118. In contrast, C/EBPe is up-regulated during 
terminal granulocyte differentiation. Examination of fetal livers obtained from C/EBPa 
knockout mice demonstrated that the absence of C/EBPa blocks myeloid differentiation at 
the promyelocytic stage. Furthermore, the G-CSF receptor and IL-6 receptor were not 
expressed in these mice 119. Ectopic expression of C/EBPa in a U937 cells is sufficient to 
induce granulocyte differentiation, whereas monocyte differentiation is blocked 118. 
Furthermore, ectopic expression of C/EBPa in multi-potent hematopoietic progenitors 
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from chickens results in increased eosinophil differentiation 120. Although C/EBPe 
knockout mice are normal at birth, at the age of 3-4 months they develop increased levels 
of immature myeloid cells and decreased levels of terminally differentiated neutrophils 
and eosinophils 121. A role for C/EBPe in granulocyte differentiation was confirmed by 
ectopic expression of C/EBPe in the 32D cell line which resulted in improved G-CSF 
induced granulocyte differentiation 122. During granulocyte differentiation, various 
granule proteins are differentially expressed. Recently, it has been demonstrated that both 
C/EBPa and C/EBPe can regulate transcription of the neutrophil granule protein 
Lactoferrin, at different stages of neutrophil differentiation 123. Furthermore, the 
eosinophil specific granule protein Eosinophil Derived Neurotoxin (EDN) can be highly 
up-regulated by C/EBPa and C/EBPd and to a lesser extent by C/EBPb and C/EBPe 124. 
C/EBPb and C/EBPd? are also up-regulated during myeloid differentiation. Ectopic 
expression of C/EBPb in MEPs induces myeloid differentiation 120. In addition, ectopic 
expression of C/EBPb ?drives eosinophil differentiation 125 and regulates transcriptional 
activation of the eosinophil specific gene major basic protein (MBP) 126.  
 
4.3.3. GATA/PU1 
The Ets-transcription factor PU.1 is exclusively expressed within the hematopoietic 
system. PU.1 is highly expressed in B lymphocytes and monocytes/ macrophages 127; 128, 
whereas lower levels of PU.1 are detectable in granulocytes, megakaryocytes and 
erythrocyte precursors 129. The role of PU.1 in myeloid differentiation has been 
demonstrated by transient expression of PU.1 in a non-leukemic hemopoietic cell line 
(FDCP mix), in which it inhibits erythrocyte differentiation and induces myeolopoiesis. 
Furthermore, constitutive expression of PU.1 in the same cells favors macrophage 
differentiation over granulocyte differentiation 130. Furthermore, PU.1 deficient mice 
exhibit reduced levels of mature neutrophils and completely lack B-lymphocytes and 
monocytes 131; 132. 
PU.1 mediated monocyte/macrophage differentiation requires the expression of c-Jun, 
which is a co-activator of PU.1. C/EBPa inhibits monocyte differentiation by blocking 
transcription of c-Jun and by association with PU.1 itself, thereby inhibiting its 
transcriptional activity. This explains why C/EBPa expression levels must be down-
regulated during terminal monocyte differentiation. However, it has been suggested that, 
at least during early myeloid differentiation expression of both C/EBP and PU.1 is 
required for differentiation of  myeloid lineages, since transcriptional regulation of several 
receptors necessary for myeloid differentiation, including the common b chain of the IL-
3/IL-5/GM-CSF receptor family, requires cooperative transcriptional activation by PU.1 
and C/EBPs 133.  
Whereas PU.1 is capable of inhibiting erythrocyte differentiation, a zinc finger 
transcription factor, GATA-1, which is expressed in megakaryocytes, eosinophils, mast 
cells and their progenitors 134, is required for erythrocyte differentiation 135-137 and is 
essential for survival of developing mouse embryos 138. In the absence of GATA-1, 
erythroid precursor cells display arrested maturation and undergo apoptosis 139. GATA-1 
mediated erythrocyte differentiation requires the presence of the coactivator Friend of 
GATA (FOG). Association of PU.1 with GATA-1 inhibits erythrocyte differentiation, 
whereas association of GATA-1 with c-Jun prevents monocyte and granulocyte 
differentiation. 
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GATA-1 has also been demonstrated to play an important role in eosinophil and basophil 
differentiation. For example, GATA-1 is involved in transcriptional regulation of the 
eosinophil granule protein MBP 140. Although interaction of FOG with GATA-1 is 
required for erythrocyte differentiation, this association inhibits eosinophil differentiation. 
In order to promote eosinophilopoiesis, FOG expression levels are down-regulated by 
C/EBPb?40 . This suggests that a balance between C/EBPs, GATA-1, and PU.1 is involved 
in determining hematopoietic cell fate during differentiation.  
 
4.3.4. Id transcription factors and regulation of hematopoiesis 
Lymphoid differentiation has been demonstrated to be regulated by several transcription 
factors, including members of the family of basic Helix Loop Helix (bHLH) transcription 
factors. The family of bHLH proteins consist of several members, including the E-proteins 
E12 and E47, which are named after their ability to bind to the canonical E-box DNA 
sequences. These E-proteins are ubiquitously expressed, whereas other members of the 
bHLH family, such as MyoD and SCL, are expressed in a lineage specific manner. This 
family of transcription factors consists of three different domains, an N-terminal 
transactivation domain, a highly conserved helix loop helix domain required for 
dimerization, and a basic DNA binding domain. Dimerization of bHLH transcription 
factors is required to enable binding to E-box DNA consensus motifs resulting in 
trancriptional regulation. Another class of bHLH transcription factors, the Id proteins lack 
the DNA binding domain and act as dominant-negative regulators of transcription.  So far, 
four different Id proteins have been identified in humans , Id1, Id2, Id3, and Id4. These Id 
proteins are all capable of heterodimerizing with E-proteins, thereby inhibiting the 
transcriptional regulation of E-box dependent target genes. As a result, Id proteins can 
inhibit lineage specific transcription and can alter the differentiation program of cells. 
Lymphoid differentiation is characterized by several stages of development, based on the 
presence or absence of cell surface markers. Early, double-negative (DN) T cells express 
neither CD4 or CD8 and can be negative for TCRa gene rearrangements. Subsequently, 
these DN-cells can be divided into four distinct populations (DNI-DNIV) based on the 
expression of CD25 and CD44 and the status of TCR gene rearrangement. These DN-T 
cells subsequently differentiate towards CD4 and CD8 double positive cells and finally 
develop to either CD4 or CD8 positive cells. Id2 expression is high in DNI cells and is 
down-regulated during the following DN-stages, whereas expression of the E-proteins 
E2A and HEB remains equal during all DN stages 142. The DNI stage consists of cells 
differentiating to either Natural Killer (NK)-cells or T lymphocytes. Within this 
population, the expression of Id2 is highest in cells differentiating towards NK-cells, 
whereas E-protein expression is highest in cells differentiating towards T-lymphocytes. 
This suggests that Id2 is required to inhibit E-protein activity in differentiating cells, 
resulting in a lineage switch towards NK cells rather than T-lymphocytes. This hypothesis 
is supported by the observation that Id2 deficient mice display a defect in production of 
NK-cells 143.  
Id3 has been demonstrated to play a similar role in lymphoid differentiation. Ectopic 
expression of Id3 in CD34+ cells, mediated by retroviral transduction, completely blocks 
T lymphocyte differentiation, whereas NK-cell development is enhanced 144. Id3 also 
plays a role in final maturation of T-Lymphocytes by inhibition of recombination 
activating genes, and disrupts the development of pre-T cells into TCRab cells 145. In  
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addition to its role in T-lymphocyte and NK cell development, Id3 also plays an important 
role in B-lymphocyte development. Ectopic expression of Id3 in CD34+ cells completely 
abolished B-lymphocyte development, at an early stage, before expression of the IL-7Ra 
146. During normal B-cell development, both Id1 and Id2 are expressed in pro-B cells and 
their expression is down-regulated during differentiation, suggesting that development is 
inhibited by expression of Id1 and Id2. Although Id1 deficient mice do not exhibit severe 
abnormalities, a role for Id1 in B-cell development has been demonstrated by transgenic 
mice constitutively expressing Id1. These experiments demonstrated that B-cell 
development is inhibited at an early stage 147. Id1 transgenic mice also exhibit low levels 
of T-cells due to massive apoptosis in thymocytes at a young age. In the later stages of 
their life, however, these mice frequently develop T-cell lymphoma 148.  
These studies clearly demonstrate that Id proteins are regulated during lymphoid 
differentiation and play an important role in regulation of lymphoid lineages. Id proteins, 
however, are not exclusively expressed in lymphoid cells but are also expressed in other 
hematopoietic lineages. Although differential expression patterns have been observed, the 
role of Id proteins during myeloid differentiation remains to be established and their role 
in granulocyte differentiation will be discussed in chapter 7 of this thesis. 
 
5. Granulocyte differentiation 
 
5.1. Morphological development and granule formation during eosinophil 
differentiation 
 
The CMP differentiates into a granulocyte/macrophage progenitor (CFU-GM) from which 
both eosinophils and basophils are derived. The existence of cells consisting of both 
basophilic and eosinophillic features suggests that eosinophils and basophils share an 
intermediate progenitor. Although the IL-5 receptor a chain is expressed in both 
eosinophilic and basophilic progenitors, basophil differentiation can be induced by IL-3, 
whereas terminal eosinophil differentiation requires IL-5. In contrast, other studies have 
also suggested the existence of a common erythrocyte/eosinophil progenitor 149. During 
eosinophil differentiation from CD34+ progenitors, different morphological stages can be 
observed (Figure 5). CD34+ cells develop from myeloblast cells towards pro-myelocyte 
type I, pro-myelocyte type II, myelocyte, meta-myelocyte, and finally mature eosinophils 
with segmented nuclei. These stages can be distinguished by the size of the cells, ratio of 
cytoplasm versus nucleus present, appearance of eosinophilic granules and the shape of 
the nuclei. During eosinophil differentiation, cytotoxic proteins are formed and stored in 
different granules. Unfortunately, the terminology used to describe different granule 
populations is not well defined, and the term ‘primary granule’ is used to describe both the 
immature core-less specific granules and the core-less CLC proteins containing granules. 
These immature core-less specific granules are formed at the myeloblast or promyelocytic 
stage, consisting of cationic proteins including Major Basic Protein (MBP), Eosinophil 
Derived Neurotoxin (EDN), Eosinophil Cationic Protein (ECP) and Eosinophil Peroxidase 
(Epo) 150. In mature eosinophils these proteins play an important role in microbial killing. 
During maturation of cells, these immature, core-less specific granules condense and 
become core-containing specific granules 151. Within these specific granules many 
cytokines and growth factors are also stored 152 including TNFa, TGFa 153 and GM-CSF  
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154. During maturation of these specific granules, the crystalloid core is formed by MBP, 
whereas the other proteins including Epo, ECP, and EDN are located in the surrounding 
matrix of the granules. Although the majority of granules in promyelocytes are immature, 
core-less specific granules, promyelocytes also consists of core-less primary granules, 
predominantly containing Charcot-Leyden Christal (CLC) proteins 155. In addition to CLC 
protein, Epo can also be present in these primary granules. At the myelocyte and 
metamyelocyte stage secretory vesicles are formed which coincides with the decrease in 
plasma membrane area 156. These secretory vesicles contain cytochrome b558, CD11b, 
which play a role in the respiratory burst and migration of eosinophils, respectively 155. In 
addition, low numbers of small-type granules, containing arylsulphatase B, are also 
present in mature eosinophils 157. The morphological development of the granules during 
eosinophilopoiesis can be used as a marker of differentiation and is described in Chapter 
4.  
 
 
Figure 5. Eosinophil differentiation. Cells differentiating towards eosinophils undergo distinct stages: 
myeloblast, promyelocyte I, promyelocye II, myelocyte, metamyelocyte and mature eosinophils.  These stages 
are characterized by changes in morphology and the development of granules.  The expression profiles of the 
granule proteins are based on the development of the different types of granules.  
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Morphological development and granule formation during neutrophil maturation 
In contrast to eosinophil differentiation, neutrophil differentiation from the 
granulocyte/macrophage presursor does not seem to involve any intermediate shared 
progenitors. Terminal differentiation of neutrophils from the CFU-GM requires 
stimulation with G-CSF. During neutrophil differentiation from CD34+ progenitors, the 
same morphological stages can be observed as during eosinophil differentiation 158; 159 
(Figure 6). Neutrophilic myeloblasts differentiate from promyelocyte type I and type II 
towards myelocytes, and metamyelocytes. During terminal differentiation, cells with 
banded nuclei and finally mature neutrophils containing segmented nuclei are formed. 
Similar to eosinophils, mature neutrophils consists of a variety of granules. Primary 
azurophilic granules are formed in neutrophilic myeloblasts. These granules express a 
variety of proteins including Myeloperoxidase, Elastase and Defensins, which play a role 
in bacterial killing by mature neutrophils. As differentiation continues, secondary specific 
granules are formed at the myelocytic stages. In these granules Lactoferrin is stored 
together with CD11b and the fMLP receptor 160; 161. Tertiary gelatinase containing 
granules are formed in neutrophils with banded nuclei. Finally, secretory vescicles, 
consisting of cytochrome b558 and adhesion molecules are formed in mature neutrophils 
with segmented nuclei.  
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Figure 6. Neutrophil differentiation. Cells differentiating towards neutrophils undergo distinct stages: 
myeloblast, promyelocyte I, promyelocye II, myelocyte, metamyelocyte and mature neutrophils with banded and 
segmented nuclei. These stages are characterized by changes in morphology and the development of granules. 
The expression profiles of the granule proteins are based on the development of the different types of granules, 
combined with RNA levels of the granule proteins in neutrophil progenitors 
 
Granulocyte function 
During infections granulocytes are directed from the blood towards the site of 
inflammation by chemoattractants. The presence of chemoattractants results in firm 
adhesion of granulocytes to the endothelium of the blood vessel followed by spreading of 
the cell. This process is mediated by integrins which bind to their ligands on the 
endothelial cells. After firm adhesion, granulocytes transmigrate through the endothelial 
layer to arrive at the site of inflammation, a process termed diapedesis 162. Once 
granulocytes have arrived at the site of inflammation, microbial agents can be killed by 
phagocytosis in conjunction with the release of toxic oxygen metabolites, and cytotoxic 
proteins. The NADPH oxidase is a multicomponent complex which is activated in 
neutrophils and translocates from the cytoplasm (p67-phox, p40-phox, p47-phox, and rac-
2) and the granules (cytochrome b558) to the plasma membrane 162. The active NADPH 
oxidase complex produces reactive oxygen species by reduction of oxygen into 
superoxide.  
Besides their normal function in immunity against parasitic infection, eosinophils are 
thought to play an important role in the pathogenesis of allergic diseases, such as asthma 
and dermatitis, where release of granular contents at the inflammatory locus can result in 
long-term tissue damage 164; 165. Neutrophils have also been demonstrated to play a role in 
the abnormal inflammatory response observed in, for example, patients with Chronic 
Obstructive Pulmonary Disease (COPD) 166. Elevated numbers of neutrophils are 
observed in the airways of these patients. These activated neutrophils release cytotoxic 
proteins by degranulation resulting in gradually increased damage to the lung tissue. 
 
6. Scope of this thesis 
Although it is clear that hematopoiesis is a series of events that is highly regulated at 
many levels, in order to maintain the hematopoietic stem cell pool and to obtain the 
required numbers of mature hematopoietic cells, the precise regulatory mechanisms in 
vivo responsible for this regulation are still incompletely understood. There is still a 
debate concerning the gradual restriction in differentiation potential from HSCs towards 
mature myeloid and lymphoid cells via CMPs and CLPs. In addition, a similar 
controversy has continued concerning the origin of eosinophils deriving from either a 
basophil/eosinophil or erythrocyte/eosinophil progenitor, and further research is needed to 
better understand these processes. 
Most studies, until recently, have focused on murine development. Although murine 
systems, including the use of knockout mice, are suitable and important model systems to 
study hematopoiesis, differences, for example, in gene expression profiles compared to 
hematopoiesis in man have been observed 69. Therefore it is also important to study 
regulatory mechanisms underlying myeloid differentiation in primary human systems. 
Although studies have proposed that the balance between transcription factor is actively 
involved in cell fate determination, the precise mechanisms specifically regulating 
eosinophil and neutrophil differentiation are still incompletely understood.   
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This thesis focuses on the regulatory mechanisms underlying granulopoiesis and 
investigates the differences and similarities between eosinophil and neutrophil 
differentiation. Previously, the majority of the experiments performed to investigate the 
regulatory mechanisms underlying granulocyte differentiation were performed in either 
leukemic or transformed cell lines. In our studies granulocyte differentiation was analyzed 
utilizing an ex-vivo system which enables us to investigate differentiation from human 
cord blood derived CD34+ cells. Our results suggest that the regulation of distinct signal 
transduction pathways by external stimuli regulate cell fate choices during granulopoiesis.  
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Abstract 
 
Signal Transducer and Activator of Transcription 5 (STAT5) activity is induced by a 
plethora of cytokines and growth factors resulting in transcriptional activation of specific 
target genes. STAT5 plays an important role in a variety of cellular processes, including 
proliferation, differentiation, and apoptosis. Aberrant regulation of STAT5 has been 
observed in solid tumors as well as in patients with either chronic or acute myeloid 
leukemia. Kinase inhibitors are currently being developed to negatively regulate STAT5 
activity for clinical purposes. 
  
Introduction 
 
In the early 1990s, studies revealed the existence of a signal transduction pathway 
regulating interferon induced gene transcription. This pathway was shown to be regulated 
by the STAT family of transcription factors, named after their dual role in signal 
transduction and activation of transcription. In mammals, seven STAT proteins have been 
identified, including two highly homologous STAT5 isoforms which are encoded by two 
tandemly linked genes on chromosome 17. Although both STAT5 isoforms are roughly 
95 % homologous at level of cDNA, they exhibit both redundant and non-redundant 
functions in vivo, probably due to differences in their transactivation domain (see below). 
 
  
Figure 1. Schematic representation of the STAT5 isoforms demonstrating the conserved domains including the 
N-terminal domain (     ), the DNA binding domain (     ), a putative SH3 domain (     ), the SH domain (     ), and 
the transactivation domain (     ).The phosphorylation sites on tyrosine (Y) and serine residues are indicated.  
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Structure 
 
All members of the STAT family exhibit a similar protein structure comprising of several 
conserved domains1 (see figure 1). The amino-terminal region consists of a series of eight 
short interactive helices and has been implicated in playing a role in the association of two 
independent STAT dimers, bound to adjacent STAT DNA consensus sequences, which is 
required for optimal transcriptional activation. The DNA-binding domain, containing 
several b-sheets, is located in the centre of the protein, while C-terminal of this domain is 
a putative SH3-domain, followed by a classical SH-2 domain, which are separated by a 
conserved tyrosine residue. The SH-2 domain, required for intracellular recruitment to cell 
surface receptors and for STAT dimerisation, is followed by the C-terminal 
transactivation domain.  
 
Regulation of STAT5 activation  
 
Both STAT5 isoforms can be activated by various cytokines and growth factors and the 
signalling paradigm mediating this pathway has been elucidated in detail 2 (see figure 2). 
In general, receptor dimerisation by engaging ligand, results in activation of members of 
the receptor-associated Janus kinase family (JAK) through cross-phosphorylation. 
Subsequently, JAK-induced tyrosine phosphorylation of the intracellular domains of the 
receptor occurs, creating docking sites for STAT5. STAT5a and STAT5b are 
subsequently phosphorylated by JAK kinases on tyrosine residues Y694 and Y699, 
respectively. Homo- or heterodimers of STAT5a and STAT5b are formed and subsequent 
translocation to the nucleus results in transcriptional activation of a variety of genes, 
including cell cycle regulators such as cyclin D1, cyclin D2, p21WAF/Cip1 and p27kip , anti-
apoptotic genes such as Bcl-xl and Bcl-2, as well as genes involved in regulation of 
differentiation such as Whey Acidic Protein. In addition to tyrosine phosphorylation, 
serine phosphorylation of STAT5a and STAT5b can occur on serine residues S725 and 
S730, respectively. Although the biological significance of STAT5 serine phosphorylation 
is incompletely understood, it has recently been demonstrated that p21-activated kinase 
associates and phosphorylates STAT5a on Ser779, which is required for induction of b-
casein promoter activity 3. Until recently, JAKs were considered to be the only kinases 
involved in STAT5 activation, however, studies now support the hypothesis that Src-
kinases can also activate STAT5.  
Relatively little is known regarding the down-regulation of STAT5-induced signaling. 
However, several pathways have been implicated in playing a role in this process 1.  
For example, the C-terminal transactivation domain of STAT5 is required for down-
regulation of phosphorylated STAT5 in a proteasome-dependent manner 4.  
In addition, dephosphorylation of STAT5 by both nuclear and cytoplasmic phosphatases 
including SHP1, SHP2, and PTP1B. Members of the SOCS family (Suppressors of 
Cytokine Signalling) are also capable of inhibiting STAT5 by association with either the 
phosphorylated cytokine receptors as has been demonstrated for CIS, or by association 
with JAKs thereby inhibiting their catalytic activity. STAT5 regulates transcription of 
members of the SOCS family, thereby resulting in a negative feedback loop. Furthermore, 
in the nucleus, the PIAS (Proteins that Inhibit Activated STATs) family interact with  
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tyrosine phosphorylated STATs. However, for STAT5 the specific regulatory member of 
the PIAS family remains to be elucidated. 
 
 
Figure 2. Schematic diagram of STAT5 signal transduction pathway. Cytokine stimulation results in receptor 
dimerization followed by phosphorylation of the receptor by activated JAK kinases. STAT5 is subsequently 
recruited to the receptor and becomes phosphorylated resulting in dimerization and translocation to the nucleus. 
STAT5 subsequently associated with STAT DNA consensus sequences resulting in transcriptional activation. 
STAT5 activation can be negatively regulated by members of the SOCS and PIAS protein families and 
phosphatases.  
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Biological function 
 
STAT5 plays a role in a variety of cellular processes as has been demonstrated by 
observation of STAT5 knockout mice 5, 6. While STAT5a (-/-) mice exhibit normal 
development, female STAT5a (-/-) mice fail to lactate suggesting an important role in 
mammary gland production. Furthermore, STAT5a (-/-) mice also exhibit defects in T-
lymphocyte and NK-cell proliferation. Development of STAT5b (-/-) mice is disturbed, 
male characteristic body growth rates drop to levels normally observed in female mice, 
and differences in liver gene expression profiles between female and male mice are lost. 
STAT5ab double knockout mice have also been generated and are smaller 
compared to their wild type littermates while female mice were infertile. Furthermore, 
STAT5 also plays an important role in hematopoiesis. The myelolymphoid repopulating 
activity in STAT5 double knockout mice is completely disturbed, and animals have 
decreased numbers of lymphocytes, myelocytes, and erythrocytes.7 STAT5 has been 
implicated to play an important role in proliferation, differentiation and protection against 
apoptosis during hematopoiesis. Recently, it has been suggested that STAT5 plays a role 
in B-lymphocyte differentiation. PAX-5 is required for normal B-cell differentiation, and 
is regulated by STAT5 upon stimulation of early B-cells with the Early B-cell Factor 8. In 
addition, it is thought that STAT5 also plays an important role in early myeloid 
differentiation 7,9. Whereas STAT5 predominantly regulates proliferation and 
differentiation of progenitor cells, it is thought to regulate survival in mature myeloid 
cells. 
Although, the two STAT5 isoforms, STAT5a and STAT5b, are highly homologous and 
are thought to have overlapping functions, the differences in sex-specific differences in 
STAT5a and STAT5b knockout mice demonstrate that the two STAT5 isoforms also 
possess non-redundant, unique functions in some cell types. In addition, both STAT5a and 
STAT5b can regulate transcription of the Estrogen receptor-alpha gene, whereas 
regulation of the Estrogen receptor-beta gene is exclusively mediated by STAT5b 10. 
Besides the two full length STAT5 isoforms, two truncated STAT5 proteins have also 
been described (p77 and p80). STAT5a and STAT5b are proteolytically cleaved by a 
nuclear protease. These truncated proteins lack the transactivation domain and as a 
consequence function as dominant-negative inhibitors of STAT5. It has been 
demonstrated that these truncated STAT5 isoforms are predominantly observed in 
immature myeloid cells, suggesting a potential role in regulation of myeloid 
differentiation.  
 
Possible medical applications 
 
Constitutive expression of STAT5b has been reported to contribute to increased malignant 
proliferation in several solid tumors, including human head and neck squamous cell 
carcinomas (HNSCC). Src specific inhibitors block STAT5 phosphorylation in these cells 
and have been demonstrated to reduce tumor growth in vitro11. The receptor tyrosine 
kinase FLT3 is constitutively activated by an internal tandem duplication (ITD) mutation 
in 20-30% of patients with chronic myeloid leukemia. Recently, it was demonstrated that 
ITD-FLT3 primarily signals via STAT5, whereas wild-type FLT3 predominantly signals  
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via MAPK. Although many FLT-3 inhibitors have been reported to inhibit proliferation of 
leukemic cells, a recently developed inhibitor termed GTP14564 specifically inhibits ITD-
FLT3 mediated STAT5 activity without interfering with wild-type FLT3 12. Therefore, 
this inhibitor might be a promising and specific therapeutic agent. Furthermore, STAT5 
has been demonstrated to be constitutively activated in many patients with acute myeloid 
leukaemia, and inhibition of STAT5 activity often results in induction of apoptosis in 
leukemic cell lines, making STAT5 a suitable target for therapy.  
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Abstract 
 
Binding of IFN-g to its heterodimeric receptor induces activation of the tyrosine kinases 
JAK1 and JAK2 followed by tyrosine phosphorylation of STAT1a. Selective activation 
of STAT1a at the IFN-g receptor is achieved by specific interaction between a cytosolic 
tyrosine motif including Y440 in the IFN-g receptor a-chain and the SH2 domain of 
STAT1a. Here we demonstrate that besides STAT1a, STAT3 is also activated by IFN-g 
in human neutrophils. The activation of STAT3 was not found in human eosinophils, 
monocytes, and HL-60 cells, although the STAT3 protein was expressed in these cells. 
The cell type specific activation of STAT3 by IFN-g was also observed in neutrophils 
which are differentiated in vitro from human CD34+ hematopoietic stem cells. These 
results indicate that a single cytokine receptor can activate different STAT family 
members in a cell specific manner, which might result in cell specific gene transcription.  
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Introduction 
 
Interferon-g (IFN-g), a cytokine produced by activated T cells and natural killer cells 1;2 is 
a potent activator of cells of the mononuclear lineage and plays a critical role in host 
defense and inflammation 3. Stimulation of polymorphonuclear neutrophils (PMNs) with 
IFN-g potentates their capability to release toxic oxygen intermediates and the contents of 
specific granules in response to different agonists 4. A major effect of IFN-g on 
neutrophils occurs through the induction of high-affinity IgG receptors, resulting in 
increased phagocytosis and cytotoxicity 5;6. IFN-g exerts its pleiotropic effects on these 
cells through an interaction with a specific receptor expressed on the cell surface 3. 
Functionally active IFN-g receptors consist of two matched polypeptide chains, a 90 kDa 
a-chain that is necessary for ligand binding 7, and a 62 kDa b-chain that is required for 
signal transduction 8;9. In general, cytokine receptors do not contain intrinsic kinase 
activity, yet many become rapidly and reversibly tyrosine phosphorylated following 
ligand binding. Detailed analysis of the ability of interferon-a (IFN-a) signaling has led to 
the identification of a new signaling paradigm, the JAK-STAT pathway 10. Subsequently, 
many other cytokines including IFN-g have also been shown to utilize the JAK-STAT 
signaling pathway 11-14. The Janus kinases (JAK) consists of a family of cytoplasmic 
tyrosine kinases that comprise four known members in mammals; JAK1, JAK2, JAK3, 
and Tyk2. STAT (signal transducers and activators of transcription) comprise a family of 
latent cytoplasmic transcription factors with seven known members, which are activated 
by tyrosine phosphorylation 15. When IFN-g binds to its heterodimeric receptor, two 
members of the JAK family, JAK1 and JAK2, are activated 16;17. These kinases in turn 
mediate the activation of STAT1 18-20. In accordance with the general model for STAT 
activation, selectivity of STAT1 activation by IFN-g is determined by a specific 
interaction between the STAT1 SH2 domain and a short sequence in the IFN-g receptor a-
chain. This sequence contains a phosphorylated tyrosine residue (Y440) 21;22, which has 
been shown to be crucial for IFN-g-mediated signal transduction 23. STAT1 is then 
phosphorylated on a single tyrosine residue 24, most likely by the JAKs, and subsequently 
translocates as a dimer to the nucleus where it activates gene transcription. Specific gene 
expression is further controlled by the precise sequence and arrangement of gamma 
interferon activation site (GAS) elements in the promoters of cytokine inducible genes 25-
28. Recently a IFN-g responsive region (GRR) was identified in the human FcgRI/CD64 
promoter 29. However, the induction of FcgRI gene expression by IFN-g is restricted to 
some myeloid lineages 30;31. Whereas, this receptor is hardly detectable on neutrophils and 
eosinophils, but its expression can be greatly upregulated by IFN-g on neutrophils in vitro 
and in vivo 32;33, but is only slightly enhanced on eosinophils 34.   
In this report we demonstrate that IFN-g can also activate STAT3 besides STAT1 in 
human myeloid precursor cells and mature neutrophils. The activation of STAT3 by IFN-g 
was not observed in human monocytes, eosinophils, and HL60 cells. Activation of both 
STAT1 and STAT3 leads to the formation of STAT1 and STAT3 homodimers and 
STAT1/STAT3 heterodimers binding to the GRR. The formation of multiple DNA- 
binding complexes in neutrophils might contribute to cell specific differences in gene 
activation by IFN-g. 
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Materials and Methods 
 
Cell culture and reagents 
Blood was obtained from healthy volunteers from the bloodbank, Utrecht, the Netherlands. 
Human polymorphonuclear neutrophils (PMN) were isolated as previously described 35. 
Eosinophils were subsequently isolated by the method described by Hansel et al 36. 
Neutrophils and eosinophils were >95% pure as judged by microscopic analysis. Human 
monocytes were purified by elutriation as described before 37, and were 90% pure. HL-60 
cells were maintained in RPMI 1640 supplemented with 8% FCS (Hyclone, Greiner). Human 
interleukin-5 (IL-5) was a gift of Dr. D. Fattah (Glaxo-Wellcome group research, Stevenage, 
UK). Human granulocyte macrophage-colony stimulating factor (GM-CSF) and human 
interleukin-3 (IL-3) were obtained from Genzyme (Cambridge, MA), and human 
granulocyte-colony stimulating factor (G-CSF) from Amgen (Thousand Oaks, CA). Human 
fms like tyrosine kinase-3 (FLT-3) ligand and stem cell factor (SCF) were obtained from 
Pepro Tech (Rocky Hill, NJ). Interferon-g  (IFN-g) was obtained from Boehringer Mannheim. 
 
Isolation of human CD34+ stem cells from cord blood 
Citrated cord blood was collected from healthy newborns after informed consent of the 
mother and used within 24 hours. Mononuclear cells were isolated from cord blood samples 
by density centrifugation (2000 rpm, 20 min) over Ficoll-Hypaque solution (density 1.077 
g/ml). The resulting mononuclear cells (MNC) were subjected to hypothonic lysis of red 
cells. Using the mini MACS immunomagnetic system according to the manufacturer’s 
instructions, about  0.4 - 1.0 x 106 CD34+ cells were isolated from the mixed cell population  
 
Culturing and differentiation of CD34+ cells 
The isolated stem cells were cultured in a 24-well plate, starting with about 0.5x106 cells in 
1.0 ml of IMDM (Gibco,  Paisley, UK) supplemented with 10% FCS and 2 mmol/l L-
glutamine, human SCF (50ng/ml), FLT-3 ligand (50 ng/ml), IL-3 (0.1 nmol/l), GM-CSF (0.1 
nmol/l) and IL-5 (0.1 nmol/l) for eosinophil differentiation 38 or G-CSF (30 ng/ml) for 
neutrophil differentiation 39. Cells were maintained at a density between 1x106 and 3x106 
cells and growth and viability were determined by light microscopic evaluation with 1% 
trypan blue exclusion. Viability remained >95% throughout the 28-day experiment period. 
 
Antibodies and synthetic oligonucleotides 
The monoclonal antibody anti-STAT1 (S21120, directed against amino acids (aa) 592-731) 
was obtained from signal transduction laboratories (Lexington, KY). The polyclonal antibody 
directed against STAT3 (C-20, aa 750-769 and H-190, aa 50-240) was obtained from Santa 
Cruz Biotechnology (Santa Cruz, CA). The following oligonucleotides were used in this 
study: human ICAM-1 IRE (5'-AGCTTAGTTTCCGGGAAAGCAC-3'),  
c-fosSIEm67(5'-AGCTTCATTTCCCGTAAATCA-3'),FcgRI(5'-AGCTTGAGATGTATTT 
CCCGAAAAGA-3'), b-casein (5’-AGC TTAGATTTCTAGGAATTC AAATCA-3’). 
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Gel retardation assay 
Nuclear extracts were prepared from unstimulated and IFN-g stimulated cells following a 
previously described procedure 40. Oligonucleotides were labeled by filling in the cohesive 
ends with [a-32P]dCTP using Klenow fragment of DNA polymerase I. Gel retardation assays 
were carried out according to published procedures with slight modifications 41. Briefly, 
nuclear extracts (10 mg) were incubated in a final volume of 20 ml, containing 10 mM 
HEPES, pH 7.8, 50 mM KCL, 1 mM EDTA, 5 mM MgCl2, 10% (v/v) glycerol, 5 mM 
dithiothreitol, 2 mg poly(dI-dC) (Pharmacia), 20 mg bovine serum albumin and 1.0 ng of 32P-
labeled oligonucleotide for 20 min at room temperature. Subsequently, samples were 
electrophorized for 4.5 hr. on 5% non-denaturing polyacrylamide gels at room temperature. 
Supershift analysis were performed by pre-incubating 10 mg of nuclear extract with  1 mg of 
anti-STAT1 or STAT3 antibody for 30 min on ice prior to the addition of the binding buffer 
and 32P-labeled probe. 
 
Immune precipitation 
Neutrophils and HL60 were either stimulated with 100 U/ml IFN-g or with 100 ng G-CSF 
for 15 min. Reactions were stopped by adding ice-cold phosphate-buffered-saline. Cells 
were lyzed in 750 ml RIPA buffer (150 mmol/l NaCl, 20 mmol/l Tris pH 7.4, 5 mmol/l 
ethylenediaminetetraacetic acid (EDTA), 1% Nonidet P-40, 0.1% sodium dodecyl 
sulphate (SDS), 0.5% sodium deoxycholate, 1 mmol/l phenylmethylsulphonylfluoride 
(PMSF), 2 µg/ml leupeptin, 4 µg/ml aprotinin, 1.5 µg/ml pepstatin, 1 µg/ml trypsin 
inhibitor and 50 mmol/l NaF) for 10 minutes on ice. Cell lysates were centrifuged to 
remove the insoluble material, supernatants were precleared with protein A-Sepharose 
beads for 15 min at 4°C. Hereafter, supernatants were incubated with a polyclonal 
antibody against  STAT3 for 1.5 hours at 4°C. Protein A-Sepharose was added to the 
reaction mixture and the incubation was continued for 45 minutes. Beads were collected 
by centrifugation and were washed four times with cold RIPA buffer, resuspended in  
Laemmli sample buffer, and boiled for five minutes. Protein samples were analyzed by 
Western blotting as described below. 
 
Western blot analysis 
Protein samples were separated on 8% sodium dodecyl sulphate (SDS)-polyacrylamide 
gel, and electro-transferred to Immobilon-P membranes (Millipore, Bedford MA, USA). 
Membranes were blocked in TBST-buffer (150 mmol/L NaCl, 10 mmol/L Tris pH 8.0, 
0.3% Tween 20) containing 5% bovine serum albumin (BSA) for 30 minutes and probed 
with either an anti-phosphotyrosine mAb 4G10, or a pAb against human STAT3 (K15, aa 
750-769) for 1 hour. After three washes with TBST the membranes were incubated for 
one hour with either antiperoxidase-conjugated rabbit-anti-mouse antibodies (after mAb) 
or antiperoxidase-conjugated swine-anti-rabbit antibodies (DAKO, Denmark) (after pAb), 
followed by five washes with TBST. Proteins were visualized with enhanced 
chemiluminescence (ECL, Amersham) 
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Results 
 
STAT1a and STAT3 are activated by IFN-g in human neutrophils. 
In order to understand the molecular basis of cell specific gene regulation by IFN-g, we 
investigated STAT activation by this cytokine in several human myeloid lineages. For 
these experiments we used freshly isolated human neutrophils, eosinophils, monocytes 
and the human promyelocytic HL-60 cell line. We prepared nuclear extracts from 
untreated and IFN-g (100 U/ml) stimulated cells and analyzed these for STAT binding in a 
bandshift assay using 32P-labeled oligonucleotides containing either the mutated sis-
inducible element (SIE/m67) from the c-fos promoter or the IFN-g  response region 
(GRR) from the FcgRI promoter. As can be seen in Figure 1A, a single DNA-protein 
complex (C1) is activated when eosinophils or HL-60 cells were stimulated with IFN-g for 
15 min using the SIE or FcgRI elements as a probe, while monocytes also displayed a 
minor complex C2. However, in human neutrophils IFN-g induces the activation of three 
DNA-protein complexes (C1, C2, and C3) to either the SIE and the FcgRI.   
 
Figure 1. Activation of STAT protein complexes by IFN-g in neutrophils, eosinophils monocytes and HL-60 cells. 
A - Nuclear extracts were prepared from neutrophils, eosinophils, monocytes and HL60 cells  either left unstimulated, 
or treated for 15 min with IFN-g. Nuclear extracts were tested for STAT binding in a bandshift assay using  either the 
32P-labeled SIE/m67 or FcgRI  element as a probe. Multiple DNA-protein complexes were activated by IFN-g in 
human neutrophils. B - Nuclear extracts from IFN-g stimulated neutrophils, HL-60 cells and monocytes were pre-
incubated with either anti-STAT1 or anti-STAT3 antibodies. Nuclear extracts were assayed for binding to a 32P 
labeled SIE/m67 element and analyzed in a bandshift experiment. As a control for STAT3 activation, G-CSF induced  
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neutrophils were used. These results show that STAT1 and STAT3 are activated by IFN-g in neutrophils, resulting in 
STAT1 and STAT3 homo- and STAT1/STAT3 heterodimers 
 
To identify the components in the DNA-binding complexes activated by IFN-g in human 
neutrophils, we performed supershift analysis with antibodies against STAT1 or STAT3. 
Nuclear extracts from IFN-g stimulated neutrophils and HL-60 cells were pre-treated for 
30 min with anti-STAT1 or anti-STAT3 antibodies and analyzed in a bandshift assay 
using the SIE/m67 as a probe. Figure 1B shows that the anti-STAT1 antibody partially 
supershifted DNA-protein complexes C1 and C2, whereas the anti-STAT3 antibody 
supershifted the DNA-protein complex C3 completely and C2 partially. This STAT3 
supershift exactly co-migrated with a STAT3 supershift observed in G-CSF treated 
neutrophils (Fig. 1B), in which STAT3 is known to be activated. Furthermore, complex 
C1 which was also activated in HL-60 cells and monocytes was also supershifted by the 
anti-STAT1 antibody but not by the anti-STAT3 antibody. The nature of the minor C2 
complex in monocytes is not completely clear, since it was partially supershifted with 
STAT1-, but not with STAT3 antibodies. These data indicate that the DNA-protein 
complex C1 is a STAT1 homodimer and is activated both in neutrophils, monocytes and 
HL-60 cells. The neutrophil specific activation of STAT3 by IFN-g results in the 
formation of the DNA-protein complexes C2 and C3 containing STAT1/STAT3 
heterodimers and STAT3 homodimers, respectively. Kinetic studies showed that the 
activation of the STAT1 homodimer in neutrophils was rapid (1 min) and sustained for 
several hours (Figure 2, lane 2). However, compared to the rapid activation of STAT1 
homodimers, the induction of the DNA-protein complexes C2 and C3 by IFN-g was 
slower as well as more transient. The activation of these DNA-protein complexes by IFN-
g peaked after 30 minutes and decreased within 4 hours. 
 
Figure 2. Time course of IFN-g induced STAT activation in neutrophils. Nuclear extracts were prepared from 
neutrophils stimulated with IFN-g for the time indicated. Nuclear extracts were tested for STAT binding in a 
bandshift assay using the 32P-labeled SIE/m67 element as a probe. STAT1 and STAT3 are activated by IFN-g in 
different kinetics. Data shown are representative for three independent experiments. 
 
Supporting evidence for the activation of STAT3 by IFN-g in human neutrophils was 
provided by an immunoprecipitation experiment with anti-STAT3 antibodies. As can be 
seen in Figure 3, STAT3 is tyrosine phosphorylated after IFN-g stimulation in human 
neutrophils but not in HL-60 cells. As a control we stimulated both neutrophils and HL-60 
cells with G-CSF which results in the tyrosine phosphorylation of STAT3 in both cell 
types.  
STAT1
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Figure 3. Tyrosine phosphorylation of STAT3 by IFN-g. Neutrophils and HL-60 cells were untreated or stimulated 
with 100 U/ml IFN-g or 100 ng G-CSF for 15 min. Endogenous STAT3 was immunoprecipitated from these cells 
with a polyclonal antibody against STAT3 (K15). Immunoprecipitates were analyzed by Western blotting with the 
anti-phosphotyrosine antibody 4G10 (upper panel). The membrane was stripped and reprobed with the STAT3 
specific antibody (lower panel). IFN-g clearly induces the tyrosine phosphorylation of STAT3 in neutrophils, but not 
in HL-60 cells. Data shown are representative for three independent experiments. 
 
Lineage specific activation of STAT3 by IFN-g in CD34+ derived neutrophils. 
Next we performed an experiment to evaluate STAT activation during eosinophil and 
neutrophil development from human CD34+ haematopoietic stem cells. CD34+ cells were 
isolated from cord blood and grown in suspension in the presence of the growth factors 
(FLT-3L, SCF, GM-CSF, IL-3) 42, and the addition of either G-CSF to promote neutrophil 
differentiation 39 or IL-5 to promote eosinophil differentiation 38. The morphological 
appearance of cells in cultures of cord-blood derived CD34+ cells observed after different 
times resembled the properties previously described 43. During the differentiation period 
we collected nuclear extracts at day 0, 7, 14, 21 and 28 from unstimulated and IFN-g 
treated cells of both the neutrophil and eosinophil lineage. Prior to  
stimulation the cells were washed and cytokine-starved for 16 hours. Shown in figure 4 
are the results of a bandshift assay using the 32P-labeled SIE/m67 as a probe. In 
undifferentiated CD34+ cells, IFNg activates complex C1, a little bit of complex C2 and a 
trace of C3.  After 7 days culture, IFN-g activated in cells of the neutrophil lineage (N7) 
three DNA-binding complexes (C1, C2 and C3), while in eosinophilic cells (E7) complex 
C3 was hardly visible. Activation of the three DNA-binding complexes by IFN-g was also 
observed in later stages of neutrophil differentiation (N14, 21 and 28), while in cells of the 
eosinophil lineage C1 remained the major complex observed, with only minor traces of 
C3. To determine the nature of the three DNA-protein complexes activated by IFN-g in in 
vitro differentiated neutrophils, we pre-incubated nuclear extracts from day 28 with 
antibodies against STAT1 and STAT3. As shown in Figure 4, the anti-STAT1 antibody 
supershifted a major portion of the DNA-protein complexes C1 and C2, whereas complex 
C3 was completely supershifted by the anti-STAT3 antibody. Taken together these results 
show that the STAT3 activation by IFN-g is differentially regulated during myeloid 
differentiation.  
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Figure 4. Neutrophil lineage specific activation of STAT3 by IFN-g. 
Nuclear extracts were prepared from cells of different stages (day 0, 7, 14, 21 and 28) during eosinophil or 
neutrophil differentiation. Cells were either unstimulated or treated for 15 min with IFN-g. Nuclear extracts from 
day 28 of the neutrophil differentiation treated with IFN-g were preincubated with either an anti-STAT1 or anti-
STAT3 antibody. Nuclear extracts were analyzed in a bandshift assay with a 32P-labeled SIE/m67 element as a 
probe.  
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Discussion 
 
Although recent reports have improved our knowledge of the events involved in IFN-g-
induced gene regulation, the mechanisms underlying the restricted expression of IFNg-
induced genes in a particular cell type are still poorly understood. Therefore experiments 
were performed to characterize the STAT proteins activated by IFN-g in a number of 
myeloid lineages. In accordance with recent reports 30;44;45 we found that IFN-g activates 
STAT1 in monocytes, eosinophils and the myeloid cell line HL-60. However, in myeloid 
precursor cells and mature neutrophils IFN-g activates also STAT3 in addition to STAT1. 
The mechanism by which STAT proteins are activated via cytokine receptors is well 
documented. It has been shown that the activation of STAT1 is mediated through a 
cytosolic tyrosine motif Y440 in the IFN-g  receptor a-chain 21. The activation of STAT3 
is mediated via recruitment to a specific phosphorylated tyrosine module with the 
sequence YXXQ found within several cytokine receptors activating STAT3 46-49. 
Interestingly, the YXXQ sequence is not present within the intracellular domain of the 
IFN-g receptor. Therefore it is likely that the activation of STAT3 is not mediated via 
phosphorylated tyrosine residues in the receptor. An alternative mechanism could be that 
the JAK kinases can act as adaptor molecules for STAT proteins, which then can be 
phosphorylated by the JAK kinase. Supporting evidence for this model came from a 
recent report where it was shown that activation of STAT5 by the gp130 receptor chain 
occurs independently of receptor tyrosine phosphorylation but is mediated by a direct 
interaction between JAK1 and STAT5 50. An explanation for the cell specific activation of 
STAT3 can be that the interaction between STATs and JAKs may depend on the amount 
of JAKs and STATs expressed in cells. However, it is not excluded that other additional 
factors are involved in the direct activation of STAT proteins.  
The finding that different STAT family members are activated by IFN-g in a cell specific 
manner suggests that this might contribute to cell specific differences in gene expression. 
Recently, it has been shown that the ability of cytokines to activate gene transcription 
depends on the particular pattern of STAT proteins activated 26. Although there are only 
minor differences between the optimal binding sites for STAT1 and STAT3, only binding 
of STAT1/STAT3 heterodimers results in the transcriptional activation of a promoter 
containing a single STAT-binding site 26. The activation of STAT3 by IFN-g in human 
neutrophils, leading to the formation of STAT1/STAT3 heterodimers might explain the 
specific activation of the FcgRI gene in neutrophils, resulting in increased phagocytosis 
and cytotoxicity of these cells 5;6. The low induction of the FcgRI receptor by IFN-g on 
human eosinophils suggest that STAT1 homodimers are poor activators of this gene. By 
contrast, in human monocytes STAT1 homodimers are capable to induce FcgRI gene 
expression by cooperating with the myeloid specific transcription factor PU1 51. Taken 
together, these data indicate that the lineage specific activation of STAT proteins by IFN-g 
might contribute to the different functional effects IFN-g exhibit on several myeloid 
lineages 52.    
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Abstract 
 
Signal transducers and activators of transcription (STATs) have been reported to play a 
critical role in differentiation of several myeloid cell lines, although the importance of 
STATs in differentiation of primary human hematopoietic cells remains to be established. 
Terminal eosinophil differentiation is induced by IL-5, which has also been demonstrated 
to activate STAT5. We have investigated whether STAT5 plays a critical role during 
eosinophil differentiation, using umbilical cord blood (UCB) derived CD34+ cells. In this 
ex-vivo system, both STAT5 expression and activation are high early during 
differentiation, and STAT5 protein expression is down-regulated during the final stages of 
eosinophil differentiation. Retroviral transductions were performed to ectopically express 
both wild-type and dominant-negative STAT5a (STAT5aD750) in CD34+ cells. 
Transduction of cells with STAT5a resulted in enhanced proliferation compared to cells 
transduced with empty vector alone. Interestingly, ectopic expression of STAT5a also 
resulted in an accelerated differentiation. In contrast, ectopic expression of STAT5aD750 
resulted in a block in differentiation while proliferation was also severely inhibited. 
Similar results were obtained with dominant-negative STAT5b. Forced expression of 
STAT5a enhanced expression of the STAT5 target genes Bcl-2 and p21WAF/Cip1, 
suggesting they may be important in STAT5a mediated eosinophil differentiation. These 
results demonstrate that STAT5 plays a critical role in eosinophil differentiation of 
primary human hematopoietic cells. 
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Introduction 
 
Eosinophils play an important role in immunity against helminth infection. Parasite 
infection results in both enhanced eosinophil numbers, migration towards and 
degranulation at the site of parasite invasion. In vitro studies demonstrated that 
eosinophils are capable of adhering to parasites in presence of different antibody isotypes 
(IgE, IgG, and IgA)1; 2 and complement components (C3b) 3. At the site of contact, 
eosinophils degranulate resulting in damage of the tegumental membranes and eventually 
in death of parasites 4. The toxic effect of eosinophilic granule proteins such as 
Eosinophilic Cationic Protein (ECP) is complemented by the generation of toxic oxygen 
metabolites 5. Besides their role in immunity against parasitic infection, eosinophils are 
thought to play an important role in the pathogenesis of allergic diseases, such as asthma 
and dermatitis. Eosinophils are recruited to the site of allergic inflammation by 
chemoattractants such as C5a and PAF 6; 7, and release of granular contents at the 
inflammatory locus can result in long-term tissue damage. For example, airway 
epithelium can be damaged during airway inflammation 8; 9.  
Eosinophils are derived from pluripotent hematopoietic stem cells (HSC) in the bone 
marrow. These progenitors are defined as precursors for all lineages of mature blood cells 
and they are capable of self-renewal. Such cells can be divided into long-term 
repopulating (LT-HSC) and short-term repopulating hematopoietic stem cells (ST-HSC). 
ST-HSC can differentiate to multipotent progenitor cells, which are capable of 
differentiation towards a subset of the hematopoietic lineage. These multipotent stem cells 
include both the common lymphoid precursor 10, and common myeloid precursor 11. 
Common myeloid progenitor cells, known as the CFU-GEMM (colony-forming unit 
granulocyte/ erythrocyte/ macrophage/ megakaryocyte) can differentiate towards the 
erythroid, megakaryocytic and myelomonocytic lineage.  It has been demonstrated that 
genes specific for either erythroid, myeloid or megakaryocytic lineages are transcribed in 
the common myeloid progenitors before commitment to a single lineage. Genes specific 
for differentiation towards other lineages are down-regulated upon commitment to a 
single lineage 12. Myeloid differentiation is regulated by a variety of cytokines, including 
Erythropoietin (EPO), Granulocyte colony-stimulating factor (G-CSF), Thrombopoietin 
(TPO), Interleukin-3 (IL-3), Granulocyte-macrophage colony-stimulating factor (GM-
CSF), Macrophage colony-stimulating factor (M-CSF) and Interleukin-5 (IL-5).  IL-3 and 
GM-CSF are cytokines regulating proliferation and survival during myeloid 
differentiation of various lineages, whereas EPO, T, G-CSF, M-CSF and IL-5 are required 
for final maturation of erythrocytes 13, megakaryocytes, platelets 14; 15, neutrophils, 
monocytes 16 and eosinophils 17; 18 respectively.  
Hematopoietic cytokines can activate several signal transduction pathways, including the 
Ras/Raf/Erk 19-23, PI3K 24-26 and JAK/STAT pathway 27; 28. The JAK-STAT signal 
transduction pathway is thought to play an important role in myeloid differentiation 29, 
and the signaling paradigm mediating this pathway has been elucidated in detail 30. In 
short, upon ligand binding, cytokine receptor dimerization results in activation of 
members of the receptor-associated Janus kinase family (JAK) through cross-
phosphorylation. Subsequently, tyrosine phosphorylation of the intracellular domains of 
the dimerized receptor occurs, enabling STAT transcription factors to associate with the 
receptor. STATs are subsequently phosphorylated by the receptor-associated JAK kinases. 
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Homo- or heterodimers are formed and after translocation to the nucleus, transcription can 
be regulated via STAT specific DNA binding sites 31.32-34 
It has been demonstrated that stimulation of cells with IL-5, which is required for terminal 
eosinophil differentiation, results in activation of STAT5 35; 36. In this study, we have 
investigated the role of STAT5 during IL-5 mediated eosinophil differentiation. Our data 
demonstrates that STAT5 is expressed throughout the eosinophil differentiation program 
of CD34+ progenitor cells. Both STAT5 expression and activation are high during early 
differentiation, but STAT5 expression is down-regulated during terminal eosinophil 
differentiation. In order to determine whether STAT5 plays a critical role in the 
differentiation process, wild-type STAT5a, dominant negative STAT5a, and dominant-
negative STAT5b were ectopically expressed in CD34+ cells by retroviral transduction. 
Our experiments demonstrate that STAT5a, as well as STAT5b, play an important role in 
proliferation and maturation during eosinophil differentiation. Ectopic expression of 
STAT5a was found to induce expression of both Bcl-2, an anti-apoptotic protein, and 
p21WAF/Cip1 , a cyclin-dependent kinase inhibitor, in differentiating eosinophils. These data 
demonstrate that STAT5 plays a critical role in regulating the differentiation of primary 
human hematopoietic cells towards eosinophils.  
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Materials and Methods 
 
Isolation and culture of human CD34+ cells 
CD34+ cells were isolated as previously described 35. In short, mononuclear cells were 
isolated from umbilical cord blood by density centrifugation over a ficoll-paque solution 
(density 1.077 g/ml). MACS immunomagnetic cell separation (Miltenyi Biotech, Auburn, 
USA) using a hapten conjugated antibody against CD34, which was coupled to beads, was 
used to isolate CD34+ cells. CD34+ cells were cultured in Iscove’s Modified Dulbecco’s 
Medium (Gibco, Paisley, UK) supplemented with 10% FCS, 50 mM b-mercaptoethanol, 
10 U/ml penicillin, 10 mg/ml streptomycin, and 2mM glutamine at a density of 0.3 x 106 
cells/ml. Cells were differentiated towards eosinophils upon addition of SCF (50 ng/ml), 
FLT-3 ligand (50 ng/ml), GM-CSF (0.1 nmol/l), IL-3 (0.1 nmol/l), and IL-5 (0.1 nmol/l). 
Every 3 or 4 days, cells were counted and fresh medium was added to a density of 0.5 x 
106 cells/ml. After 3 days of differentiation, only IL-3 and IL-5 were added to the cells.  
Neutrophil differentiation was induced upon addition of  SCF (50 ng/ml), FLT-3 (50 
ng/ml) ligand, GM-CSF (0.1 nmol/l), IL-3 (0.1 nmol/l) and G-CSF (30ngl/ml). After 6 
days of culture only G-CSF was added to the cells. 
 
Viral transduction of CD34+ cells 
A bicistronic retroviral DNA construct was utilized, consisting of the gene of interest, and 
an Internal Ribosomal Entry Site (IRES) followed by the gene encoding for eGFP (LZRS-
eGFP). LZRS-eGFP retrovirus was produced by stable transfection of the retroviral 
packaging cell line, Phoenix-ampho37, by calcium phosphate co-precipitation. Cells were 
plated in 6-cm dishes, 24 hours before transfection. 5 minutes prior to transfection 25 mM 
chloroquine diphosphate was added to the cells. A total of 10 mg of DNA was used per 
transfection. Medium was refreshed, 16 hours after transfection. After an additional 24 
hours, cells were split into 75 cm2 culture flasks (Greiner, Frickenhausen, Germany) and 2 
mg/ml Puromycin was added to the cells. After two weeks of selection, cells were plated 
into 25 cm2 flasks (Greiner, Frickenhausen, Germany ) and were grown to a confluency of 
90%. Subsequently, cells were grown in a minimal amount of medium (2.5 ml) for 24 
hours. Viral supernatants were collected and filtered through a 0.45 mm filter. 
CD34+ cells were transduced in 24 wells dishes pre-coated with 20 mg/cm2 recombinant 
human fibronectin fragment CH-296 (RetroNectin; Takara, Otsu , Japan) for two hours, 
and 2% BSA for 30 minutes. Transduction was performed by addition of 0.5 ml viral 
supernatant to 0.5 ml medium containing 0.5 x 106 cells. 24 hours after transduction, 0.7 
ml medium was removed from the cells and 0.5 fresh virus supernatant was added 
together with 0.5 ml fresh medium and cytokines (IL-3 and IL-5). The percentage of 
eGFP positive, living cells was determined every 3 or 4 days by FACS analysis (FACS 
Vantage, Becton Dickinson, CA).  
 
Histochemical staining of eosinophil and neutrophil precursors 
The percentage of eosinophil differentiation was determined by histochemical staining of 
the cells. The percentage of cells differentiating towards eosinophils was determined by 
Luxol Fast Blue staining (Avocado Res. Chem. Ltd., Heysham, UK), a dye  specifically 
staining eosinophil granules. Cytospins were prepared from 5 x 104 differentiated  
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eosinophils. Slides were dried on silica gel for 24 hours before fixing them in dry-acetone 
for 10 minutes. Slides were stained with 0.15 % w/v Luxol Fast Blue in urea saturated 
ethanol for 2 hours. 
May-Grunwald Giemsa staining was used to analyze both differentiating eosinophils and 
neutrophils. Cytospins were prepared from 5 x 104 differentiating eosinophils and were 
fixed in methanol for 3 minutes. After fixation cytospins were stained in a 50% Eosin 
Methylene Blue solution according to May-Grunwald (Sigma-Aldrich GmbH, Seelze, 
Germany) for 20 minutes, rinsed in water for  5 seconds, and the nuclei were counter-
stained with 10% Giemsa solution (Merck kGaA, Darmstadt, Germany) for 15 minutes. 
During eosinophil differentiation, different stages of maturation can be observed. Cells 
differentiate from blast cells towards pro-myelocyte type I, pro-myelocyte type II, 
myelocyte, meta-myelocyte, and finally mature eosinophils with segmented nuclei. These 
stages can be distinguished by the size of the cells, ratio of cytoplasm versus nucleus 
present, presence of azurophilic granules, appearance of  eosinophilic granules and the 
shape of the nuclei. ‘Juvenile’ eosinophils were characterized as cells belonging to the 
stages of pro-myelocyte II, myelocyte, metamyelocyte and mature eosinophils. These 
cells were all observed to contain eosinophilic granules. 
 
Electrophoretic Mobility Shift Assay 
Nuclear extracts were prepared from differentiating eosinophils as described previously 38. 
Oligonucleotides were labeled by filling in the cohesive ends with [a-32P] dCTP using 
Klenow fragment of DNA polymerase I. Nuclear extracts were incubated in a final 
volume of 20 ml, containing 10mM Hepes, pH 7.8, 50mM KCl, 1 mM EDTA, 5 mM 
MgCl2,, 10% (v/v) glycerol, 5mM dithiothreitol, 2 mg poly(dI-dC), 20 mg bovine serum 
albumin, and 1 ng of 32-P labeled oligonucleotide for 20 minutes at room temperature. 
Subsequently, samples were subjected for electrophoresis for 3 hours on a 5% non-
denaturing polyacrylamide gel. Supershift analysis was performed by pre-incubating 10 
mg of nuclear extracts with 3 mg of antibodies against either STAT5, STAT3 
(Transduction Laboratories, Lexington, KY), and STAT1 (Transduction Laboratories, 
Lexington, KY) for 2 hours on ice prior to the addition of the binding-buffer and the 32P-
labeled oligo nucleotide. 
 
Western Blot analysis 
Western blot analysis was performed using standard techniques. In short, for detection of 
STAT5 expression and phosphorylation, differentiating eosinophils were lysed in 
Laemmli buffer (0.12 M Tris HCl pH 6.8, 4% SDS, 20% glycerol, 0.05mg/ml 
bromophenol blue, and 35 mM b-mercaptoethanol), and boiled for 5 minutes. Equal 
amounts of total lysate were analyzed by 8% SDS-polyacrylamide gel electrophoresis. 
Proteins were transferred to Immobilon-P and incubated with blocking buffer (Tris 
Buffered Saline/Tween20 ) containing 5% low fat milk or BSA for 16 hours at 4 oC before 
incubating with either an N-terminal STAT5 antibody (Santa Cruz Inc., Santa Cruz, 
USA), an anti-phosphoSTAT5 (Y695) antibody  (Cell Signaling Technology, Beverly 
,USA), an antibody against b-actin (Santa Cruz Inc, Santa Cruz, USA), an antibody 
against Bcl-2 (Santa Cruz Inc, Santa Cruz, USA), or an antibody against p21WAF/Cip1 
(Santa Cruz Inc, Santa Cruz, USA) for 2 hours in the same buffer. Subsequently, blots 
were incubated with peroxidase conjugated secondary antibodies for 1 hour. Enhanced  
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Chemical Luminescence  (ECL) was used as a detection method according to the 
manufacturers protocol (Amersham Pharmacia, Amersham, UK). 
 
Measurement of Apoptosis 
CD34+ cells were transduced with a retroviral vector (SFCMM-3) expressing a truncated 
NGF receptor (NGFR) as a surface marker. During eosinophil differentiation, the 
percentage of Annexin V positive cells was determined. Cells were incubated for 20 
minutes on ice with a primary mouse antibody against NGFR. After washing the cells 
with PBS, the cells were simultaneously incubated with both a PE conjugated Goat anti 
Mouse antibody and Annexin V-FITC in Annexin binding buffer (Bender Medsystems, 
Austria) for 20 minutes on ice. The percentages of transduced and apoptotic cells were 
determined by FACS analysis. As a positive control, a cell-permeable tat-peptide 
consisting of the BH3 domain of the pro-apoptotic protein Bim 
(YGRKKRRQRRREIWIAQELRRIGDEFNAYY) was used. The cells were incubated for 
1 hour with 40 mM of the peptide at 37 oC.  
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Results 
 
Characterization of ex-vivo Eosinophil differentiation 
CD34+ progenitor cells, isolated from umbilical cord blood, were differentiated towards 
eosinophils in presence of the cytokines IL-3 and IL-5 as described in Materials and 
Methods. The morphology of differentiating eosinophils was analyzed by May-Grunwald 
Giemsa staining (Figure 1a). The percentage of juvenile eosinophils was expressed in 
Figure 1b. After 7 days of differentiation, 20 % of the cells were characterized as juvenile 
eosinophils, and the majority of the cells belonged to the pro-myelocyte I stage. After 17 
days of culture, differentiation increased up to 58 % of juvenile eosinophils of which the 
majority of cells were mature myelocytes. During eosinophil differentiation, granules are 
formed. Final maturation of eosinophil differentiation was further investigated with Luxol 
Fast Blue (LFB) staining, which specifically stains eosinophil granules (Figure 1c). The 
percentage of LFB positive cells increased from 15% after 10 days of differentiation up to 
35 % after 17 days of differentiation (Figure 1d). 
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Figure 1. Eosinophil differentiation from CD34+ cells ex-vivo. Isolated CD34+ cells from cord blood were 
cultured in presence of SCF, FLT-3, GM-CSF, IL-3, and IL-5 for 3 days (See Materials and Methods) After 3 
days of differentiation cells were cultured in presence of IL-3 and IL-5 only. After 7, 10, 14, and 17 days of 
differentiation cytospins were made and (A) were stained with the May-Grunwald Giemsa solution. (B) The 
percentage of juvenile eosinophils was expressed as an average ± S.E.M. of four individual experiments. (C) 
Cytospins were also stained with Luxol Fast Blue for 2 hours after fixation with dry-acetone. (D) The percentage 
of LFB positive cells was expressed as an average ± S.E.M. of  four individual experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. STAT5 expression and activation during eosinophil differentiation. (A) Protein lysates were 
prepared from CD34+ cells, and cells differentiated towards eosinophils for 7, 10, 14, and 17 days.  Western Blot 
analysis was performed with an an N-terminal antibody against STAT5 (top panel), an antibody against tyrosine 
phosphorylated STAT5 (middle panel) and as a control for equal loading with an antibody against b-Actin 
(bottom panel). The experiment shown is representative of three additional experiments. (B) Nuclear extracts 
were prepared from differentiating eosinophils at day 7, 10, 14, and 17. Nuclear extracts were analyzed by an 
Electrophoretic Mobility Shift assay using a 32P-labeled b-casein probe. Competition experiments were 
performed with an unlabeled b-casein probe in lane 6, and with a non-specific probe in lane 7. Supershift 
analysis was performed with nuclear extracts prepared from differentiating eosinophils stimulated with IL-5 for 
15 minutes, with antibodies against STAT5, STAT3 and STAT1, respectively (lane 9-11) The experiment shown 
is representative of three individual experiments. 
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STAT5 expression and activation during eosinophil differentiation  
In order to investigate the regulation of STAT5a during eosinophil differentiation, protein 
lysates were prepared from CD34+ cells immediately after isolation from umbilical cord 
blood, and during subsequent eosinophil differentiation. Equal amounts of protein were 
separated by SDS-PAGE, and western blotting was performed with an N-terminal 
antibody against STAT5, or an antibody against tyrosine phosphorylated STAT5 (Figure 
2a). STAT5 was highly expressed in CD34+ cells, as the non-phosphorylated, inactive 
form. However, STAT5 became phosphorylated upon stimulation with IL-5. Both STAT5 
expression and phosphorylation were high early during eosinophil differentiation, but 
interestingly protein expression was down-regulated after 14-17 days of differentiation. 
To demonstrate that STAT5 phosphorylation indeed correlates with STAT5 activation 
during eosinophil differentiation, nuclear extracts were prepared and electrophoretic 
mobility shift assays performed using a b-casein element as a STAT5 binding site 39. 
Figure 2b shows that the specific slower migrating (C1) DNA-protein complex, 
corresponding to STAT5a (as demonstrated by supershift analysis with an antibody 
against STAT5) 40, decreased after 17 days of differentiation. These experiments 
demonstrate that STAT5 is indeed expressed in differentiating eosinophils but is down-
regulated during terminal maturation. 
 
Retroviral transduction of CD34+ progenitor cells 
In order to investigate the role of STAT5a during eosinophil differentiation, a bicistronic 
retroviral DNA construct was utilized co-expressing eGFP. CD34+ cells, differentiated 
towards eosinophils for 2 days, were transduced with virus expressing either STAT5a, 
STAT5aD750 or empty vector. STAT5aD750 is a dominant-negative STAT5 mutant, 
which can bind to DNA but is unable to activate transcription 41. Expression of both 
STAT5a and STAT5aD750 in transduced cells was confirmed by western blotting of 
protein lysates from transduced cells with a STAT5 antibody (Figure 3a). An 
Electrophoretic Mobility Shift Assay (EMSA) was also performed to analyze the DNA 
binding of STAT5a and STAT5aD750 in transduced cells (Figure 3b). After 7 or 14 days 
of differentiation, cells transduced with eGFP alone, STAT5aD750 or STAT5a were 
starved of cytokines for 16 hours before being stimulated with IL-5 for 15 minutes. 
Nuclear extracts were analyzed using a b-casein element as a probe for STAT5 binding. 
Nuclear extracts prepared from transduced cells with STAT5a retrovirus showed 
increased DNA binding compared to cells transduced with eGFP. Stimulation of cells 
transduced with STAT5aD750, also resulted in an increased DNA binding to the b-casein 
element. The DNA-protein complex C2 migrated faster compared to the DNA-protein 
complex C1 in cells transduced with STAT5a (Figure 3b). This clearly demonstrates that 
retroviral transduction results in ectopic expression of STAT5a and its inactive mutant. 
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Figure 3. Expression and activation of STAT5a in transduced cells. (A) Protein lysates were prepared from 
CD34+ cells transduced with eGFP, STAT5a or STAT5aD750 and a Western Blot was performed with an N-
terminal antibody against STAT5. (B) Nuclear extracts were made of cells transduced with eGFP, STAT5a, or 
STAT5aD750. Cells were starved of cytokines for 16 hours before stimulation with or without IL-5 for 15 
minutes. Nuclear extracts were analyzed with an Electrophoretic Mobility Shift Assay using a 32P-labeled b-
casein probe.  
 
Regulation of proliferation during eosinophil differentiation by STAT5 
In order to determine whether STAT5 plays a critical role in regulating eosinophil 
differentiation, umbilical cord blood derived cells were transduced with either eGFP, 
STAT5a or STAT5aD750. The percentage of eGFP positive cells represents the 
percentage of transduced cells, and was determined by FACS analysis (Figure 4a). The 
transduction efficiency of cells transduced with eGFP was approximately 32%, whereas 
transduction of cells with either STAT5a or STAT5aD750 resulted in an average 
transduction efficiency of approximately 25% and 21%, respectively. We observed an 
increase in the percentage of eGFP positive cells after transduction with STAT5a (from 
25% to 48%), indicating that STAT5a positively influences proliferation during 
eosinophil differentiation compared to cells transduced with eGFP alone. We also 
observed a decrease in eGFP positive cells after transduction with STAT5aD750 
compared to cells transduced with eGFP alone. This demonstrates that STAT5a is both 
necessary and sufficient for progenitor cell proliferation. In order to determine whether 
STAT5 was indeed critical in the regulation of proliferation during eosinophil 
differentiation, CD34+ cells were transduced with either eGFP, STAT5a or STAT5aD750. 
Proliferation was determined by counting the total amount of eGFP positive cells. 
Transduction of cells with eGFP resulted in an induction of proliferation of approximately 
15-fold between day 7 and day 17 (Figure 4b). Transduction of cells with STAT5a 
resulted in an increase in proliferation to approximately 27-fold, and this was mainly due 
to enhanced proliferation during the first 14 days of differentiation. In contrast, 
transduction of cells with STAT5aD750 resulted in a decrease of proliferation 
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Figure 4. Regulation of proliferation during eosinophil differentiation by STAT5. CD34+ cells were 
transduced with eGFP, STAT5a or STAT5aD750. (A) The percentages of eGFP positive cells were determined 
by FACS analysis after 7, 10, 14, and 17days of differentiation. Results are expressed as an average ± S.E.M. of 
five individual  experiments. (B) Proliferation was determined by counting the eGFP positive cells. Results are 
expressed as fold increase in cell numbers compared with day 7 as an average ± S.E.M. of five individual 
experiments. (C) Cells were transduced with either empty vector or STAT5aD750. The percentage of apoptotic 
cells in NGFR positive cells was determined with Annexin V-FITC by FACS analysis. As a positive control for 
apoptosis, cells were pre-incubated for 1 hour with a cell-permeable Bim tat-peptide. 
 
In order to investigate whether the inhibition of proliferation in cells ectopically 
expressing dominant negative STAT5a was due to enhanced apoptosis, Annexin-V 
staining was performed in transduced cells. It has previously been described that eGFP 
tends to leak from apoptotic cells 42, and indeed in our experiments, no eGFP positive 
apoptotic or dead cells could be detected (results not shown). Therefore, an alternative 
retroviral vector expressing a truncated NGF receptor as a surface marker was utilized. 
The percentage of apoptotic cells during eosinophil differentiation is very low, 
approximately  10 %. No difference could be observed in the percentage of Annexin-V 
positive cells between cells transduced with empty vector alone, and cells transduced with  
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STAT5aD750 (Figure 4c). A cell-permeable tat-peptide consisting of the BH3 domain of 
Bim was used to demonstrate that apoptosis can be measured in our CD34+ cells 
differentiating towards eosinophils (Figure 4c, lower panel). These data demonstrate that 
STAT5a is indeed required for optimal proliferation during eosinophil differentiation, and 
does not play a critical role in regulating apoptosis. 
 
Regulation of eosinophil differentiation by STAT5 
In order to investigate whether STAT5a also plays a role in eosinophil differentiation per 
se, cells were again transduced with either eGFP, STAT5a or STAT5aD750. After 7, 10, 
14, and 17 days of differentiation, eGFP positive cells were sorted by FACS from the non-
transduced cells and cytospins prepared. The morphology of the differentiating 
eosinophils was analyzed by May-Grunwald Giemsa staining as described in Materials 
and Methods (Figure 5a). The percentage of juvenile eosinophils is expressed in Figure 
5b. Transduction of cells with either eGFP or STAT5a resulted in approximately 70% 
juvenile eosinophils after 17 days of differentiation, of which the majority were mature 
myelocytes or meta-myelocytes. 
After transduction of cells with STAT5a, approximately the same percentage of juvenile 
eosinophils compared to cells transduced with eGFP were observed. However, since cells 
transduced with STAT5a show an increase in proliferation, there was an increase in total 
numbers  
of juvenile eosinophils. Transduction of cells with STAT5aD750 resulted, after 17 days of 
differentiation, in a very low percentage of juvenile eosinophils, approximately 7%, which 
were promyelocytes II. However, the majority of the cells belonging to the eosinophil 
lineage were blocked in differentiation at the stage of pro-myelocytes I. Proliferation of 
cells transduced with STAT5aD750 was also inhibited, resulting in a decrease of 
approximately 95% in total numbers of juvenile eosinophils compared to cells transduced 
with eGFP 
Eosinophil differentiation was also analyzed by Luxol Fast Blue (LFB) staining of the 
granules (Figure 5c). After fixation, cells were stained with LFB for two hours. After 10 
days of differentiation, approximately 33% of the cells transduced with eGFP were 
positive for LFB. This percentage increased to 38% after 21 days of differentiation 
(Figure 5d). Transduction of cells with STAT5a resulted in an accelerated eosinophil 
differentiation. After only 10 days of differentiation more than 40% of the cells were 
positive for LFB. The percentages of LFB positive cells increased to 52% after 17 days of 
differentiation. In contrast, cells ectopically expressing STAT5aD750 were potently 
inhibited in eosinophil differentiation as measured by LFB staining. The percentage of 
LFB positive cells remained less than 20%, while proliferation was severely disturbed 
(Figure 5d). These data clearly demonstrate that STAT5a plays a critical role during 
eosinophil differentiation.  
To determine whether STAT5a and STAT5b may have different functional activities in 
eosinophil differentiation, cells were transduced with either eGFP or dominant-negative 
STAT5b (Figure 5e). Expression of dominant negative STAT5b in CD34+ cells resulted in 
a block in eosinophil differentiation which was comparable to the inhibition in 
differentiation caused by STAT5aD750. Proliferation was also comparably inhibited by 
ectopic expression of dominant negative STAT5b (data not shown), suggesting that the 
two STAT5 isoforms have similar if not redundant roles. 
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Although STAT5 is thought to play a role in differentiation of neutrophils, this has only 
been demonstrated in the murine 32D cell line 43. In order to determine whether STAT5a 
also plays a role in neutrophil differentiation from human CD34+ cells, cells were 
transduced with either eGFP or STAT5aD750 and differentiated towards neutrophils in 
response to G-CSF (Figure 5f). The percentage of differentiating neutrophils was defined 
as the percentage of cells consisting of either banded or segmented nuclei. Transduction of 
cells with either eGFP or STAT5a resulted in approximately 30% differentiated 
neutrophils, whereas transduction of cells with STAT5aD750 resulted in less than 5% 
differentiated neutrophils. Neutrophil differentiation was blocked at the stage of  
promyelocytes comparable to the situation observed in eosinophil differentiation. 
Proliferation was also inhibited after transduction with STAT5aD750 (data not shown).  
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Figure 5. Regulation of eosinophil differentiation by STAT5. CD34+ cells were transduced with eGFP, 
STAT5a or STAT5aD750. After 10, 14, and 17 days of differentiation transduced cells were separated from the 
non-transduced cells, and cytospins were made. (A) Cytospins were stained with May-Grunwald Giemsa 
solution. (B) Eosinophil differentiation was expressed as percentage of juvenile eosinophils. Data was expressed 
as and average ± S.E.M. of 5 independent experiments. (C) Cytospins were fixed with dry-acetone for 10 
minutes before they were stained with Luxol Fast Blue for 2 hours. (D) The percentage of Luxol Fast Blue 
positive cells were determined by microscopy (left panel) and data was expressed as an average ± S.E.M. of five 
individual experiments. (E) CD34+ cells were transduced with eGFP or dominant-negative STAT5b (5BDN). 
After 14 days of differentiation, cytospins were made of eGFP positive cells and stained with May-Grunwald 
Giemsa solution. The percentage of juvenile eosinophils was expressed as an average ± S.E.M. of three 
independent experiments. (F) CD34+ cells transduced with eGFP, STAT5a, or STAT5aD750 were differentiated 
towards neutrophils. After 17 days of differentiation, eGFP positive cells were sorted and cytospins were made 
and stained with May-Grunwald Giemsa solution. Neutrophil differentiation was expressed as the percentage of 
cells consisting of banded or segmented nuclei. Data is expressed as an average ± S.E.M. of three independent 
experiments. 
 
Regulation of STAT5 target genes during eosinophil differentiation  
Our results demonstrate that STAT5 plays an important role during eosinophil 
differentiation. To confirm the functionality of STAT5, the expression of several STAT5 
target genes was evaluated. Protein lysates were prepared from differentiating eosinophils, 
and these were separated by SDS-PAGE (Figure 6a). Western blotting was performed 
with antibodies against Bcl-2 and p21WAF/Cip1, two previously described STAT5 target 
genes 44; 45. Bcl-2  expression was high early during eosinophil differentiation, whereas 
expression was down-regulated during final maturation. In contrast, p21WAF/Cip1 
expression was absent after three days of eosinophil differentiation, and was upregulated 
during final maturation. 
Ectopic expression of either STAT5a and STAT5aD750 perturbed the expression of  both 
Bcl-2 and p21 WAF/Cip1 (Figure 6b). Forced expression of STAT5a in CD34+ cells resulted 
in enhanced expression of Bcl-2, which was not down-regulated during final maturation. 
Also p21WAF/Cip1 expression was enhanced under these conditions. In agreement, ectopic 
expression of STAT5aD750 in CD34+ cells resulted in a decreased expression of both Bcl-
2 and p21WAF/Cip1. These data indicate that increased expression of Bcl-2 and p21WAF/Cip1 
can be regulated by STAT5a, and this may play a role in the processes regulating 
eosinophil differentiation. 
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Figure 6. Regulation of STAT5 target genes during eosinophil differentiation. (A) Protein lysates were 
prepared from CD34+ cells differentiated towards eosinophils for 0, 7, 10, 14, and 17 days.  Western Blot 
analysis was performed with an antibody against Bcl-2 (top panel), p21WAF/Cip1 (middle panel) and as a control for 
equal loading with an antibody against b-Actin (bottom panel). The experiment shown is representative of three 
independent experiments. (B) CD34+ cells were transduced with eGFP, STAT5a or STAT5aD750. After 7 , 14, 
and 17 days of differentiation eGFP positive cells were sorted and protein lysates were prepared and analyzed by 
Western Blotting. 
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Discussion 
 
In this study we have investigated the role of STAT5a during eosinophil differentiation. 
Our experiments indicate that, during eosinophil differentiation of CD34+ umbilical cord 
blood progenitors, STAT5a protein is differentially expressed and its activity is regulated. 
Ectopic expression of STAT5a results in both an enhanced proliferation as well as an 
accelerated differentiation of UCB derived CD34+ cells. Furthermore, ectopic expression 
of STAT5aD750 results in an inhibition of proliferation and a block in differentiation at 
the promyelocytic stage. 
Although previous studies have suggested that STAT transcription factors may play an 
important role during myeloid differentiation, these studies were performed in myeloid 
leukemic cell lines and not in primary hematopoietic cells 43. We have utilized an ex-vivo 
differentiation system, which results in differentiation of a high percentage of juvenile 
eosinophils (Figure 1). Several studies have previously utilized similar ex-vivo 
differentiation protocols for eosinophil differentiation from CD34+ progenitor cells 
derived either from cord blood or peripheral blood 46-48. Recently, Hashida et al. 
demonstrated that 80% of the cord blood derived CD34+ cells, in their system, developed 
into mature eosinophils after 17 days of differentiation. However, they did only 
distinguished between blast cells without mentioning the other stages of eosinophil 
differentiation 49. The same percentages of eosinophil-like cells, after 21 days of 
differentiation, were described by Velazquez et al. 50 Our differentiation protocol results 
in approximately the same percentages of differentiated and juvenile eosinophils 
compared to these previous studies. This ex-vivo system of eosinophil differentiation, 
results in a high number of juvenile eosinophils which were positive for LFB and 
eosinophil peroxidase (data not shown), and is an important tool for analyzing the role of 
transcription factors during early stages of the differentiation process. 
Retroviral transduction experiments were performed to ectopically express either STAT5a 
or STAT5aD750 in CD34+ cells. Enhanced differentiation is often thought to be 
accompanied by a decrease in proliferation. In contrast, our experiments have 
demonstrated both enhanced differentiation as well as an increase in proliferation in cells 
transduced with STAT5a compared to cells transduced with eGFP (Figures 4b, and 5a-d). 
A role for STAT5 in proliferation during myeloid differentiation has been suggested by 
the observation that expression of dominant-negative STAT5 results in an inhibition of 
proliferation in IL-3 dependent cell lines 43; 51. Bone marrow derived macrophages 
obtained from STAT5a (-/-) knockout mice also proliferate more slowly upon GM-CSF 
stimulation 52. Furthermore, it has been demonstrated that thymocytes derived from 
STAT5a (-/-) STAT5b (-/-) mice fail to proliferate in response to stimulation with IL-2 53.  
Proliferation in cells transduced with STAT5a might be enhanced by reduction of 
apoptosis. Bcl-x is an anti-apoptotic gene which might play a role in survival during 
eosinophil differentiation 54.  It is expressed in CD34+ cells and is down-regulated during 
final stages of neutrophil differentiation, whereas expression remains high during 
monocyte differentiation 55. It has also been demonstrated that A1, another anti-apoptotic 
Bcl-2 family member, is down-regulated in STAT5a deficient mice 40. We have 
demonstrated that STAT5 expression is high during early eosinophil differentiation, 
whereas STAT5 expression is down-regulated during final maturation. STAT5 might 
modulate survival during eosinophil differentiation via transcriptional regulation of  
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members of the Bcl-2 family. We have demonstrated that expression of both Bcl-2 and 
Bcl-xl (data not shown) was high during early eosinophil differentiation, and was down-
regulated during final maturation. Ectopic expression of STAT5a in CD34+ cells resulted 
in enhanced levels of Bcl-2 during eosinophil differentiation. Previously, it has been 
demonstrated that ectopic expresion of dominant-negative STAT5 in ts21E26 transformed 
chicken myeloblasts results in increased apoptosis. This was corroborated by the 
demonstration of  enhanced apoptosis in  bone marrow cells derived from STAT5a/b (-/-) 
knockout mice 54. However, we demonstrate that ectopic expression of dominant-negative 
STAT5a in differentiating eosinophils results in decreased levels of Bcl-2, without 
affecting the levels of apoptosis. This suggests that although STAT5a might enhance 
survival during eosinophil differentiation, the absence of STAT5a and Bcl-2 are not 
sufficient in themselves to cause apoptosis. It is likely that survival of differentiating 
eosinophils is regulated by several redundant signaling pathways. Proliferation during 
eosinophil differentiation might be enhanced by regulation of the cell-cycle regulators 
Cyclin D156 and Cyclin D2. Dominant-negative STAT5a has been demonstrated to inhibit 
induction of both Cyclin D2 mRNA levels by IL-2 in a pro-B cell line 57, and inhibited IL-
3 induced Cyclin D1 promoter activity58. Another STAT5 target gene implicated in 
playing a role in regulation of proliferation is Pim-1. Northern blot analysis demonstrated 
that constitutive activation of STAT5a in an IL-3 dependent cell line resulted in an up 
regulation of Cyclin D2, Bcl-x and Pim-1. Furthermore, ectopic expression of Pim-1 in 
Ba/F3 cells, resulted in IL-3 independent proliferation. Importantly, it has also been 
demonstrated that Pim-1 levels are high in leukemic cell lines which express 
constitutively activated STAT5 59.  
Although little is known about STAT5 target genes regulating differentiation, activation 
of p21WAF1/Cip1 60 and p27kip1, cyclin-dependent kinase inhibitors, have been demonstrated 
to be involved in megakaryocytic differentiation 61. Ectopic expression of both p21WAF/Cip1 
and p27kip1 in a human megakaryoblastic leukemia cell line resulted in induction of 
megakaryocyte differentiation. Ectopic expression of p21WAF/Cip1 also resulted in 
morphological differentiation of Ba/F3 cells 59. We have demonstrated that p21WAF/Cip1 
expression levels are upregulated during eosinophil differentiation. Ectopic expression of  
STAT5a also resulted in enhanced expression of p21WAF/Cip1 , whereas p21WAF/Cip1 
expression is reduced in cells transduced with dominant-negative STAT5a. This suggests 
that the transcriptional activation of p21WAF/Cip1 is involved in the STAT5 dependent 
eosinophil differentiation, by inducing a cell cycle arrest which might be necessary for 
induction of terminal differentiation.  
In chicken, it has been demonstrated that C/EBPa and C/EBPb 62 play an important role 
in regulating eosinophil differentiation 63. C/EBPs have been demonstrated to 
synergistically activate transcription with STAT5 in some promoter studies 64. For 
example, C/EBP is required for full basal promoter activity of the Oncostatin M promoter, 
an IL-6 subfamily member, while STAT5 is responsible for GM-CSF induced promoter 
activity 65. Furthermore, STAT5 has been demonstrated to induce transcriptional 
activation of b-casein 66; 67, whereas C/EBP binding sites are also required for hormonal 
transcription activation of b-casein 68; 69. It is possible that co-operation of STAT5 and 
C/EBPs are responsible for final maturation during eosinophil differentiation.  
The two STAT5 gene products, STAT5a and STAT5b, are highly homologous and are 
thought to have overlapping functional roles 70. Recently, it has been demonstrated that 
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STAT5b can be differentially regulated compared to STAT5a. Both isoforms are 
phosphorylated by Src kinases, whereas only STAT5b subsequently translocates to the 
nucleus  in NIH 3T3 cells Furthermore, it has been demonstrated that STAT5b may have 
unique transcriptional functions. For example, both STAT5a and STAT5b can regulate 
transcription of the Estrogen receptor-alpha, whereas regulation of the Estrogen receptor-
beta gene is exclusively mediated by STAT5b 71. These results suggest that STAT5a and 
STAT5b are non-redundant and can possess unique functions in some cell types. 
However, it has also been demonstrated that STAT5a and STAT5b posses redundant 
functions in T cells, including either Il-2 regulation of CD25 and NK cell function 72. 
Ectopic expression of either dominant-negative STAT5a or dominant-negative STAT5b in 
differentiating eosinophils resulted in a similar block in differentiation,  as well as 
comparable  reduced levels of proliferation. This indicates that during eosinophil 
differentiation the two STAT5 isoforms have similar, if not redundant functions.  
STAT5 expression and phosphorylation are high during early stages of eosinophil 
differentiation, whereas protein expression of STAT5 is down-regulated at later stages. 
This indicates that STAT5 might play a critical role mainly during early eosinophil 
differentiation. Indeed, transduction of cells with STAT5a results in an acceleration of 
differentiation, but does not result in cells with a more mature morphology. To support 
this hypothesis, it has been recently suggested that STAT5 plays a role in early 
hematopoiesis. In STAT5a (-/-) and 5b (-/-) knockout mice high numbers of early 
erythroblasts were observed, which could not progress in the differentiation process 73.  
Taken together, this is the first study which clearly demonstrates that STAT5a plays a 
critical role in human eosinophil differentiation. The precise molecular mechanism 
underlying this process remains to be clarified. However, our data suggests that 
transcriptional regulation of critical cell cycle and anti-apoptotic genes are important in 
regulating differentiation fate. 
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Abstract 
 
Hematopoiesis is a highly regulated process resulting in the formation of all blood 
lineages. The specific cytokine-induced signal transduction pathways responsible for 
modulating lineage choices are at the moment unresolved. Phosphatidylinositol 3-kinase 
(PI3K) has been reported to play a critical role in proliferation and survival of a variety of 
cell types, however, a role in regulating cell fate choices during hematopoiesis has not 
been intensively investigated. We have utilized an ex-vivo differentiation system, using 
human umbilical cord blood derived CD34+ hematopoietic progenitor cells, to investigate 
the role of PI3K in myeloid differentiation. Inhibition of PI3K, with the phamacological 
inhibitor LY294002, completely blocked proliferation and differentiation during 
granulopoiesis. To pin-point the molecular mechanisms responsible for this effect, we 
utilized specific pharmacological inhibitors of PKB or mTOR, both down-stream targets 
of PI3K. Inhibition of either mTOR or PKB blocked progenitor proliferation without 
affecting cell survival. Interestingly, inhibition of PKB, abrogated neutrophil maturation, 
but conversely enhanced terminal differentiation of eosinophils. Retroviral transductions 
were performed to force constitutive expression of active PKB (myrPKB) in CD34+ cells. 
Transduction of cells with myrPKB resulted in enhanced neutrophil differentiation 
compared to cells transduced with empty vector alone. Conversely, ectopic expression of 
myrPKB resulted in an almost complete block in eosinophil differentiation resulting in 
neutrophil differentiation. Taken together, these results demonstrate that PKB activity can 
play a critical role in the regulation of cell fate choices during myeloid lineage 
commitment. 
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Introduction 
 
Hematopoietic stem cells (HSCs) are defined as cells which can both undergo self-
renewal and differentiate towards all myeloid and lymphoid cell types. This HSC pool can 
be divided into two different sub-populations based on their functionality, long-term 
reconstituting HSCs (LT-HSCs) and short-term reconstituting HSCs (ST-HSCs). HSCs 
can differentiate to multipotent progenitor cells, which are themselves capable of 
differentiation towards a specific subset of hematopoietic lineages in response to 
cytokines and growth factors. These multipotent stem cells include both the common 
lymphoid precursor 1, and common myeloid precursor 2. Common myeloid progenitor 
cells, known as the CFU-GEMM (colony-forming unit granulocyte/ erythrocyte/ 
macrophage/ megakaryocyte) can selectively differentiate towards the erythroid, 
megakaryocytic and myelomonocytic lineage. 
Two different models have been proposed to understand hematopoiesis, a “stochastic” and 
an “inductive” model. In the stochastic model it is assumed that progenitor cells are 
randomly committed towards a certain lineage by an inherent, yet to be defined, 
mechanism and cytokine stimulation is merely required for their survival and 
proliferation. The inductive model, on the other hand, proposes that cytokines can 
specifically determine the outcome of each division and therefore specifically drive cell 
fate during differentiation. To date, no evidence has been presented excluding either of 
these models. Myeloid differentiation is supported by a variety of cytokines. For example, 
Erythropoietin (EPO), and Thrombopoietin (TPO) are required for differentiation of 
erythrocytes and megakaryocytes, respectively, while Granulocyte colony-stimulating 
factor (G-CSF), Macrophage colony-stimulating factor (M-CSF) and Interleukin-5 (IL-5) 
are both cricital and sufficient for terminal maturation of neutrophils 3, monocytes 4, and 
eosinophils 5; 6, respectively. Although it is evident that myelopoiesis requires the action 
of specific cytokines resulting in the regulation of several transcription factors, the signal 
transduction pathways mediating these stimulatory signals are at the moment unclear. The 
PI3K signal transduction pathway has been demonstrated to play an important role in 
survival and proliferation of hematopoietic cells and recent evidence suggests that PI3K 
may play a role in regulating hematopoiesis. Mice deficient for p110g, the catalytic 
subunit of the class 1b PI3K, demonstrated impaired T-lymphocyte development 7, while 
B-cell development is blocked at the pro-B cell stage in mice deficient of p85a, a 
regulatory subunit of the class 1a PI3K 8. Furthermore, PI3K activity has been 
demonstrated to be required for EPO induced eythropoiesis from CD34+ hematopoietic 
progenitors as well as for EPO mediated survival of erthroid precursors 9. However, from 
these experiments, it is unclear whether the reduction in mature cells is caused by 
inducing apoptosis in the progenitor cells rather than blocking the intrinsic differentiation 
program. Protein Kinase B (PKB) a serine/threonine kinase, also known as Akt, is an 
important effector of PI3K signaling 10; 11. PKB has been demonstrated to play an 
important role in regulating cell survival and proliferation in a variety of systems 12 
including hematopoietic cells. PKB has, for example, been demonstrated to promote 
survival of T-lymphocytes in transgenic mice ectopically expressing constitutively active 
PKB (gagPKB) 13. Analysis of PKB deficient mice has revealed that PKB plays an 
important role in organismal growth, and demonstrate both embryonic and postnatal  
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defects in growth 14- 17. A role for PKB in modulating hematopoiesis has however not been 
investigated. 
To determine whether PI3K-mediated signal transduction is critical for myelopoiesis an 
ex-vivo granulocyte differentiation system was utilized. Our data demonstrates that 
regulation of PKB activity is sufficient to directly modulate lineage choices.  
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Materials and Methods 
 
Isolation and culture of human CD34+ cells 
CD34+ cells were isolated as previously described 18. In short, mononuclear cells were 
isolated from umbilical cord blood by density centrifugation over a ficoll-paque solution 
(density 1.077 g/ml). MACS immunomagnetic cell separation (Miltenyi Biotech, Auburn, 
USA) using a hapten conjugated antibody against CD34, which was coupled to beads, was 
used to isolate CD34+ cells. CD34+ cells were cultured in Iscove’s Modified Dulbecco’s 
Medium (Gibco, Paisley, UK) supplemented with 10% FCS, 50 mM b-mercaptoethanol, 
10 U/ml penicillin, 10 mg/ml streptomycin, and 2mM glutamine at a density of 0.3 x 106 
cells/ml. Cells were differentiated towards eosinophils upon addition of SCF (50 ng/ml), 
FLT-3 ligand (50 ng/ml), GM-CSF (0.1 nmol/l), IL-3 (0.1 nmol/l), and IL-5 (0.1 nmol/l). 
Every 3 or 4 days, cells were counted and fresh medium was added to a density of 0.5 x 
106 cells/ ml. After 3 days of differentiation, only IL-3 and IL-5 were added to the cells.  
Neutrophil differentiation was induced upon addition of SCF (50 ng/ml), FLT-3 (50 
ng/ml) ligand, GM-CSF (0.1 nmol/l), IL-3 (0.1 nmol/l) and G-CSF (30ngl/ml). After 6 
days of culture only G-CSF was added to the cells. Pharmacological inhibitors were 
freshly added to the cells every 3 or 4 days. 10 mM LY294002 (Biomol, Plymouth 
meeting, PA) 20 mM of HIMO (1L-6-hydroxymethyl-chiro-inositol-2-(R)-2-O-methyl-3-
O-octadecylcarbonate) (Calbiochem, San Diego, CA), and 20 ng /ml rapamycin (Biomol, 
Plymouth meeting, PA ) were used to inhibited PI3K activity, PKB activity, and MTOR 
during granulopoiesis. 
 
Viral transduction of CD34+ cells 
A bicistronic retroviral DNA construct was utilized, consisting of myrPKB, and an 
Internal Ribosomal Entry Site (IRES) followed by the gene encoding for eGFP (LZRS-
eGFP), (kindly provided by H. Spits, Amsterdam, The Netherlands). LZRS-eGFP 
retrovirus was produced by transient transfection of the retroviral packaging cell line, 
Phoenix-ampho 19, by calcium phosphate co-precipitation. Cells were plated in 6-cm 
dishes, 24 hours before transfection. 5 minutes prior to transfection 25 mM chloroquine 
diphosphate was added to the cells. A total of 10 mg of DNA was used per transfection. 
Medium was refreshed, 16 hours after transfection. After an additional 24 hours, viral 
supernatants were collected and filtered through a 0.45 mm filter. 
CD34+ cells were transduced in 24 wells dishes pre-coated with 20 mg/cm2 recombinant 
human fibronectin fragment CH-296 (RetroNectin; Takara, Otsu, Japan) for two hours, 
and 2% BSA for 30 minutes. Transduction was performed by addition of 0.5 ml viral 
supernatant to 0.5 ml medium containing 0.5 x 106 cells. 24 hours after transduction, 0.7 
ml medium was removed from the cells and 0.5 fresh virus supernatant was added 
together with 0.5 ml fresh medium and cytokines (IL-3 and IL-5).  
 
Histochemical staining of eosinophil and neutrophil precursors 
May-Grunwald Giemsa staining was used to analyze both differentiating eosinophils and 
neutrophils. Cytospins were prepared from 5 x 104 differentiating eosinophils and were 
fixed in methanol for 3 minutes. After fixation, cytospins were stained in a 50% Eosin 
Methylene Blue solution according to May-Grunwald (Sigma-Aldrich GmbH, Seelze, 
Germany) for 15 minutes, rinsed in water for 5 seconds, and the nuclei were counter-
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stained with 10% Giemsa solution (Merck kGaA, Darmstadt, Germany) for 20 minutes. 
During eosinophil differentiation, different stages of maturation can be observed. Cells 
differentiate from blast cells towards pro-myelocyte type I, pro-myelocyte type II, 
myelocyte, meta-myelocyte, and finally mature eosinophils with segmented nuclei. These 
stages can be distinguished by the size of the cells, ratio of cytoplasm versus nucleus 
present, presence of azurophilic granules, appearance of eosinophilic granules and the 
shape of the nuclei. ‘Juvenile’ eosinophils were characterized as cells belonging to the 
stages of pro-myelocyte II, myelocyte, metamyelocyte and mature eosinophils. These 
cells were all observed to contain eosinophilic granules. Neutrophil differentiation can 
also be characterized by distinct stages from myeloblast, promyelocyte I, promyelocyte II, 
myelocyte and metamyelocytes towards neutrophils with banded or segmented nuclei. 
Differentiated neutrophils were characterized as cells containing either banded or 
segmented nuclei. 
Neutrophil differentiation was also analyzed by intracellular staing of lactoferrin. Cells 
were first washed in PBS and resuspended in 100 ml Intraprep fixation reagent ( 
Immunotech, Marseille, France). After 15 minutes incubation at room temperature, cells 
were washed with PBS and resuspended in 100 ml Intraprep permeabilisation reagent. 
After 5 minutes incubation at room temperature, PE-conjugated anti-lactoferrin (Beckman 
Coulter, Mijdrecht, the Netherlands) was added and incubated for another 25 minutes. 
Cells were again washed in PBS and the percentage of lactoferrin positive cells were 
subsequently detected by FACS analysis (FACS Vantage, Beckton Dickinson). 
 
Measurement of Apoptosis 
During granulocyte differentiation, the percentage of apoptotic cells was determined by 
analyzing Annexin-V positive cells. Cells were incubated for 20 minutes Annexin-V-
FITC (Bender Medsystems, Vienna, Austria) in Annexin binding buffer ( 10 mM Hepes 
NaOH pH 7.4, 150 mM NaCl, 2.5 mM CaCl2). Cells were subsequently washed and 
resuspended in binding buffer. Propidium Iodide was added (1 mg/ml) was added and the 
percentage of apoptotic cells was detected by FACS analysis.  
 
Migration assay 
Granulocyte migration was measured in the modified boyden Chamber assay as described 
20. Cellulose nitrate filter (pore width 8 mm, thickness 150 mm; Sartorius) were soaked in 
Iscove’s Modified Dulbecco’s Medium (Gibco, Paisley, UK) supplemented with 10% 
FCS, 50 mM b-mercaptoethanol, 10 U/ml penicillin, 10 mg/ml streptomycin, 2mM 
glutamine. The assays were performed for 2 hours at 37 oC in a CO2 incubator. Filters 
were fixed, stained with heamatoxyllin (Weigert’s method) and embedded in malinol. 
Analysis of the filters was done by an image analysis system (Quantimet 570 C) and an 
automated microscope to score the number of cells at 15 intervals of 10 mm in the Z-
direction of the fiters. The results are expressed as the chemotactic index, indicating the 
mean migrated distance, excluding non-migrating cells. 
 
Western Blot analysis 
Western blot analysis was performed using standard techniques. In short, for detection of 
FOXO3a phosphorylation, differentiating eosinophils were lysed in Laemmli buffer (0.12 
M Tris HCl pH 6.8, 4% SDS, 20% glycerol, 0.05mg/ml bromophenol blue, and 35 mM b- 
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mercaptoethanol), and boiled for 5 minutes. Equal amounts of total lysate were analyzed 
by 8% SDS-polyacrylamide gel electrophoresis. Proteins were transferred to Immobilon-P 
and incubated with blocking buffer (Tris Buffered Saline/Tween20 ) containing 5% BSA 
or low fat milk for 1 hour before incubating with either an anti-phosphoFOXO3 (T32) 
antibody (UBI, Veenendaal, The Netherlands), or an antibody against b-actin (Santa Cruz 
Inc, Santa Cruz, USA) for 16 hours in the same buffer. Subsequently, blots were 
incubated with peroxidase conjugated secondary antibodies (DAKO A/S, Glostrup, 
Denmark) for 1 hour. Enhanced Chemical Luminescence  (ECL) was used as a detection 
method according to the manufacturers protocol (Amersham Pharmacia, Amersham, UK). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                              Chapter 5 
 101 
 
Results 
 
PI3K is required for normal development of eosinophil progenitors. 
PI3K has been demonstrated to play an important role in both proliferation and survival of 
hematopoietic cells 7-9. In order to determine whether PI3K plays a critical role in 
regulating myelopoiesis, human umbilical cord blood derived CD34+ cells were 
differentiated to eosinophilic granulocytes in presence of a specific pharmacological 
inhibitor of PI3K, LY294002. Proliferation was determined by counting the total number 
of living cells as measured by Trypan blue exclusion (Figure 1a). In presence of the PI3K 
inhibitor LY294002, proliferation was completely abrogated during eosinophil 
differentiation. In order to investigate whether this inhibition of proliferation was due to 
enhanced apoptosis or a block in cell cycle progression, annexin-V staining was 
performed with differentiating cells. Although the percentage of annexin-V positive cells 
remained around 20% during eosinophil differentiation, the percentage of annexin-V 
positive, apoptotic cells increased dramatically after 10 days of differentiation in presence 
of LY294002 (Figure 1b). After 17 days of eosinophil differentiation, more than 60 % of 
the cells cultured in presence of LY294002 were annexin-V positive. 
Although the majority of the cells were apoptotic after 17 days of culture in presence of 
LY294002, it was of interest to investigate whether the few surviving cells demonstrated 
attenuated eosinophil differentiation. Cytospins were prepared after 14 and 17 days of 
culture, and the morphology of the differentiating granulocytes was analyzed by May-
Grunwald Giemsa staining as described in Materials and Methods (Figure 1c). The 
percentage of juvenile eosinophils is approximately 40 % after 17 days of normal 
eosinophil differentiation (Figure 1d). Treatment of cells with LY294002 completely 
blocked eosinophil differentiation at the promyelocytic stage and the percentage of 
juvenile eosinophils was less than 15 % after 17 days of culture. These data demonstrate 
that PI3K activity is critical for cell survival during granulopoiesis. 
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Figure 1. PI3K is required for normal development of eosinophil progenitors. Umbilical Cord Blood  (UCB) 
derived CD34+ cells were differentiated towards eosinophils in presence of the cytokines FLT-3 ligand, SCF, 
GM-CSF, IL-3, and IL-5. After 3 days of culture, cells were only cultured in presence of IL-3 and IL-5. The 
PI3K inhibitor LY294002 (20 mM) was added to the cells directly after isolation from cord blood and medium 
and inhibitor was refreshed every 3 days. (A) Proliferation was determined by counting the number of living 
cells. Results are presented as fold increase in cell numbers compared to day zero as an average of five 
independent experiments ± S.E.M. (B) The percentage of apoptotic cells was determined by flow cytometry 
analysis of the percentage of Annexin-V positive cells. Results were presented as an average of four independent 
experiments ± S.E.M. (C) Cytospins were made of differentiating eosinophils and stained with May-Grunwald 
Giemsa solution. (D) Eosinophil differentiation was expressed as percentage of juvenile eosinophils. Data was 
expressed as and average of four independent experiments ± S.E.M. 
 
PKB and mTOR are required for normal eosinophil development 
PI3K is required for many processes, and inhibiting PI3K completely blocks all down-
stream targets of PI3K and finally results in death of progenitors. To investigate whether 
PI3K plays a role in regulating granulopoiesis, PKB and mTOR, both downstream 
effectors, of PI3K were inhibited. To demonstrate the effectiveness of the PKB inhibitor 
(HIMO) we analyzed the effect of addition of this compound to progenitors on FOXO3a 
phosphorylation, a known substrate for PKB in vivo. Figure 2a demonstrates that addition 
of HIMO to eosinophil progenitors indeed blocked phosphorylation of FOXO3a. Cells 
differentiated towards eosinophils were cultured in absence or presence of either HIMO or 
rapamycin for 17 days (see Materials and Methods). Both HIMO and rapamycin 
significantly reduced proliferation during eosinophil differentiation (Figure 2b). In order 
to investigate whether this was due to enhanced levels of apoptosis, the percentage of 
annexin-V positive cells was determined (Figure 2c). In contrast to cells cultured in 
presence of LY294002, neither inhibition of PKB or mTOR resulted in increased levels of 
apoptosis, demonstrating that their activity is regulating cell-cycle progression. 
In order to determine whether both PKB and mTOR also play an important role in 
eosinophil differentiation per se, cells were differentiated towards eosinophils for 17 days 
in presence or absence of HIMO and rapamycin. Cytospins were prepared, and the 
morphology of the differentiating granulocytes was analyzed (Figure 2d). In untreated 
progenitors, the percentage of juvenile eosinophils was approximately 40 % after 17 days 
of differentiation (Figure 2e). However, eosinophil differentiation was dramatically 
enhanced in cells cultured in presence of HIMO, and terminally differentiated fully  
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mature eosinophils could be observed in these cultures. In contrast, inhibition of mTOR 
by rapamycin did not result in altered levels of differentiated eosinophils. In order to 
demonstrate that cells differentiated towards eosinophils in presence of HIMO were not 
only morphologically more mature but also functionally, a Boyden Chamber chemotaxis 
assay was performed (see Materials and Methods) (Figure 2f). Mature eosinophils are 
capable of migrating through a nitrocellulose filter upon stimulation with 
chemoattracttants such as C5a. Migration, after C5a stimulation, was dramatically 
improved in cells differentiated towards eosinophils in presence of HIMO, demonstrating 
also increased functional competence of these cells.  
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Figure 2. PKB and mTOR are required for normal eosinophil development. HIMO (20 mM) and rapamycin 
(20 ng/ml) were added to the cells directly after isolation from cord blood and medium and inhibitors were 
refreshed every 3 day. (A) Protein lysates were made from freshly isolated CD34+ cells and cells cultured either 
in absence of presence of HIMO. Western blot analysis was performed with an antibody against phosphorylated 
FOXO3a or as a control for equal loading an antibody against b-actin. The experiment shown is representative of 
three independent experiments. (B) Proliferation was determined by counting the living cells. Results are 
presented as fold increase in cell numbers compared to day zero as an average of six individual experiments ± 
S.E.M. (C) The percentage of apoptotic cells was determined by flow cytometry analysis of the percentage of 
Annexin-V positive cells. Results were presented as an average of three independent experiments ± S.E.M. (D) 
Cytospins were made of differentiating eosinophils and stained with May-Grunwald Giemsa solution. (E) 
Eosinophil differentiation was expressed as percentage of juvenile eosinophils. Data was expressed as and 
average of three independent experiments ± S.E.M. (F) Eosinophil migration in the Boyden chamber was 
stimulated with C5a (10-7 M). The results are expressed as chemotactic index as an average of three independent 
experiments  ± S.E.M. 
 
PI3K activity plays a critical role in neutrophil survival 
Our data suggest that activation of PI3K-PKB signaling is critical for terminal eosinophil 
differentiation. It is, therefore, of interest to know whether this pathway plays an 
important role in granulopoiesis in general, or specifically regulates eosinophil 
differentiation. In order to address this question directly, CD34+ hematopoietic progenitors 
were differentiated towards neutrophils for 17 days in absence or presence of the PI3K 
inhibitor LY294002. Comparable to eosinophil differentiation, proliferation was 
completely blocked in cells cultured in presence of LY294002 (Figure 3a). Furthermore, 
the percentage of apoptotic cells, determined by annexin-V staining, was dramatically 
increased after 17 days of culture in presence of LY294002 (Figure 3b). 
Again to determine whether PI3K, similar to eosinophil differentiation, plays a critical 
role in neutrophil differentiation per se, cytospins were prepared from the surviving cells, 
and the morphology of the differentiating neutrophils was analyzed by May-Grunwald 
Giemsa  (Figure 3c). Neutrophil differentiation was defined as the percentage of cells 
consisting of banded or segmented nuclei, and the percentage of differentiated neutrophils 
is expressed in Figure 3d. Neutrophil differentiation was inhibited in cells cultured in 
presence of the inhibitor LY294002, and the percentage of cells with banded or segmented 
nuclei after 17 days of differentiation remained far below that of untreated cultures. Thus  
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PI3K activity is critical for the survival and normal development of hematopoietic 
progenitors during both eosinophil and neutrophil differentiation. 
 
PKB activity is required for neutrophil differentiation  
To determine whether PKB activity can also critically regulate neutrophil differentiation, 
cells differentiated in the presence of G-CSF were cultured in absence or presence of 
HIMO. Proliferation was reduced in cells cultured in presence of HIMO compared to 
control cells (Figure 4a). Similar to eosinophil differentiation, inhibition of PKB did not 
result in increased levels of apoptosis during neutrophil development (Figure 4b).  
However, in complete contrast to eosinophil differentiation, terminal differentiation of 
neutrophils was inhibited in cells cultured in presence of HIMO. After 17 days of 
neutrophil differentiation, approximately 30 % of the cells consisted of banded or 
segmented nuclei, whereas only 15 % of the cells cultured in  
presence of HIMO were characterized as mature neutrophils (Figure 4d). Thus, in contrast 
with eosinophil differentiation, down-regulation of PKB activity appears to be detrimental 
for both proliferation and differentiation during neutrophil development.  
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Figure 4. PKB activity is required for neutrophil differentiation. HIMO (20 mM) was  added to the cells 
directly after isolation from cord blood and medium and inhibitors were refreshed every three day. (A) 
Proliferation was determined by counting the number of living cells. Results are presented as fold increase in cell 
numbers compared to day zero as an average of five independent  experiments ± S.E.M. (B) The percentage of 
apoptotic cells was determined by flow cytometry analysis of the percentage of Annexin-V positive cells. 
Results were presented as an average of three independent experiments ± S.E.M. (C) Cytospins were made from 
differentiating neutrophils asn were stained with May-Grunwald Giemsa solution. (D) Neutrophil differentiation 
was expressed as percentage of maturing neutrophils. Data was expressed as and average of six independent 
experiments ± S.E.M. 
 
Activation of PKB inhibits eosinophil differentiation, but enhances neutrophil 
differentiation 
In order to confirm the results obtained by treatment of differentiating cells with a 
pharmacological inhibitor of PKB, a bicistronic retroviral plasmid was utilized co- 
expressing an active form of PKB (myrPKB) and eGFP. Retrovirus was generated and 
used to infect CD34+ cells, differentiated towards either eosinophils or neutrophils. eGFP 
positive cells were sorted by FACS from the non-transduced cells and cytospins were 
prepared. The morphology of the differentiating neutrophils were subsequently analyzed 
by May-Grunwald Giemsa staining (Figure 5a). Ectopic expression of myrPKB resulted in 
increased percentages of neutrophils with banded or segmented nuclei (Figure 5b). Similar 
results were obtained utilizing the neutrophil specific granule protein lactoferrin as a 
marker for neutrophil differentiation (Figure 5c). 
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Transduction of cells with eGFP alone resulted in approximately 60% juvenile eosinophils 
after 17 days of culture in presence of IL-5, of which the majority were mature 
myelocytes or meta-myelocytes. Ectopic expression of myrPKB, however, resulted in a 
complete block of eosinophil differentiation and less than 10 % of the cells were juvenile 
eosinophils after 17 days of differentiation (Figure 5d and 5e). Interestingly, 
approximately 70% of the cells had differentiated towards the neutrophil lineage in the 
absence of G-CSF, of which approximately 45% cells with banded or segmented nuclei 
(Figure 5f). Furthermore, the percentage of lactoferrin positive cells increased from 
approximately 2% in normal eosinophil differentiation to about 16% in cells ectopically 
expressing myrPKB (Figure 5g). Whereas neutrophil development was dramatically 
induced in cells expressing myrPKB, the percentage of monocytic cells also slightly 
increased in presence of IL-5 (data not shown). These data clearly demonstrate that PKB 
activity is not only critical for myelopoiesis, but that it can also determine lineage 
commitment decisions.  
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Figure 5. Activation of PKB inhibits eosinophil differentiation, but enhances neutrophil differentiation. 
CD34+ cells were transduced with eGFP or myrPKB. After 14 and 17 days of neutrophil differentiation, 
transduced cells were separated from the non-transduced cells, and cytospins were made. (A) Cytospins were 
made from differentiating neutrophils and were stained with May-Grunwald Giemsa solution. (B) Neutrophil 
differentiation was expressed as percentage maturing neutrophils. Data was expressed as and average of four 
independent experiments ± S.E.M. (C) Neutrophil differentiation was also analyzed by the percentage of 
lactoferrin positive cells. Results were expressed as an average of three individual experiments ± S.E.M. (D) 
After 14 and 17 days of eosinophil differentiation, transduced cells were sorted and cytospins were stained with 
May-Grunwald Giemsa staining. (E) Eosinophil differentiation was expressed as the percentage of juvenile 
eosinophils as an average of three individual experiments ± S.E.M. (F) The percentage of developing neutrophils 
during IL-5 induced differentiation was presented as an average of three independent experiments ± S.E.M. (G) 
The percentage of lactoferrin positive cells during IL-5 induced differentiation was presented as an average of 
three individual experiments ± S.E.M. 
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Discussion 
In this study we have investigated the role of the PI3K-PKB mediated signal transduction 
pathway during granulopoiesis. Inhibition of PI3K completely blocked proliferation and 
differentiation in progenitor cells, ultimately resulting in cell death. Our data demonstrates 
that inhibition of two downstream targets of PI3K, PKB and mTOR, block proliferation in 
progenitor cells without inducing apoptosis. Furthermore, down-regulation of PKB 
activity is required for terminal differentiation of eosinophils but conversely it inhibits 
final maturation of neutrophils. In addition, ectopic expression of a constitutively 
activated PKB (myrPKB) demonstrates that high levels of PKB activity are detrimental 
for eosinophil differentiation, inducing neutrophil differentiation even in the absence of 
G-CSF. 
 
Previously it has been demonstrated that inhibition of PI3K induces apoptosis in mature 
granulocytes. For example, LY294002 blocks IL-3 induced survival in basophils 21, and 
abrogates GM-CSF and IL-8 delayed apoptosis in neutrophils 22. Similarly , GM-CSF was 
unable to rescue spontaneous apoptosis in neutrophils mice deficient of p85, the 
regulatory subunit of PI3K 23. Our data demonstrates that, during granulopoiesis, 
inhibition of PI3K in early progenitors does not induce apoptosis. The percentage of 
apoptotic cells only increases after extended culture in presence of LY294002. This could 
be explained by the hypothesis that it is the combined block in proliferation and 
differentiation that actually results in induction of programmed cell death by intrinsic 
control signals, indirectly of PI3K.  
An important difference between early and mature hematopoietic cells is the expression of 
anti- and pro-apoptotic proteins. Human CD34+ hematopoietic stem cells express both 
Bcl-2 and Bcl-Xl at relatively high levels compared to mature granulocytes, whereas the 
expression of pro-apoptotic proteins, such as Bad, Bak, and Bax, is very low 24. We have 
previously demonstrated that Bcl-2 and Bcl-Xl are highly expressed in early progenitors 
and are both down-regulated during terminal differentiation of eosinophils 25.The 
observation that inhibition of PI3K does not immediately induce apoptosis in early 
granulocyte progenitors but only after extended culture, could be due to the high levels of 
Bcl-2 in these early progenitors.  
Recently it has been demonstrated that PKB not only plays an important role in 
proliferation and survival of cells but can also play a role in regulation of differentiation. 
PKB has, for example, been demonstrated to positively regulate neuronal differentiation 
of P19 cells 26. Neurogenin-3 is a bHLH transcription factor that plays an important role in 
neuronal differentiation 27. PKB has been demonstrated to significantly enhance the 
transcriptional activity of neurogenin-3 by inducing complex formation between 
neurogenin-3 and the co-activators p300 and CBP, suggesting that PKB induces neuronal 
differentiation via regulation of the activity of bHLH transcription factors 26. Similarly, 
PKBb positively regulates muscle development in C2.7 myeloblasts 28 by inducing 
transcription of MyoD. MyoD is also a bHLH transcription factor that plays a critical role 
in muscle development. Interestingly, PKB expression itself is upregulated by MyoD 
thereby creating a positive feedback loop between MyoD and PKBb during muscle 
differentiation 29.  
Our data clearly demonstrates that PKB activity is critical for successful neutrophil 
differentiation, whereas down-regulation of PKB activity is required for maturation of  
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eosinophils. Although the regulatory mechanisms underlying granulocyte differentiation 
by PKB are at the moment unclear, it is tempting to hypothesize that PKB, similar to 
muscle development and neuronal differentiation, regulates the activity of one or more 
bHLH transcription factors. Recently PKB has also been shown to regulate a subfamily of 
Forkhead transcription factors (FOXO) by direct phosphorylation resulting in inactivation 
30. The function of FOXO3a has been investigated by the observation of FOXO3a 
knockout mice. FOXO3a deficient mice exhibit, among other abnormalities, hematologic 
disturbances, including a mild anemia 31. Unfortunately, the exact hematological 
deficiencies, as observed in peripheral blood, have so far not been described. In addition, 
retroviral transduction of a constitutively active FOXO3a mutant in mouse bone marrow  
derived progenitor cells resulted in decreased numbers of myeloid and erythroid colonies 
32. In this study, it was hypothesized that increased levels of apoptosis, resulted in the 
decreased numbers of CFUs. Whereas PKB is activated by a variety of cytokines and 
growth factors including G-CSF and IL-5, additional signal transduction pathways are 
most likely involved in down-regulation of PKB activity in order to enable eosinophil 
differentiation. Rho GTPase, a member of the Ras superfamily of small GTP binding 
proteins, is capable of down-regulating PKB activity in human endothelial cells 33. 
Although it has been demonstrated that PKB activity is down-regulated via Rho kinase 
(Rock), the exact mechanism of PKB inhibition is at the moment unknown. Stromal cells, 
in vivo, have been demonstrated to induce granulopoiesis 34. Since Rho can be activated 
by integrins 35, it could be speculated that cell contact between stromal cells and 
granulocyte precursors induces activation of Rho and subsequent inhibition of PKB 
activity, which is required to induce eosinophil development. Another known inhibitor of 
PI3K signaling is SHIP (SH2-containing inositol-5-phosphatase) which hydrolyzes PIP3 
to form PIP2 and thus inhibits PKB activation 36. SHIP is highly expressed in the bone 
marrow 37 and has been demonstrated to play a role in hematopoiesis. Although SHIP 
knockout mice exhibited no differences in the absolute numbers of white blood cells, a 
substantial increase in the percentage of circulating monocytes and neutrophils in 
peripheral blood and their progenitors in the spleen and bone marrow was observed. 
Interestingely, at the age of 8-10 weeks the percentage of eosinophils in the peripheral 
blood, determined by Wright-Giemsa staining, was decreased 38; 39. These data support the 
hypothesis that regulation of PKB activity plays a role in cell fate determination. 
Recently, two specific modulators of PKB activity have been described; Trb3 40 and 
Carboxy-Terminal Modulator Protein (CTMP) 41. CTMP has been demonstrated to be 
expressed in many different tissues 41, whereas Trb3 has been demonstrated to be 
expressed in liver 40. Both proteins are capable of inhibiting PKB activation by direct 
association. Although not much is known regarding the mechanisms regulating Trb3 and 
CTMP activity it would be of interest to investigate whether regulation of their expression 
is critical in modulating PKB activity and thus lineage choice decisions. 
Another protein implicated to play an important role in cell fate determination is PKC. In 
hematopoietic progenitors, transformed by the avian E26 leukemia virus, has been 
demonstrated that high levels of PKC results in eosinophil differentiation, whereas 
conversely low levels of PKC activity induces myeolomonocytic differentiation 42. 
Although a role for the regulation of PKB by PKC is somewhat controversial, recent 
evidence demonstrated that inhibition of PKCb resulted in enhanced PKB activity. 43. In  
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addition, PKB activity is negatively regulated by PKCz due to a direct interaction between 
both molecules 44. 
Interestingly, inhibition of eosinophil differentiation, by ectopic expression of 
constitutively active PKB, enables neutrophil differentiation in absence of G-CSF. 
Conversely, however, inhibition of neutrophil differentiation by inhibition of PKB does 
not enable eosinophil differentiation. This suggests that neutrophil differentiation may be 
the “default” pathway in granulopoiesis. Furthermore, our data suggests that PKB activity 
has to be actively down-regulated to enable eosinophil development. It is tempting to 
speculate that regulation of granulopoiesis is mediated by an inductive process in which 
PKB activity is modulated by cytokines rather than a stochastic process in which the 
relative expression levels of PKB pre-determines cell fate. Indeed, we were unable to find 
differences in PKB expression levels among populations of freshly isolated CD34+ 
progenitors (data not shown). Our data also supports the notion that hematopoietic 
progenitor cells are not “pre-programmed” to become a certain lineage during early 
myelopoiesis, but that lineage choices can be subsequently made upon stimulation with 
cyokines and growth factors. Although the precise molecular mechanisms responsible for 
down-regulation of PKB activity to enable eosinophil differentiation in vivo remain to be 
established, this is the first study that clearly demonstrates that PKB activity plays a 
critical role in lineage choices during hematopoiesis.  
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Abstract 
 
p38 MAPKs have been shown to play an important role in regulation of a variety of 
cellular processes. Although p38 has been demonstrated to regulate differentiation of 
several cell types, its role in regulation of granulopoiesis remains to be established. 
Utilizing an ex-vivo hematopoietic differentiation system, we have investigated whether 
p38 activity is required for regulation of eosinophil and neutrophil maturation from human 
cord blood derived CD34+ cells. Inhibition of p38 with the specific phamacological 
inhibitor SB203580 resulted in inhibition of both proliferation as well as differentiation 
during eosinophil differentiation. Conversely, inhibition of p38 during neutrophil 
development enhanced both proliferation as well as differentiation. These data 
demonstrate that p38 plays an important, but differential role in lineage development 
during myelopoiesis. 
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Introduction 
 
A plethora of external stimuli mediate their intracellular responses, in part, through   
members of the Mitogen-Activated Protein Kinases (MAPK) family. This group of 
kinases consists of three major sub-types: the extracellular signal-regulated kinases 
(ERK), c-Jun N-terminal Kinases (JNK), and p38 MAPKs (p38) (reviewed in 1). To date, 
four different p38 isoforms have been observed in mammals, p38a, -b,-g, and -d 2-5. 
Although p38 was initially described as a stress-activated protein kinase 6, it has become 
evident that its activity is important for the regulation of a variety of cellular processes 
including proliferation, survival, apoptosis, and differentiation in a cell type specific 
manner. Similar to other MAP-kinases, p38 is activated through a kinase cascade: MAPK 
kinase kinase (MKKK or MEKK) activates a MAPK kinase (MKK or MEK), which in 
turn activates MAPK via dual phosphorlyation of a Thr-X-Tyr motif  7. MKK6 directly 
phosphorylates all p38 isoforms, while MKK3 is more restricted and activates only p38a, 
p38g and p38d, 4; 8-11, while MKK4 only activates p38a 12 . Upon activation, p38 can 
phosphorylate several downstream targets including the kinases MAPKAP2 and –3 13; 14. 
p38 also phosphorylates the small heat shock protein Hsp27 15 and several transcription 
factors, including C/EBPb 16 ATF-1/2 17, CHOP 18 and STAT1 and STAT3 19. 
It is evident that myeloid differentiation is regulated by specific cytokines resulting in the 
activation of several transcription factors. The signal transduction pathways mediating 
these stimulatory signals remain however unclear. p38 MAPK activity can be regulated by 
several hematopoietic cytokines such as IL-3 20, GM-CSF 21, IL-5 22, and G-CSF 23. IL-3, 
and GM-CSF play an important role in regulating proliferation and survival during 
differentiation of various myeloid lineages. In contrast, G-CSF, and IL-5 are lineage 
restricted and are required for final maturation of neutrophils 24, and eosinophils 25; 26 
respectively. Various substrates of p38, such as C/EBPb are considered to play an 
important role in hematopoiesis 27. Our data demonstrates that p38 plays an important role 
in regulating proliferation in a lineage specific manner during granulopoiesis. 
Proliferation was enhanced by incubation of progenitors with a pharmacological inhibitor 
of p38 activity (SB203580) during neutrophil differentiation. On the other hand, 
proliferation was inhibited during eosinophil development. Furthermore, inhibition of p38 
resulted in enhanced maturation of neutrophils but inhibited terminal differentiation of 
eosinophils. These data suggest that regulation of p38 activity plays a critical role in 
regulating the outcome of granulopoiesis. 
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Materials and Methods 
 
Isolation and culture of human CD34+ cells 
CD34+ cells were isolated as previously described 28. In short, mononuclear cells were 
isolated from umbilical cord blood by density centrifugation over a ficoll-paque solution 
(density 1.077 g/ml). MACS immunomagnetic cell separation (Miltenyi Biotech, Auburn, 
USA) using a hapten conjugated antibody against CD34, which was coupled to beads, was 
used to isolate CD34+ cells. CD34+ cells were cultured in Iscove’s Modified Dulbecco’s 
Medium (Gibco, Paisley, UK) supplemented with 10% FCS, 50 mM b-mercaptoethanol, 
10 U/ml penicillin, 10 mg/ml streptomycin, and 2mM glutamine at a density of 0.3 x 106 
cells/ml. Cells were differentiated towards eosinophils upon addition of SCF (50 ng/ml), 
FLT-3 ligand (50 ng/ml), GM-CSF (0.1 nmol/l), IL-3 (0.1 nmol/l), and IL-5 (0.1 nmol/l). 
Every three days, cells were counted and fresh medium was added to a density of 0.5 x 
106 cells/ ml. After three days of differentiation, only IL-3 and IL-5 were added to the 
cells. Neutrophil differentiation was induced upon addition of SCF (50 ng/ml), FLT-3 (50 
ng/ml) ligand, GM-CSF (0.1 nmol/l), IL-3 (0.1 nmol/l) and G-CSF (30ngl/ml). After six 
days of culture only G-CSF was added to the cultures. 
 
Histochemical staining of eosinophil and neutrophil precursors 
May-Grunwald Giemsa staining was used to analyze both differentiating eosinophils and 
neutrophils. Cytospins were prepared from 5 x 104 granulocyte precursors and were fixed 
in methanol for 3 minutes. After fixation cytospins were stained in a 50% Eosin 
Methylene Blue solution according to May-Grunwald (Sigma-Aldrich GmbH, Seelze, 
Germany) for 15 minutes, rinsed in water for  5 seconds, and the nuclei were counter-
stained with 10% Giemsa solution (Merck kGaA, Darmstadt, Germany) for 20 minutes. 
During eosinophil differentiation, different stages of maturation can be observed. Cells 
differentiate from blast cells towards pro-myelocyte type I, pro-myelocyte type II, 
myelocyte, meta-myelocyte, and finally mature eosinophils with segmented nuclei. These 
stages can be distinguished by the size of the cells, ratio of cytoplasm versus nucleus 
present, presence of azurophilic granules, appearance of eosinophilic granules and the 
shape of the nuclei. ‘Juvenile’ eosinophils were characterized as cells belonging to the 
stages of pro-myelocyte II, myelocyte, metamyelocyte and mature eosinophils. These 
cells were all observed to contain eosinophilic granules. Neutrophil differentiation can 
also be characterized by distinct stages from myeloblast, promyelocyte I, promyelocyte II, 
myelocyte and metamyelocytes towards neutrophils with banded or segmented nuclei. 
‘Differentiated’ neutrophils were characterized as cells containing either banded or 
segmented nuclei. 
 
Measurement of Apoptosis 
During granulocyte differentiation, the percentage of apoptotic cells was determined by 
analyzing Annexin V positive cells. Cells were incubated for 20 minutes Annexin V-FITC 
(Bender Medsystems, Vienna, Austria) in Annexin binding buffer ( 10 mM Hepes NaOH 
pH 7.4, 150 mM NaCl, 2.5 mM CaCl2). After 20 minutes of incubation at room 
temperature, cells were washed and resuspended in binding buffer. Propidium Iodide was 
added (1 mg/ml) and the percentage of apoptotic cells was detected by FACS analysis.  
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Results 
 
Regulation of proliferation during granulocyte differentiation by p38 
In order to determine whether p38 activity plays a critical role in regulating 
granulopoiesis, umbilical cord blood (UCB) derived hematopoietic progenitor cells were 
incubated either in absence or presence of the specific p38 inhibitor SB203580. Cells were 
subsequently cultured for 17 days in presence of IL-5 or G-CSF resulting in eosinophil or 
neutrophil differentiation, respectively. Proliferation was determined by counting the total 
numbers of living cells, as determined by trypane blue exclusion. Proliferation during 
eosinophil differentiation was decreased in cells cultured in presence of SB203580 
(Figure 1a). 
In order to determine whether this SB203580 mediated inhibition of proliferation was due 
to enhanced apoptosis, Annexin-V binding was analyzed in differentiating cells after 3, 
10, and 17 days of culture. In cells treated either with or without SB203580 the percentage 
of annexin V positive cells was approximately 15% after three days of culture and no 
differences were observed during the entire 17 day period of differentiation (Figure 1b). 
Thus these data demonstrate that p38 is indeed required for optimal proliferation during 
eosinophil differentiation, but is not required for progenitor survival. Surprisingly, in 
contrast to the situation observed with eosinophil differentiation, proliferation was 
actually enhanced during neutrophil differentiation in the presence of SB203580 (Figure 
1c), and this was not due to enhanced survival (Figure 1d ).  
These data demonstrate that p38 activity has the potential to modulate the number of 
granulocytes produced in a lineage specific manner. 
 
 
 
 
 
 
A B
0
100
200
300
400
500
0 3 7 10 14 17
Eosinophil differentiation
(days)
Pr
ol
if
er
at
io
n
(f
ol
d
in
du
ct
io
n)
Control
SB203580
0
20
40
60
80
100
3 10 17
Eosinophil differentiation 
(days)
A
nn
ex
in
-V
po
si
tiv
e 
ce
lls
(%
)
Control
SB203580
Pr
ol
if
er
at
io
n
(f
ol
d
in
du
ct
io
n)
A
nn
ex
in
-V
po
si
tiv
e 
ce
lls
(%
)
Pr
ol
if
er
at
io
n
(f
ol
d
in
du
ct
io
n)
A
nn
ex
in
-V
po
si
tiv
e 
ce
lls
(%
)
                                                                                                                              Chapter 6 
 123 
 
 
 
Figure 1. Regulation of proliferation during granulopoiesis by p38 MAPK. Umbilical Cord Blood (UCB) 
derived CD34+ cells were differentiated towards eosinophils in presence of FLT-3 ligand, SCF, GM-CSF, IL-3, 
and IL-5. After 3 days of culture, cells were only cultured in presence of IL-3 and IL-5 for eosinophil 
differentiation or G-CSF for neutrophil development. The p38 inhibitor SB203580 (10 mM) was added to the 
cells directly after isolation from cord blood and every three days medium and inhibitor were refreshed. 
Proliferation during (A) eosinophil differentiation and (C) neutrophil development was determined by counting 
the living cells. Results are presented as fold increase in cell numbers compared to day zero as an average of four 
individual experiments ± S.E.M.. The percentage of apoptotic cells during (B) eosinophil and (D) neutrophil 
differentiation was determined by flow cytometry analysis of the percentage of Annexin-V positive cells. Results 
were presented as an average of three independent experiments ± S.E.M. 
 
Regulation of granulopoiesis by p38 
In order to investigate whether p38 also plays a role in regulating granulopoiesis per se, 
CD34+ progenitors were differentiated towards eosinophils or neutrophils for 17 days 
either in presence or absence of SB203580. After 17 days of differentiation, the 
morphology of the differentiating eosinophils and neutrophils was analyzed by May-
Grunwald Giemsa staining as described in Materials and Methods (Figure 2a). After 17 
days of culture, inhibition of p38 resulted in a 50% reduction in the percentage of juvenile 
eosinophils (Figure 2b). Conversely, inhibition of p38 resulted in increased percentages of 
neutrophils with banded or segmented nuclei (Figure 2c, and 2d). These data clearly 
demonstrate that p38 plays an important but differential role in regulation of neutrophil 
and eosinophil development during granulopoiesis. p38 activity is required for eosinophil 
differentiation but is detrimental for neutrophil development.  
 
 
C D
0
50
100
150
200
250
300
350
0 3 7 10 14 17
Neutrophil differentiation 
(days)
Pr
ol
ife
ra
tio
n
(f
ol
d
in
du
ct
io
n)
Control
SB203580
0
20
40
60
80
100
3 10 17
Neutrophil differentiation 
(days)
A
nn
ex
in
-V
 p
os
iti
ve
ce
lls
(%
)
Control
SB203580
Pr
ol
ife
ra
tio
n
(f
ol
d
in
du
ct
io
n)
A
nn
ex
in
-V
 p
os
iti
ve
ce
lls
(%
)
Regulation of p38 MAPK modulates granulocyte numbers 
 124 
 
 
Figure 2. Regulation of granulopoiesis by p38 MAPK. CD34+ cells were differentiated to either eosinophils or 
neutrophils for 17 days after which cytospins were made. (A) Cytospins were stained with May-Grunwald 
Giemsa solution. (B) Eosinophil differentiation was expressed as percentage juvenile eosinophils. Data was 
expressed as and average of three independent experiments ± S.E.M. (C) Cytospins were stained with May-
Grunwald Giemsa staining, (D) and neutrophil differentiation was expressed as the percentage of  differentiated 
neutrophils as an average of three independent experiments ± S.E.M. 
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Discussion 
In this study we have investigated the role of p38 MAPK in regulation of granulopoiesis. 
Our data demonstrates that inhibition of p38 activity is detrimental for proliferation of 
eosinophil precursors, and down-regulates terminal differentiation of these granulocytes. 
In contrast, inhibition of p38 activity actually enhances both proliferation as well as final 
maturation during neutrophil differentiation. This is the first example that demonstrates 
that regulation of p38 can modulate lineage choices during granulopoiesis. 
p38 has been proposed to play an important role in regulating proliferation of various cell 
types, although no consensus is present as to the molecular mechanisms. p38 has, for 
example, been demonstrated to positively regulate proliferation during erythropoiesis 
from human CD34+ derived erythroid progenitors 29, and several erythroid cell lines 30-32; 
32; 33. In contrast, p38 negatively regulates proliferation in fibroblasts 34; 35 and during 
muscle development 36. Our data demonstrates that p38 inhibits proliferation during 
eosinophil differentiation, but conversely enhances proliferation during neutrophil 
development. The difference between the eosinophil and neutrophil progenitors might be 
explained by the observation that different p38 isoforms can have opposing functions. For 
example, AP-1 dependent transcription of the vitamin D receptor and cellular proliferation 
are activated by p38b, whereas both p38d, and p38g inhibit these processes 37. Similarly, 
p38a can induce apoptosis in Hela cells, whereas p38b induces survival in the same cells 
38. This suggests that the expression pattern of the p38 isoforms could determine whether 
p38 activation results in either enhanced or decreased levels of proliferation. Although no 
studies have so far investigated the expression of p38 isoforms in granulocyte progenitors 
it is possible that during early eosinophil and neutrophil differentiation alternative p38 
isoforms are expressed. However, it cannot be excluded that p38 substrates such as 
C/EBPb, CHOP, or ATF-2 are themselves differentially expressed in eosinophil and 
neutrophil progenitors, resulting in differential effects of p38 on transcription.  
p38 has been suggested to play a role in regulation of differentiation of several cell types 
including muscle development, and endothelial cell differentiation. In K562 cells 30; 31 , 
SKT-6 cells 33; 39, and UT-7 cells 32 erythrocyte development is regulated by p38 activity, 
and it has been demonstrated that hemoglobinization and morphological differentiation is 
p38-dependent. In contrast, in human cord blood derived erythroid progenitors, 
erythropoiesis is not inhibited by down-regulation of p38 activity 29. Although p38 
activation has also been suggested to negatively regulate neutrophil differentiation of the 
leukemic cell line HL60 40, the discrepancy between primary erythrocyte progenitors and 
leukemic cell lines exemplified that it is necessary to perform studies in primary human 
cord blood derived progenitor cells. Neutrophil differentiation from HL60 cells was only 
induced upon treatment with very high concentrations of SB203580 (60mm), at which the 
inhibitor is likely to have aspecific effects. In contrast to primary neutrophil progenitors 
(Figure 1c), proliferation was inhibited in these cells 40. We demonstrate that with much 
lower concentrations of SB203580, neutrophil proliferation and differentiation was 
increased. Although the precise molecular mechanism underlying the process of p38 
mediated granulopoiesis remains to be clarified, these data suggest that p38 activity plays 
an important role in regulating granulocyte differentiation from human cord blood derived 
progenitors. Modulating p38 activity can potentially regulate the numbers of eosinophils 
and neutrophils produced from progenitors during granulopoiesis. 
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Abstract 
 
The Id family of transcriptional regulators function as inhibitors of members of the basic 
Helix-Loop-Helix family of transcription factors and have been demonstrated to play an 
important role in regulating lymphocyte differentiation. While these proteins are 
expressed in myeloid progenitors, it is currently unclear whether they also regulate 
myelopoiesis. In this study, we have investigated the role of Id1 and Id2 in the regulation 
of eosinophil and neutrophil differentiation from human cord blood derived CD34+ 
progenitors. Id1 expression was initially upregulated during early granulopoiesis, which 
was then followed by a decrease in expression during the final phase of maturation. In 
contrast, Id2 expression was upregulated in terminally differentiated granulocytes. In 
order to determine whether timing of Id expression plays a critical role in regulating 
granulopoiesis, Id1 and Id2 were ectopically expressed in CD34+ cells by retroviral 
transduction. Our experiments demonstrate that constitutive expression of Id1 inhibits 
both proliferation and differentiation during eosinophil development, whereas in contrast 
neutrophil differentiation was modestly enhanced. Constitutive Id2 expression inhibits 
proliferation but stimulates final maturation of both eosinophil and neutrophil lineages. 
These data demonstrate that the correct temporal expression of both Id1 and Id2 plays a 
critical, although differential role in granulopoiesis. 
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Introduction 
 
Basic Helix-Loop-Helix (bHLH) transcription factors have been demonstrated to play a 
critical role in a wide variety of developmental processes, including neurogenesis 1, 
myogenesis 2, and hematopoiesis 3. The family of bHLH proteins consists of three distinct 
groups. The first encompasses the E-proteins, which consists of four different members: 
E2-2, HEB, and the E2a encoded proteins E21, and E47. They are ubiquitously expressed, 
and can both homodimerize and heterodimerize with the second class of bHLH 
transcription factors which are cell-type or tissue-specific 4. This group of tissue-specific 
transcription factors, also referred to as Class B proteins, consists of several factors which 
are involved in development of distinct cell types. For example, Human Achaete-Scute 
Homologue-1 (HASH-1) 5, Neurogenin 6 and NeuroD 7, are all involved in neurogenic 
development, whereas MyoD 8, and Myogenin 9;10 are required for normal muscle 
differentiation. Class B bHLH transcription factors have also been shown to play an 
important role in hematopoiesis. For example, both SCL/Tal-1 3 and Lyl-1 11 are required 
for normal hematopoiesis and play a role in development of  T-cell acute lymphoblastic 
leukemia. 
Heterodimerization of bHLH transcription factors results in the formation of a parallel 
four-helix bundle which allows both DNA binding domains to associate with the E-box 
recognition site 12. Transcriptional activity of these transcription factors is inhibited by a 
third group of bHLH transcription factors, the Id proteins, which lack the basic DNA 
binding domain. To date, four known Id proteins have been identified 13-18 , which are 
closely related in their HLH regions but differ in their expression patterns 19;20. It has been 
demonstrated that Id1 mRNA levels are often high in proliferating cells, but is down-
regulated in quiescent or differentiating cells 21. In contrast, Id2 mRNA levels have been 
shown to be up-regulated during differentiation of the leukemic HL60 cell line towards 
either granulocytes or macrophages 22. Id proteins have recently been demonstrated to play 
a critical role in lymphopoiesis, for example, by inhibiting B-lymphocyte development at 
an early stage of differentiation as has been demonstrated for Id1, Id2 and Id3 23;24 
Furthermore, T-lymphocyte differentiation is inhibited by Id3 25;26. In contrast, NK-cell 
development is positively regulated by both Id2 27;28 and Id3 25, suggesting a role for Id 
proteins in regulating specific lineage choices during lymphopoiesis 
In this study we have investigated for the first time the role of Id1 and Id2 in regulation of 
granulocyte differentiation utilizing a human ex-vivo granulocyte differentiation model. 
Our data demonstrates that both Id1 and Id2 play an important role in regulating 
proliferation during granulocyte differentiation. Furthermore, constitutive expression of 
Id1 blocked eosinophil differentiation, whereas conversely, Id2 expression enhanced both 
eosinophil and neutrophil differentiation. These data demonstrate that the both Id1 and Id2 
have distinct functions and correct temporal regulation of their expression is critical for 
granulopoiesis. 
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Materials and Methods 
 
Isolation and culture of human CD34+ cells 
CD34+ cells were isolated as previously described 29. In brief, mononuclear cells were 
isolated from umbilical cord blood by density centrifugation over a ficoll-paque solution 
(density 1.077 g/ml). MACS immunomagnetic cell separation (Miltenyi Biotech, Auburn, 
USA) using a hapten conjugated antibody against CD34, which was coupled to beads, was 
used to isolate CD34+ cells. CD34+ cells were cultured in Iscove’s Modified Dulbecco’s 
Medium (Gibco, Paisley, UK) supplemented with 10% FCS, 50 mM b-mercaptoethanol, 
10 U/ml penicillin, 10 mg/ml streptomycin, and 2mM glutamine at a density of 0.3 x 106 
cells/ml. Cells were differentiated towards eosinophils upon addition of SCF (50 ng/ml), 
FLT-3 ligand (50 ng/ml), GM-CSF (0.1 nmol/l), IL-3 (0.1 nmol/l), and IL-5 (0.1 nmol/l). 
Every three days, cells were counted and fresh medium was added to a density of 0.5 x 
106 cells/ ml. After three days of differentiation, only IL-3 and IL-5 were added to the 
cells. Neutrophil differentiation was induced upon addition of SCF (50 ng/ml), FLT-3 (50 
ng/ml) ligand, GM-CSF (0.1 nmol/l), IL-3 (0.1 nmol/l) and G-CSF (30ngl/ml). After 6 
days of culture only G-CSF was added to the cells. 
 
Viral transduction of CD34+ cells 
A bicistronic retroviral DNA construct was utilized, expressing either Id1 (kindly 
provided by Dr. H. Spits, Amsterdam, The Netherlands) or Id2, and an Internal Ribosomal 
Entry Site (IRES) followed by the gene encoding for eGFP (LZRS-eGFP). LZRS-eGFP 
retrovirus was produced by transient transfection of the retroviral packaging cell line, 
Phoenix-ampho 30, by calcium phosphate co-precipitation. Cells were plated in 6-cm 
dishes, 24 hours before transfection. Five minutes prior to transfection 25 mM chloroquine 
diphosphate was added to the cells. A total of 10 mg of DNA was used per transfection. 
Medium was refreshed, 16 hours after transfection. After an additional 24 hours, viral 
supernatants were collected and filtered through a 0.45 mm filter. CD34+ cells were 
transduced in 24 wells dishes pre-coated with 20 mg/cm2 recombinant human fibronectin 
fragment CH-296 (RetroNectin; Takara, Otsu, Japan) for two hours, and 2% BSA for 30 
minutes. Transduction was performed by addition of 0.5 ml viral supernatant to 0.5 ml 
medium containing 0.5 x 106 cells. 24 hours after transduction, 0.7 ml medium was 
removed from the cells and 0.5 fresh virus supernatant was added together with 0.5 ml 
fresh medium. 
 
Histochemical staining of eosinophil and neutrophil precursors 
May-Grunwald Giemsa staining was used to analyze both differentiating eosinophils and 
neutrophils. Cytospins were prepared from 5 x 104 differentiating granulocytes and were 
fixed in methanol for 3 minutes. After fixation cytospins were stained in a 50% Eosin 
Methylene Blue solution according to May-Grunwald (Sigma-Aldrich GmbH, Seelze, 
Germany) for 20 minutes, rinsed in water for  5 seconds, and the nuclei were counter-
stained with 10% Giemsa solution (Merck kGaA, Darmstadt, Germany) for 15 minutes. 
During eosinophil differentiation, cells could be characterized as differentiating from blast 
cells towards pro-myelocyte type I, pro-myelocyte type II, myelocyte, meta-myelocyte, 
and finally mature eosinophils with segmented nuclei. These stages can be distinguished 
by the size of the cells, ratio of cytoplasm versus nucleus present, presence of azurophilic  
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granules, appearance of eosinophilic granules and the shape of the nuclei. “Differentiated 
eosinophils” were characterized as cells belonging to the stages of myelocyte, 
metamyelocyte and mature eosinophils, whereas juvenile eosinophils were characterized 
as cells belonging to the promyelocyte II, myelocytes, metamyelocytes and mature 
eosinophils. Neutrophil differentiation can also be characterized by distinct stages form 
myeloblast, promyelocyte I, promyelocyte II, myelocyte, and metamyelocytes towards 
neutrophils with banded or segmented nuclei. “Differentiated neutrophils” were 
characterized as cells containing either banded or segmented nuclei. 
 
Western Blot analysis 
Western blot analysis was performed using standard techniques. In brief, for detection of 
Id1 and Id2 expression, differentiating granulocytes were lysed in Laemmli buffer (0.12 
M Tris HCl pH 6.8, 4% SDS, 20% glycerol, 0.05mg/ml bromophenol blue, and 35 mM b-
mercaptoethanol), and boiled for 5 minutes. Equal amounts of total lysate were analyzed 
by 15% SDS-polyacrylamide gel electrophoresis. Proteins were transferred to Immobilon-
P and incubated with blocking buffer (Tris Buffered Saline/Tween20) containing 5% low 
fat milk for 16 hours at 4 oC before incubating with either an Id1 antibody (Santa Cruz 
Inc., Santa Cruz, USA), an Id2 antibody (Santa Cruz Inc., Santa Cruz, USA) or an 
antibody against b-actin (Santa Cruz Inc, Santa Cruz, USA) for 2 hours in the same 
buffer. Subsequently, blots were incubated with peroxidase conjugated secondary 
antibodies for 1 hour. Enhanced Chemical Luminescence (ECL) was used as a detection 
method according to the manufacturers protocol (Amersham Pharmacia, Amersham, UK). 
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Results 
 
Id1 and Id2 protein expression is regulated during granulocyte differentiation 
CD34+ progenitor cells, isolated from umbilical cord blood, were differentiated towards 
eosinophils or neutrophils in presence of the cytokines IL-3, and IL-5 or G-CSF, 
respectively, as described in Materials and Methods. In order to investigate the regulation 
of Id expression during granulopoiesis, protein lysates were made from differentiating 
eosinophils and neutrophils. Proteins were separated by SDS-PAGE and western blotting 
was performed utilizing an antibody against either Id1 (Figure 1a, 1b) or Id2 (Figure 1c). 
The Id1 antibody, however, has cross-reactivity with Id2 (lower band). Id1 expression 
could not be detected in freshly isolated CD34+ progenitors, however, after three days of 
either eosinophil or neutrophil differentiation, Id1 expression was transiently up-regulated 
(Figure 1a). During extended culture the expression levels were again down-regulated 
(Figure 1b). In contrast, during the early stages of eosinophil differentiation, Id2 could not 
be detected, while levels were up-regulated during final maturation (Figure 1c). During 
neutrophil differentiation on the other hand, Id2 protein expression was very low and only 
modestly up-regulated (Figure 1c). These experiments suggest a possible difference in the 
regulation of eosinophil and neutrophil differentiation by Id proteins. 
 
 
Figure 1. Id protein expression is regulated during granulocyte differentiation. Umbilical cord blood derived 
CD34+ cells were differentiated towards eosinophils or neutrophils in presence of the cytokines FLT-3 ligand, 
SCF, GM-CSF, IL-3 and IL-5 or G-CSF. After three days of culture, eosinophil progenitors were cultured in 
presence of IL-3 and IL-5, whereas neutrophil progenitors were cultured in presence of G-CSF alone after six  
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days of culture. (A). Protein lysates were made from freshly isolate CD34+ cells (lane 2) and cells differentiated 
for three days in presence of IL-5 (lane 1) or G-CSF (lane 3) and Western Blot analysis was performed with an 
antibody against Id1 (top panel), and as a control for equal loading with an antibody against b- Actin (bottom 
panel). The experiment shown is representative of three independent experiments. (B) Protein lysates were made 
after 7, 10 , 14 , and 17 days of differentiation and western blot analysis was performed with an antibody against 
Id1 (top panel), and as a control for equal loading with an antibody against b-Actin (bottom panel) (C) or with an 
antibody against Id2. The experiment shown is representative of three independent experiments. 
 
Id1 inhibits eosinophil differentiation but enhances neutrophil development 
To determine whether the timing and expression level of Id1 plays a critical role in 
regulating eosinophil differentiation, a bicistronic retroviral DNA construct co-expressing 
eGFP and Id1 was utilized to generate retrovirus and subsequently to infect CD34+ cells 
(Figure 2a). Cells were subsequently differentiated towards eosinophils for 17 days. The 
percentage of eGFP positive cells corresponds to the percentage of transduced cells and 
was determined by FACS analysis (Figure 2b). During differentiation, a decrease in the 
percentage of eGFP positive cells after transduction with Id1 was observed, relative to 
control. This suggests that Id1 might play a role in inhibiting proliferation during 
eosinophil differentiation. In order to determine whether this is indeed the case, 
proliferation was determined by counting the total amount of eGFP positive cells. 
Transduction of cells with Id1 indeed resulted in decreased proliferation compared to cells 
tranduced with eGFP alone (Figure 2c). In order to investigate whether Id1 also plays a 
role in eosinophil differentiation per se, cells were again transduced with either eGFP, or 
Id1. After 14, and 17 days of differentiation, eGFP positive cells were sorted by FACS 
from the non-transduced cells and cytospins were prepared (Figure 2d). The morphology 
of the differentiating cells was analyzed by May Grunwald Giemsa staining as described 
in Materials and Methods. The percentage of differentiated eosinophils after transduction 
with Id1 was dramatically inhibited compared to cells transduced with eGFP alone (Figure 
2e). After 17 days of differentiation, the majority of the cells ectopically expressing Id1, 
were promyelocyte type I and II, whereas after 17 days of normal eosinophil development 
the majority of the cells were mature myelocytes and metamyeloyctes (Table I ). 
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Figure 2. Eosinophil differentiation is inhibited by Id1. (A) Protein lysates were prepared from CD34+ cells 
transduced with eGFP or Id1 and a Western Blot was performed with an N-terminal antibody against Id1 (top 
panel) and as a control for equal loading with an antibody against b-Actin (bottom panel). CD34+ cells were 
transduced with eGFP or Id1 and cultured in presence IL-5 for 17 days. (B) The percentages of eGFP positive 
cells were determined by FACS analysis after 7, 10, 14, and 17 days of differentiation. Results are expressed as 
an average of three independent experiments ± S.E.M. (C) Proliferation was determined by counting the eGFP 
positive cells. Results are expressed as fold increase in cell numbers compared with day seven as an average of 
three independent experiments ± S.E.M. (D) CD34+ cells were transduced with eGFP or Id1. After 14, and 17 
days of differentiation transduced cells were separated from the non-transduced cells, and cytospins were made. 
Cytospins were stained with May-Grunwald Giemsa solution. (E) Eosinophil differentiation was expressed as 
percentage of differentiated eosinophils within the eosinophil lineage. Data was expressed as an average of three 
independent experiments ± S.E.M. 
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Table I Id1 inhibits eosinophil differentiation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The above data suggest that correct temporal expression of Id1 plays a critical role in 
normal eosinophil differentiation. To determine whether this protein plays an important 
role in granulopoiesis in general, we analyzed the effect of constitutive Id1 expression 
during neutrophil maturation (Figure 3a). Interestingly, proliferation (Figure 3b) as well as 
differentiation during neutrophil development (Figure 3c and 3d, Table 2) was modestly 
enhanced in cells ectopically expressing Id1. These data suggest that Id1 plays a distinct 
role in regulation of the two lineages: down-regulation of Id1 is an absolute requirement 
for eosinophil differentiation, but is not required for neutrophil maturation. 
 
 
Table II. Id1 enhances neutrophil differentiation 
 
 
 
 
Id1 eGFP 
9,8 ± 3,3 9,0 ± 2,3 8,1 ± 3,6 6,2 ± 4,6 Segmented 
35,1 ± 9,8 32,7 ± 7,2 23,5 ± 5,2 25,4 ± 7, 4 
18,2 ± 9,3 18,4 ± 9,3 22,8 ± 9,1 24,9 ± 8,7 Myelocyte 
36,9 ± 9,2 39,8 ± 15,2 33,6 ± 10,6 35,1 ± 9,5 Myeloblast/ 
Promyelocyte I/II 
Day 17 Day 14 Day 17 Day 14 Stages of  neutrophil differentiation 
Metamyelocyte/ 
Banded 
Id1 eGFP 
0,3 ± 0,3 4,7 ± 4,5 7,8 ± 7,4 4,5 ± 3,7 Metamyelocy te/ 
Mature 
8,1 ± 1,3 21,5 ±4,9 42,5 ± 15,6 42,0 ± 6,4 Myelocyte 
29,5 ± 7,8 29,9 ± 5,8 26,8 ± 8,9 35,9 ± 5,6 Promyelocyte II 
61,9 ± 6,7 43,9 ± 6,2 22,8 ± 6,9 17,5 ± 6,6 Myeloblast/ 
Promyelocyte I 
Day 17 Day 14 Day 17 Day 14 Stages of  eosinophil 
dif ferentiation 
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Figure 3. Constitutive Id1 expression enhances neutrophil differentiation. CD34+ cells were transduced with 
eGFP or Id1 and cultured in presence of G-CSF for 17 days. (A) The percentages of eGFP positive cells were 
determined by FACS analysis after seven, 10, 14, and 17 days of differentiation. Results are expressed as an 
average of three independent experiments ± S.E.M. (B) Proliferation was determined by counting the eGFP 
positive cells. Results are expressed as fold increase in cell numbers compared with day seven as an average of 
three independent experiments ± S.E.M. (C) CD34+ cells were transduced with eGFP or Id1. After 14, and 17 
days of neutrophil differentiation transduced cells were separated from the non-transduced cells, and cytospins 
were made. Cytospins were stained with May-Grunwald Giemsa solution. (D) Neutrophil differentiation was 
expressed as percentage of differentiated neutrophils within the neutrophil lineage. Data was expressed as and 
average of three independent experiments ± S.E.M. 
 
Constitutive Id2 expression induces granulocyte differentiation 
In contrast to Id1, Id2 expression was upregulated during eosinophil differentiation. In 
order to investigate the relevance of this observation, UCB derived CD34+ cells were 
transduced with either eGFP or Id2 (Figure 4a). We observed a decrease in the percentage 
of eGFP positive cells after transduction with Id2, compared to controls (Figure 4b). This 
suggests that Id2, similarly to Id1, might play a role in regulating proliferation during 
eosinophil differentiation. To test this hypothesis, proliferation was determined by 
counting the total amount of eGFP positive cells. Indeed, transduction of cells with Id2 
resulted in a decreased proliferation compared to cells transduced with eGFP alone  
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(Figure 4c). Cells were subsequently transduced with either eGFP or Id2 to investigate 
whether Id2 plays a role in eosinophil differentiation per se. After 14, and 17 days of 
differentiation, eGFP positive cells were sorted by FACS from the non-transduced cells 
and cytospins were prepared (Figure 4d). Differentiation was analyzed by May Grunwald 
Giemsa staining as described in Materials and Methods. The percentage of differentiated 
eosinophils within the eosinophil lineage was enhanced in cells ectopically expressing Id2 
compared to the control cells (Figure 4e, Table 3). The percentage of juvenile eosinophils 
was similar in cells constitutively expressing Id2 compared to control cells, suggesting 
that it is only final maturation which is regulated by Id2 (Table III). Thus, early 
constitutive expression of Id2 results in an increased percentage of differentiated 
eosinophils. 
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Figure 4. Constitutive Id2 expression enhances eosinophil differentiation. (A) Protein lysates were prepared 
from CD34+ cells transduced with eGFP or Id2 and a western blot was performed with an N-terminal antibody 
against Id2 (top panel) and as a control for equal loading with an antibody against b-Actin (bottom panel). 
CD34+ cells were transduced with eGFP or Id2 and cultured in presence IL-5 for 17 days. (B) The percentages of 
eGFP positive cells were determined by FACS analysis after 7, 10, 14, and 17 days of differentiation. Results are 
expressed as an average of three independent experiments ± S.E.M. (C) Proliferation was determined by 
counting the eGFP positive cells. Results are expressed as fold increase in cell numbers compared with day 
seven as an average of three independent experiments ± S.E.M. (D) CD34+ cells were transduced with eGFP or 
Id2. After 14, and 17 days of differentiation transduced cells were separated from the non-transduced cells, and 
cytospins were made. Cytospins were stained with May-Grunwald Giemsa solution. (E) Eosinophil 
differentiation was expressed as percentage of differentiated eosinophils within the eosinophil lineage. Data was 
expressed as and average of three independent experiments ± S.E.M. 
 
Table III. Id2 enhances eosinophil differentiation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In order to investigate whether Id2 is also capable of regulating neutrophil differentiation, 
cells were transduced with either eGFP or Id2 and were subsequently differentiated in the 
presence of G-CSF towards neutrophils for 17 days (Figure 5a). Transduction of cells with  
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Id2 eGFP 
14,1 ± 5,9 12,4 ± 3,9 4,7 ± 1,6 4,5 ± 1,9 Metamyelocyte/ Mature 
63,1 ± 3,7 62,5 ± 4,7 43,8 ± 13,0 38,2 ± 13,3 Myelocyte 
7,6 ± 3,5 2 1,4 ± 7,7 39,8 ± 10,7 36,3 ± 8,9 Promyelocyte II 
15,1 ± 9,9 6,5 ± 3,5 13,4 ± 8,8 20,9 ± 8,8 Myeloblast/ Promyelocyte I 
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Id2 resulted in a slight decrease in proliferation (Figure 5b), whereas neutrophil 
maturation was significantly enhanced (Figure5c, 5d, Table IV). These data demonstrate 
that Id2 expression is involved in regulating both eosinophil and neutrophil development. 
 
 
Figure 5. Constitutive Id2 expression induces neutrophils differentiation. CD34+ cells were transduced with 
eGFP or Id2 and cultured in presence of G-CSF for 17 days. (A) The percentages of eGFP positive cells were 
determined by FACS analysis after 7, 10, 14, and 17 days of differentiation. Results are expressed as an average 
of three independent experiments ± S.E.M. (B) Proliferation was determined by counting the eGFP positive 
cells. Results are expressed as fold increase in cell numbers compared with day seven as an average of three 
independent experiments ± S.E.M. (C) CD34+ cells were transduced with eGFP or Id2. After 14, and 17 days of 
neutrophil differentiation transduced cells were separated from the non-transduced cells, and cytospins were 
made. Cytospins were stained with May-Grunwald Giemsa solution. (D) Neutrophil differentiation was 
expressed as percentage of maturing neutrophils within the neutrophil lineage. Data was expressed as and 
average of three independent experiments ± S.E.M. 
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Table IV. Id2 enhances neutrophil differentiation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Id2   eGFP     
16,4±  6,2   12,2 ± 5,4   7,9 ± 1,7   3,0 ± 2,6   Segmented   
49,6 ± 2,9   40,5 ± 4,8   45,5 ± 7,9   27,9 ± 7,3   
16,2 ± 1,7   13,0 ± 2,7   22,3 ±  9,0   24,7 ± 10,9   Myelocyte   
  
17,8 ± 2,0   34,3 ±  8,6   24,4 ± 6,7    44,4 ±  16,5   Myeloblast/   Promyelocyte I/II   
Da y 17   Day 14   Day 17   Day 14   
Stages of neutrophil   
differentiation   
Metamyelocyte/   
Banded   
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Discussion 
 
In this study, we have investigated the role of Id proteins during granulopoiesis. Our data 
demonstrates that expression of Id proteins is differentially regulated during eosinophil 
and neutrophil differentiation. Id1 expression is initially upregulated during early 
granulopoiesis and is down-regulated during final maturation, whereas Id2 expression is 
highly upregulated during eosinophil differentiation and is moderately enhanced in 
terminally differentiated neutrophils. Furthermore, we also demonstrate that ectopic 
expression of Id1 inhibits both proliferation and differentiation during eosinophil 
development, whereas neutrophil differentiation was modestly enhanced by Id1. In 
contrast, ectopic expression of Id2 inhibits proliferation and stimulates final maturation of 
granulocytes. 
 
Id proteins are considered as positive regulators of proliferation in a variety of cell types 
31-35. Interestingely, however, our data demonstrates that Id proteins can inhibit 
proliferation during granulopoiesis. Id proteins primarily function by heterodimerization 
with bHLH transcription factors, thereby inhibiting their transcriptional activity 36. The 
bHLH transcription factor SCL/Tal1 is primarily expressed in hematopoietic cells 37;38, 
and plays an important role in both primitive and definitive hematopoiesis during 
embryogenesis and is embryonic lethal, as observed in SCL (-/- )mice 39;40. In the adult 
hematopoietic system, SCL has been demonstrated to play an important role in the 
generation of erythrocytes and megakaryocytes 41.  In addition, enforced expression of 
SCL in human CD34+ hematopoietic stem cells, resulted in enhanced colony growth and 
size during megakaryocyte and erythrocyte development, which was attributed to a 
shortened cell cycle time 42. SCL is highly expressed in hematopoietic stem cells and is 
rapidly down-regulated during early stages of monocyte and granulocyte development 
43{Condorelli, Tocci, et al. 1997 ID: 252}. Ectopic expression of SCL in a granulocytic 
cell line (HL60 cells), results in enhanced levels of proliferation and inhibits 
differentiation 43. We observed an inhibition in proliferation during eosinophil 
differentiation in CD34+ hematopoietic progenitors ectopically expressing Id1. It is 
tempting to speculate that Id1 in these hematopoietic precursors associates with SCL and, 
thereby, inhibits proliferation. 
It has recently been suggested that enhanced differentiation induced by Id proteins is 
regulated by an alternative, bHLH independent, mechanism. Recent studies have revealed 
that Id proteins are also capable of association with several other classes of proteins 
besides bHLH transcription factors. These include MIDA1 44;45 Pax2, Pax5, and Pax8 46 
Elk-1 47 c-ets-1 48 and members of the family of retinoblastoma proteins 49-51.Knock-down 
of MIDA1 (Mouse Id Associated 1), by treatment with antisense RNA, resulted in 
decreased levels of proliferation in erythroleukemic cells 52. It has been demonstrated that 
Id1 association with MIDA1 results in disruption of its binding to DNA 53, suggesting that 
association of Id1 with MIDA1 can inhibit proliferation.  Whereas MIDA1 expression has 
only been observed in a small number of cell types, including erythroid leukemic cells, it 
would be of interest to investigate whether MIDA1 is expressed in human hematopoietic 
precursors in general. 
Id proteins have been demonstrated to play an important role in negatively regulating 
differentiation of several of hematopoietic lineages, including lymphocyte development.  
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Id2 deficient mice exhibit enhanced levels of mature B-lymphocytes in the spleen, 
indicating that Id2 expression may inhibit B-cell development 34. Furthermore, both Id1 54 
and Id3 24 have been shown to inhibit B-lymphocyte development at an early stage of 
differentiation. In addition to its role in regulating B-cell development, Id3 has also been 
demonstrated to down-regulate T-lymphocyte differentiation 25;26. Similarly, our data 
clearly demonstrates that ectopic expression of Id1 inhibits eosinophil differentiation, and 
suggests that Id1 expression needs to be down-regulated to enable eosinophilopoiesis. 
Although Id proteins, in general, are considered to be inhibitors of differentiation, recent 
studies have suggested that they are also capable of positively regulating differentiation in 
specific cell types, such as during NK-cell development. In Id2 deficient mice, for 
example, NK-cell development was completely abolished 27;28. In addition, studies with 
Id2 (-/-) knockout mice revealed that Id2 expression is required for the development of a 
specific subset of dendritic cells 55. Our data demonstrates that Id2 expression positively 
regulates granulopoiesis, and supports the hypothesis that Id proteins can have different 
cell-type specific functions. 
While different members of the family of Id proteins have been demonstrated to inhibit 
similar bHLH proteins, the question is raised as to why ectopic expression of Id1 and Id2, 
in our ex-vivo differentiation model, has distinct effects? In contrast to Id1, Id2 can 
associate with Retinoblastoma proteins and thereby abrogate Rb mediated growth arrest 
50;51. In addition, Id proteins possess several potential phosphorylation sites, and it has 
been demonstrated that Id2, Id3, Id4, but not Id1 can be phosphorlyated by the CyclinD-
CDK2 complex 56. It is thought that phosphorylation of Id2 is required for cell cycle 
progression, and ectopic expression of a non-phosphorylatable Id2 mutant was found to 
inhibit cells growth 57. It is, therefore, tempting to speculate that phosphorylation of Id 
proteins might differentially regulate their functions during terminal differentiation. 
Furthermore, it has been demonstrated that there are differences in efficiency in 
association between different Id proteins and bHLH transcription factors. Id2 for example, 
is less efficient in associating with bHLH transcription factors compared to Id1 57. In 
addition, Id1 associates more efficiently with PAX5, required for B-cell development, 
compared to Id2. The differences in ability to bind to other proteins might play an 
important role in differentially regulating differentiation of certain cell types. 
Ectopic expression of Id1 in cells cultured in presence of IL-5, blocked eosinophil 
differentiation at an early stage. Interestingly, an increase in the percentage of cells 
belonging to the neutrophil lineage could be observed in some experiments (Figure 2d). 
Neutrophil differentiation in the presence of G-CSF was also a modestly enhanced by 
ectopic expression of Id1. In contrast, Id2 expression enhances granulocyte differentiation 
in general. Although the regulatory mechanisms by which Id proteins regulate 
differentiation of specific cell types remains to be investigated, these data clearly 
demonstrate that the correct temporal expression of both Id1 and Id2 play a critical, 
though differential, role in granulocyte differentiation of primary human hematopoietic 
cells. 
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Aberrant regulation of hematopoiesis can lead to severe clinical conditions ranging from
myeloproliferative disorder to severe immune deficiencies. It is therefore important to
understand the molecular mechanisms underlying these processes. The work described in
this thesis was performed to further enhance our knowledge on the regulation of cell fate
choices during granulopoiesis. To accomplish this, an ex-vivo differentiation system was
utilized, which allowed us to investigate the mechanisms underlying granulocyte
differentiation in human cord blood derived CD34+ cells.  Retroviral transduction
experiments enabled us to ectopically express genes of interest and to determine their role
in regulating granulopoiesis.
Regulation of life and death in granulocyte progenitors
Despite the fact that many groups have investigated the regulation of survival in mature
hematopoietic cells, the mechanisms modulating cell survival and apoptosis during early
hematopoiesis are poorly defined. One known difference between regulation of survival in
mature hematopoietic cells and HSCs is the role of Fas, a member of the TNF receptor
family. Programmed cell death or apoptosis can be initiated by either the activation of
death receptors such as Fas or by intracellular signals resulting, for example, from growth
factor deprivation. Fas expression in mature hematopoietic cells is usually sufficient to
induce apoptosis upon interaction with its ligand FasL 1; 2, however, TNFa induced Fas
expression in HSCs results in inhibition of cell growth without inducing apoptosis 3; 4.
Over-expression of the anti-apoptotic protein Bcl-2 hematopoietic cell lines reduces Fas-
induced apoptosis in these cells 5; 6. Thus it is possible that the difference between HSCs
and mature hematopoietic cells can explained by differential expression levels of anti-
apoptotic genes between both cell types. Human CD34+CD38-/low hematopoietic stem cells
express Bcl-2 at relatively high levels compared to mature granulocytes, whereas the
expression of pro-apoptotic proteins, such as Bad, Bak, and Bax, is conversely very low 7.
We demonstrate in Chapter 4 that Bcl-2 and Bcl-Xl are both highly expressed in early
progenitors and down-regulated during terminal differentiation of eosinophils. However,
inhibition of Bcl-2 and Bcl-XL expression, by ectopic expression of dominant-negative
STAT5a during eosinophil differentiation, was insufficient to induce apoptosis in
progenitor cells. This suggests that it is also the absence of anti-apoptotic proteins
prohibits the induction of death in these cells. Similarly, inhibition of PI3K activity did
not induce apoptosis in early differentiating granulocytes, whereas in mature granulocytes
and other hematopoietic cells inhibition of this kinase rapidly induces apoptosis 8; 9.
Furthermore, p38 MAPK has also been demonstrated to induce or inhibit apoptosis,
depending on the cell type 10. Inhibition of p38 during granulopoiesis did not affect
survival of granulocyte progenitors (Chapter 6). Taken together, inhibition of either PI3K,
STAT5, or p38, all demonstrated to be involved in regulating survival in mature
hematopoietic cells, did not affect survival in granulocyte progenitors, demonstrating that
the cells are particularly insensitive to death inducing signals. Interestingly, addition of a
cell-permeable tat-peptide consisting of the BH3 domain of the anti-apoptotic protein Bim
was sufficient to induce apoptosis in eosinophil precursors (Chapter 4), suggesting that the
apoptotic machinery is present but cannot be activated by blocking a single anti-apoptotic
signalling pathway. Thus, multiple signal transduction pathways appear to have redundant
functions in protecting progenitor cells from apoptosis. Our data suggest that the dramatic
decrease in expression levels of anti-apoptotic Bcl-2 proteins during terminal maturation
 General Discussion
154
(Chapter 4), probably combined with an increase in pro-apoptotic Bcl-2 proteins, makes
mature cells more susceptible for apoptosis compared to granulocyte precursors.
STAT5 and Id2 can influence granulopoiesis in general, while Id1 regulates specific
cell fate choices
All myeloid lineages, including granulocytes, monocytes, and erythrocytes, originate from
the CFU-GEMM, also known as the common myeloid progenitor. Cytokines are required
for normal maturation of hematopoietic progenitors. IL-3 and GM-CSF are considered to
be primarily involved in proliferation and survival of hematopoietic precursors, while
other cytokines are more restricted and have been demonstrated to play a critical role in
terminal maturation. For example, IL-5 and G-CSF are considered to be essential for
eosinophil and neutrophil differentiation, respectively. Since the activity of transcription
factors can be regulated by cytokines, it was of interest to investigate which transcription
factors are involved in granulopoiesis from human cord blood derived CD34+ cells.
Ectopic expression of STAT5 in CD34+ cells revealed that this transcription factor is
required for both proliferation and differentiation during eosinophil and neutrophil
development. Since STAT5(-/-) knockout mice also exhibited decreased numbers of
lymphocytes and myelocytes 11, it appears that STAT5 is required for hematopoiesis in
general, and is not involved in specific lineage choices.
Another transcription factor previously demonstrated to play a role in regulating
hematopoiesis is Id2. Id proteins can block the function of bHLH transcription factors in
regulating proliferation and differentiation, and have been demonstrated to play an
important role in regulation of  lineage choices during lymphoid development. Ectopic
expression of Id2 has been demonstrated to induce NK-cell development 12; 13 and
differentiation of dendritic cells 14. In contrast, development of both B- and T-
lymphocytes 15 is inhibited by Id2. These results suggest that Id2 plays a critical role in
regulating lymphocyte development. Our data demonstrates that ectopic expression of Id2
can promote both eosinophil and neutrophil differentiation (Chapter 7). This suggests that
Id2 is not involved in regulating specific lineage decisions during granulopoiesis, but
appears to play a general role in regulating granulocyte differentiation. However, our data
do not exclude that Id2 plays a role in regulating cell fate choices at an earlier phase in
myelopoiesis, for example between erythrocytes and granulocytes. Ectopic expression of
Id1, another member of the Id family of transcription factors, has  been demonstrated to
inhibit hematopoiesis in general 16; 17. Our data, however, demonstrate that ectopic
expression of Id1 inhibits eosinophil differentiation in presence of IL-5 but only
moderately enhances neutrophil differentiation in presence of G-CSF (Chapter 7). This
suggests that regulation of Id1 expression may play a role in regulating lineage choices
during granulopoiesis. High levels of Id1 inhibits eosinophil differentiation, allowing a
default neutrophil development pathway to predominate.
PKB activity plays a critical role in regulation of lineage choices during
granulopoiesis
Many transcription factors have been demonstrated to play an important role in
myelopoiesis and are suggested to play a role in cell fate decisions (see Chapter 1).
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However, the signal transduction pathways responsible for the regulation of transcription
factor activity upon external stimuli are at the moment poorly understood. In chapter 5, we
demonstrated that the PI3K-PKB signaling pathway plays an important role in regulation
of cell fate determination during granulopoiesis. High levels of PKB activity induced
neutrophil differentiation and conversely blocked eosinophil development, while down-
regulation of PKB activity was required to induce final maturation of eosinophils.
Although high levels of active PKB predominantly induced neutrophil differentiation even
in the absence of G-CSF, monocytic development was also moderately induced under
these circumstances (data not shown). This suggests that decisions to differentiate towards
eosinophils or neutrophils are made earlier during differentiation compared to the lineage
choice between neutrophils and monocytes. It is tempting to speculate that neutrophil
differentiation is a ‘default’ pathway in myelopoiesis (see below).
Figure 1. PKB regulates both p38 activity and Id1 expression.(A) Stably transfected BAF/3 cells expressing a
tamoxifen-inducible active PKB (myrPKB-ER) were stimulated with 4-OHT for 60 minutes. Protein lysates
were made from unstimulated cells and cells stimulated for 30 and 60 minutes with 4-OHT or with IL-3 for 30
minutes. Western blot analysis was performed with an antibody against phosphorylated p38 or as a control for
equal loading an antibody against b-actin. (B) Cells were co-transfected with an Id1 promoter construct and
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increasing concentrations of FOXO3a(A3). Cells were harvested 24 hours after transfection and luciferase
activity was analyzed. (C) Stably transfected BAF/3 cells expressing a tamoxifen-inducible active FOXO3a
mutant (FOXO3a(A3)-ER) were stimulated with 4-OHT for 24 hours. Protein lysates were made and western
blot analysis was performed with an antibody against phosphorylated  FOXO3a or as a control for equal loading
an antibody against b-actin.(D) CD34+ cells were differentiated towards eosinophils for 17 either in absence or
presence of HIMO (20mM). Protein lysates were made and western blot analysis was performed with an
antibody against Id1 (top panel) or as a control for equal loading b-actin (lower panel).
We further demonstrate that, besides PKB, p38 MAPK activity is necessary for both
eosinophil and neutrophil differentiation (Chapter 6). In contrast to PKB-mediated
granulopoiesis, down-regulation of p38 activity inhibited eosinophil differentiation
whereas neutrophil differentiation was enhanced. We have asked the question whether
these observations could possibly be linked. Our preliminary data has revealed that PKB
can potentially inhibit p38 activation. Stably transfected BAF/3 cells were generated
expressing a tamoxifen-inducible active PKB (myrPKB-ER) 18. Addition of 4-OHT results
in specific activation of PKB, and after 30 minutes of treatment with 4-OHT, a decrease in
the levels of phosphorlyated p38 MAPK was observed, suggesting that PKB can actually
inhibit p38 activity (Figure 1a, A.G.M van Gorp, unpublished results). Supporting this
observation is the demonstration by Somervaille et al. that inhibition of PI3K with the
inhibitor LY294002 also results in enhanced phosphorylation of p38 in human CD34+
derived erythroid progenitors 19. However, the precise molecular mechanisms for these
observations are unclear and are at the moment under investigation. Since the effect of
p38 inhibition on granulocyte differentiation was not as dramatic as the effect of myrPKB
(Chapter 5, Figure 5), the question was raised which of the other known targets of PKB
activity are involved in regulating myelopoiesis? It has been suggested that FOXOs,
members of the large forkhead family of transcription factors, play a role in regulating
hematopoiesis. These transcription factors are phosphorylated upon PKB activation, and
this results in their translocation from the nucleus to the cytoplasm thereby abrogating
transcriptional activity 20. A role for FOXO3a in regulating hematopoiesis was suggested
by studies in FOXO3a (-/-) knockout mice. These mice exhibited hematological
disturbances, however, details concerning problems with development of specific cell
types were not extensively described 21. In addition, ectopic expression of an active
FOXO3a mutant in mouse bone marrow cells resulted in decreased numbers of myeloid
and erythroid colonies 22. Similarly, our data demonstrates that inactivation of PKB, with
concomitant activation of FOXO-3a, results in the inhibition of neutrophil development
(Chapter 5). Preliminary data has revealed that FOXO3a represses Id1 promoter activity
(Figure 1b, K. Birkenkamp, unpublished results). In addition, stimulation of an inducible
FOXO3a cell line 23 resulted in reduced protein levels of Id1. (Figure 1c, K. Birkenkamp,
unpublished results). In Chapter 7, we demonstrate that Id1 expression is upregulated
during the first three days of differentiation, and is subsequently down-regulated during
terminal eosinophil differentiation, and that ectopic expression of Id1 blocks eosinophil
development. Conversely, FOXO3a phosphorylation is upregulated during the first three
days of eosinophil differentiation (Chapter 5) and preliminary data revealed that
phosphorylation is subsequently down-regulated during differentiation (data not shown).
Furthermore, we observed that inhibition of PKB, by the PKB inhibitor, also resulted in
accelerated down-regulation of Id1 expression in eosinophil progenitors (Figure 1d).
These data suggest that activation of PKB resulting in subsequent inactivation of FOXO3a
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and induction of Id1 transcription, which results in inhibition of eosinophil development
(Figure 2, 3). Ectopic expression of both Id1 and myrPKB blocked eosinophil
differentiation, whereas neutrophil development was induced in absence of G-CSF
(Chapter 5, 7). Ectopic expression of Id1 however only moderately induces neutrophil
differentiation in presence of G-CSF (Chapter 7). It is possible that Id1 inhibits the
transcription of eosinophil specific genes, and as a consequence, ectopic expression of Id1
might be sufficient to inhibit eosinophil differentiation, but not to induce neutrophil
development. Since we suggest that neutrophil differentiation is a default pathway in
myelopoiesis, it is tempting to speculate that this is the reason why the percentage of
neutrophil progenitors increases in absence of G-SCF in cells ectopically expressing Id1.
PU.1 and C/EBPs, important players in regulation of hematopoiesis, are regulated by
PKB
Besides its role in regulating Id1 transcription, PKB activity has been demonstrated to
regulate other known mediators of hematopoiesis as well (Figure 2). The transcription
factor PU.1 is phosphorylated by PKB on serine residue 41, located in the transactivation
domain, which does not alter DNA binding but increases activity 24. Ectopic expression of
PU.1 inhibits erythropoiesis, whereas granulocyte and monocyte development are induced
25. Moderate levels of PU.1 favor granulocyte differentiation whereas monocyte
development is induced by high levels of PU.126. Interestingly, p38 has also been
demonstrated to indirectly induce phosphorylation of PU.1 on serine residue 142 upon IL-
3 stimulation in BAF/3 cells 27. Furthermore, p38 has also been suggested to induce
transcription of c-jun 28; 29, a cofactor for PU.1. This suggests that inhibition of p38 by
PKB would reduce high levels of PU.1 activity and thereby blocks monocyte
development. In addition, active GSK-3, inhibited by PKB, can phosphorylate and thereby
inactivate C/EBPa 30. C/EBPa itself plays an important role in regulating expression of
the G-CSF receptor 31; 32, and can inhibit transcription of c-jun by direct association
thereby preventing auto-regulation of its own promoter 33. Whereas C/EBPa and PU.1
appear to be involved in regulation of early myeloid differentiation, both proteins are also
suggested to play an important role in the lineage choice between neutrophils and
monocytes. During terminal differentiation of monocytes, C/EBPa is down-regulated 34
resulting in activation of c-jun and subsequent increase of PU.1 activity. Taken together,
activation of PKB could results in moderate levels of PU.1 activity through inhibition of
both p38 and GSK-3, which is essential to favor neutrophil differentiation over monocyte
development. Furthermore, p38 has been demonstrated to activate C/EBPb 35, which has
been shown to play an important role in eosinophil differentiation in chicken eosinophil
progenitor cells 36. As a consequence, activation of PKB could also result in inhibition of
C/EBPb, through inhibition of p38, thereby leading to inhibition of eosinophil
development (Figure 2).
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Figure 2. Eosinophil and neutrophil differentiation are differentially regulated by PKB. Activation of PKB
regulates the expression and activation of PU.1 and its cofactor c-jun by inhibition of p38 activity and by
regulation of phosphorylation of C/EBPa. (A) Inhibition of PKB activity results in the low expression levels of
Id1 enabling eosinophil differentiation.(B) High PKB activity results in neutrophil development.
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Figure 3. PKB activity plays a critical role in regulating myelopoiesis. The common myeloid progenitor (CMP)
differentiates to all myeloid lineages. A model with neutrophil differentiation as a “default” pathway in
myelopoiesis is proposed. The lineage choice between eosinophils and neutrophils is made at the stage of the
CMP, whereas the lineage decisions between neutrophils and monocytes are made in the CFU-GM progenitor.
Cell fate is determined by differential levels of PKB activity.
We would like to propose a model in which PKB plays a central role in regulating lineage
choices during myelopoiesis (Figure 3). High levels of PKB activity are essential for both
neutrophil and early monocyte development, whereas down-regulation of PKB activity,
resulting in activation of C/EBPb and down-regulation of Id1, in early progenitors is
required for eosinophil differentiation. PU.1 appears to be dispensable for early monocyte
development, but it is required for terminal maturation of monocytes 37. Similarly,
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C/EBPb is also thought to be required for monocyte development 38; 39. This suggests that
the high levels of active PKB in early granulocyte/ macrophage progenitors need to be
down-regulated during terminal differentiation of monocytes to induce high levels PU.1
activity and expression of C/EBPb. Continues high levels of PKB activity results in
enhanced neutrophil differentiation. It is assumed that during neutrophil differentiation,
the common myeloid progenitor (CFU-GEMM) initially differentiates to a common
granulocyte/monocyte precursor (CFU-GM) and that subsequently the lineage choice
between monocytes and neutrophils is made. However, at the moment, it is unclear where
the lineage choice between eosinophils and neutrophils is made. Our data suggests that
cell fate determination between neutrophils and monocytes occurs later during
differentiation compared to the lineage choice between neutrophils and eosinophils. We
therefore suggest that the switch between eosinophils and neutrophils most likely occurs
in the common myeloid progenitors rather than in the less immature CFU-GM where cell
fate decisions between neutrophils and monocytes are made (Figure 3).
Stromal support during granulopoiesis
Since PKB is regulated by both G-CSF and IL-5 induced signaling, additional signals
must be involved in down-regulation of PKB activity during eosinophil differentiation.
Utilizing our ex-vivo model system for granulopoiesis, we were unable to induce complete
terminal maturation of eosinophils, and differentiation generally did not proceed further
than the metamyelocytic stage, unless we inhibited PKB activity.  These results are
similar to that of other groups, who were also unsuccessful in inducing complete terminal
maturation of eosinophils ex-vivo 40-43 Preliminary data has revealed that there are indeed
differences in PKB activation between eosinophils and neutrophils, but in our
differentiation system PKB phosphorylation was never completely down-regulated (data
not shown). This may explain why our eosinophil progenitors never fully differentiated
into mature eosinophils. This suggests that, in vivo, other stimuli are required for final
maturation of eosinophils. One candidate is stromal support in the bone marrow which has
been demonstrated to be involved in hematopoiesis in general 44; 45. To investigate whether
stromal cells indeed could provide the missing signals for terminal maturation of
eosinophils, we have recently analyzed the effect of several stromal cell lines. We
observed an increase in eosinophil differentiation from CD34+ cells cultured in presence
of either a stromal cell line derived from the AGM region of the mouse embryo
(AM20.1B4) (kindly provided by E. Dzierzak, Rotterdam, The Netherlands), or primary
human bone marrow derived stromal cells. Both types of stromal cells supported final
maturation of eosinophils (Figure 4, top panel). Interestingly, proliferation of cells
cultured in conditioned medium (of AM20.1B4 and bone marrow stromal cells) was
increased (Figure 4c) whereas differentiation was not affected (Figure 4bl). It appears that
these stromal cells secrete also cytokines, which are capable of supporting proliferation in
hematopoietic precursors. This suggests that cytokine secretion by stromal cells is
insufficient to induce terminal differentiation of eosinophils, but that cell-cell interactions
are required. The molecular mechanisms by which stromal cells could interfere with
granulopoiesis are at the moment poorly understood. In contrast to the multitude of studies
regarding expression and function of integrins on mature granulocytes, the expression
profiles and function of integrins on both eosinophil and neutrophil progenitors remain to
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be investigated. It would be of interest to inhibit activation of these integrins on
progenitors by utilizing blocking antibodies and subsequently investigate whether
eosinophil differentiation is inhibited under co-culture conditions. Furthermore, it is
important to investigate whether stromal cells in general, or integrins specifically can
inhibit PKB activity during eosinophil differentiation. It is possible that known inhibitors
of PKB activity such as PKC 46 or ROCK 47, a downstream target of RhoA 48 a  member
of the Ras superfamily of small GTP binding proteins which can be activated by integrins
49, play a role in down-regulating PKB activity upon adhesion with stromal cells during
eosinophil differentiation from human cord blood derived CD34+ cells.
Figure 4. Stromal cells support eosinophil differentiation.
CD34+ cells were isolated from umbilical cord blood and cultured in presence of FLT-3 ligand, SCF, GM-CSF,
IL-3, and IL-5 for 17 days. Cytospins were made after 17 days of culture of differentiating eosinophils and
stained with May-Grunwald Giemsa solution. (A) Cells were cultured either on a confluent layer of irradiated
stromal cells derived from the bone marrow, embryonic liver (EL08.1D2) or AGM region (AM20.1B4) or (B) in
presence of conditioned medium from stromal cells derived from the bone marrow, embryonic liver (EL08.1D2)
or AGM region (AM20.1B4). Cytospins were prepared and (C) proliferation was determined by counting the
living cells. Results are presented as fold increase in cell numbers compared to day zero.
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Stochastic versus inductive
Two different models have been proposed to understand hematopoiesis: a “stochastic” and
an “inductive” model. In the stochastic model it is assumed that progenitor cells are
randomly committed towards a certain lineage by the presence of lineage specific
transcription factors, and cytokine stimulation is merely required for progenitor survival
and proliferation. The inductive model predicts that cytokines specifically determine the
outcome of each division and therefore specifically drive cell fate during differentiation.
To date, no evidence has been presented excluding either the inductive or the stochastic
model.
However, it has been demonstrated that genes specific for either erythroid, myeloid or
megakaryocytic lineages are transcribed in the common myeloid progenitors before
commitment to a single lineage. Moreover, genes specific for differentiation towards other
lineages are down-regulated upon commitment to a single lineage 50. This suggests that
early progenitors are not pre-programmed to become a certain cell type, and that external
stimuli determine cell fate. Furthermore, our data, combined with the results of other
studies, suggest that the activity of PKB regulates both the expression as well as the
activation of important mediators of hematopoiesis, including Id1, PU.1, and C/EBPa,
and -b,. We could not observe any differences in the expression levels of PKB in a
population of freshly isolated CD34+ cells (by immuno-histochemistry on cytospins).
This suggests that the relative levels of PKB “activation” controlled by external stimuli,
rather than the expression levels, determine cell fate. In the stochastic model it is assumed
that G-CSF is required to select cells which are already committed to the neutrophil
lineage, thereby enabling neutrophil differentiation rather than development of other
lineages. However, ectopic expression of myrPKB induced neutrophil differentiation in
absence of G-CSF. Preceding transduction of cells with myrPKB, these cells were
cultured with IL-5 and thereby committed to the eosinophil lineage and not to the
neutrophil lineage. This demonstrates that cell fate of cells committed to the eosinophil
lineage can be altered and neutrophil differentiation can be induced, strongly suggesting
that the regulation of lineage choices has to be considered as an inductive process. Thus,
the environmental conditions resulting in exposure to cytokines and adhesion molecules
regulate the activity of intracellular signalling pathways and determine the outcome of
differentiation.
Concluding remarks
Regulation of maturation during granulopoiesis in vivo is mediated by secretion of
specific cytokines and adhesion to stromal cells. The studies described in this thesis have
investigated the roles of several transcription factors and intracellular signalling molecules
in regulation of eosinophil and neutrophil development. We demonstrate that several
transcription factors play a critical role in regulating granulopoieisis in general, including
STAT5 and Id2, whereas other transcription factors, such as Id1, appear to play a role in
determining specific lineage choices. In addition, we presented evidence that PKB plays a
critical role in regulation of cell fate determination. Although these results enhance our
knowledge regarding the mechanisms regulating granulopoiesis, further research is critical
to understand the precise role of stromal cells in cell fate choices and to understand
exactly how PKB activity is regulated and what the specific downstream targets of this
kinase are that can regulate cell fate.
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In ons bloed komen verschillende soorten cellen voor die allemaal een belangrijke,
specifieke functie in het lichaam vervullen. De “rode bloedcellen”, bijvoorbeeld, zorgen er
voor dat zuurstof vanuit de longen naar alle weefsels wordt vervoerd, terwijl bloedplaatjes
een belangrijke rol spelen bij het herstel van bloedvaten na een verwonding. Naast deze
twee soorten cellen bestaat er ook nog een grote groep cellen die “witte bloedcellen”
genoemd worden. Deze witte bloedcellen hebben als belangrijkste taak het beschermen
van het lichaam tegen allerlei ziekteverwekkers zoals bacteriën en virussen. De
levensduur van bloedcellen is relatief kort en daarom moeten er voortdurend nieuwe
bloedcellen gemaakt worden. De ontwikkeling van alle bloedcellen is een gecompliceerd
proces dat voornamelijk plaats vindt in het beenmerg en “hematopoiese” genoemd wordt.
In het beenmerg bevinden zich specifieke voorlopercellen of “hematopoietische
stamcellen” die de mogelijkheid hebben om zich voortdurend te vernieuwen en zich tot
alle soorten bloedcellen kunnen ontwikkelen. De vernieuwing van deze cellen is
noodzakelijk om er voor te zorgen dat de ontwikkeling van bloedcellen plaats kan vinden
gedurende het hele leven. Wanneer er fouten gemaakt worden in de regulatie van dit
proces kan het voorkomen dat sommige bloedcellen zich niet volledig kunnen
ontwikkelen wat als gevolg kan hebben dat het lichaam niet goed meer beschermd kan
worden tegen ziekteverwekkers. De ontwikkeling van bloedcellen is bijvoorbeeld
verstoord bij patiënten die lijden aan de ernstige ziekte “leukemie”. Om betere therapieën
te kunnen ontwikkelen voor patiënten die lijden aan dit soort ziektes is het van groot
belang om te begrijpen hoe de normale ontwikkeling van bloedcellen gereguleerd is.
In dit proefschrift is onderzocht hoe de ontwikkeling van twee soorten witte bloed cellen:
de “eosinofiele granulocyt” en de “neutrofiele granulocyt” gereguleerd is. Gedurende
infecties worden er door het lichaam signalen verstuurd die er voor zorgen dat deze cellen
geactiveerd worden om zich vanuit de bloedvaten naar de plaats van infectie begeven.
Daar aangekomen worden er door deze granulocyten onder andere schadelijke eiwitten
uitgescheiden die zich in korrels (granula) in de cel bevinden. Terwijl de eosinofiele
granulocyt specifieke eiwitten maakt die parasieten kunnen doden, produceren neutrofiele
granulocyten voornamelijk eiwitten die bacteriën doden. Om te kunnen begrijpen hoe
deze granulocyten zich ontwikkelen hebben we een systeem opgezet waarmee we buiten
het lichaam die ontwikkeling kunnen volgen. Hematopoietische stamcellen bevinden zich
niet alleen in het beenmerg, maar kunnen ook worden geïsoleerd uit navelstrengbloed.
Deze hematopoietische stamcellen kunnen zich vervolgens, met behulp van een specifieke
mix van groeifactoren, ook wel cytokines genoemd, ontwikkelen naar eosinofiele
granulocyten of neutrofiele granulocyten. Terwijl de cytokine genaamd IL-5 er voor zorgt
dat een cel een eosinofiele granulocyt wordt, zorgt G-CSF, een andere cytokine, ervoor
dat een neutrofiele granulocyt gemaakt wordt. Omdat beide soorten granulocyten uit
dezelfde voorlopercellen ontstaan, is het belangrijk om te onderzoeken wanneer er tijdens
de ontwikkeling besloten wordt tot welk soort bloedcel de voorlopercel zich gaat
ontwikkelen en hoe deze beslissing genomen wordt. Daarnaast is het van belang om te
begrijpen welke eiwitten er in de voorloper cel essentieel zijn om ervoor te zorgen dat
deze zich ook daadwerkelijk kan ontwikkelen tot een volwassen granulocyt. Om te
onderzoeken welke eiwitten er een belangrijke rol spelen bij de ontwikkeling van
granulocyten hebben we “vreemde” eiwitten geïntroduceerd in hematopoietische
stamcellen met behulp van “retrovirussen”. Retrovirussen kunnen heel efficiënt
hematopoietische stamcellen binnendringen (infecteren) en zij zorgen er vervolgens voor
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dat de specifieke eiwitten waarin wij geïnteresseerd zijn tot expressie komen in de cellen.
In een cel kan de specifieke code van DNA afgelezen worden om eiwitten te maken.
Hiervoor moet in de eerste plaats een afschrift van het DNA gemaakt worden tijdens een
proces dat transcriptie heet. Dit proces wordt gereguleerd door verschillende eiwitten
genaamd “transcriptiefactoren”. Dit afschrift, ook wel RNA genoemd, wordt dan
vervolgens weer gebruikt om eiwitten te maken. De verandering in de expressie van
eiwitten wordt gereguleerd door signalen van bijvoorbeeld groeifactoren. Deze
groeifactoren bevinden zich buiten de cel en kunnen hun opdrachten doorgeven door
contact te maken met specifieke eiwitten die vastzitten in de celmembraan en gedeeltelijk
buiten de cel steken. Deze eiwitten worden “receptoren” genoemd. Door binding van een
groeifactor aan zijn receptor wordt in de cel een hele reeks van eiwitten geactiveerd die er
uiteindelijk voor zorgen dat specifieke transcriptiefactoren hun werk kunnen doen en er
voor kunnen zorgen dat er meer of minder RNA wordt gemaakt. Dit heeft uiteindelijk als
resultaat dat de hoeveelheid eiwit verandert. Dit wordt ook wel een “signaaltransductie
route” genoemd. Deze verandering in de expressie van eiwitten bepaalt of een cel gaat
delen of zich gaat ontwikkelen of zelfs dood gaat. In hoofdstuk 4 hebben we van
retrovirussen gebruik gemaakt om te onderzoeken wat de rol is van de transcriptiefactor
STAT5 tijdens de ontwikkeling van de granulocyt. Deze transcriptiefactor wordt normaal
gesproken ook tijdens de ontwikkeling van granulocyten gemaakt en geactiveerd. Uit onze
experimenten is gebleken dat STAT5 nodig is voor de ontwikkeling van zowel de
eosinofiele granulocyt als de neutrofiele granulocyt. Een verhoogde expressie van STAT5
versnelt zowel de celdeling als de ontwikkeling van voorlopercellen. Wanneer we STAT5
remmen door de cellen te infecteren met een virus dat een gemuteerde vorm van STAT5
in de cellen brengt, wordt de ontwikkeling van beide soorten granulocyten in een heel
vroeg stadium geremd. In hoofdstuk 5 hebben we een signaaltransductie route onderzocht
waarvan bekend is dat deze een belangrijke rol speelt in de regulatie van celdeling en
overleving van cellen. Door gebruik te maken van een farmacologische remmer kan
specifiek één eiwit van deze route uitgeschakeld worden en kan onderzocht worden of dit
eiwit, genaamd Protein Kinase B (PKB), een rol speelt in de ontwikkeling van
granulocyten. PKB blijkt inderdaad een belangrijke functie te hebben in de ontwikkeling
van granulocyten. Remming van de activiteit van PKB blijkt namelijk nodig te zijn voor
de ontwikkeling van voorloper cellen tot volwassen eosinofiele granulocyten, terwijl de
ontwikkeling van de neutrofiele granulocyt geremd wordt. Verhoogde expressie van actief
PKB, met behulp van retrovirussen, heeft het tegenovergestelde resultaat: de ontwikkeling
van de neutrofiele granulocyt wordt sterk verbeterd terwijl de ontwikkeling van de
eosinofiele granulocyt geblokkeerd wordt. Dit duidt er op dat de mate van PKB activering
een belangrijke rol speelt in de beslissing van een voorlopercel of deze een eosinofiel of
een neutrofiel wordt. Naast PKB lijkt een ander eiwit ook een rol te spelen in deze keuze.
In hoofdstuk 6 laten we zien dat remming van het eiwit p38 MAPK ervoor zorgt dat de
ontwikkeling van de eosinofiele granulocyt geremd wordt, terwijl die van de neutrofiele
granulocyt wordt verbeterd. In hoofdstuk 8 laten we zien dat activering van PKB ervoor
zorgt dat p38 MAPK uitgezet wordt. Dit betekent dus dat PKB waarschijnlijk een deel
van zijn functie vervult door remming van de activiteit van p38 MAPK.
Omdat het effect van remming van p38 MAPK niet zo dramatisch is als de activering van
PKB betekent dit hoogstwaarschijnlijk dat PKB zijn rol in de ontwikkeling van
granulocyten ook op een andere manier vervult.
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Een mogelijke kandidaat hiervoor is een andere transcriptiefactor genaamd Id1. Van deze
transcriptiefactor was al bekend dat deze een negatieve rol speelt in de ontwikkeling van
andere soorten cellen. Tijdens de ontwikkeling van cellen wordt de aanmaak van Id1
geblokkeerd. Dit betekent dat de aanmaak van Id1 moet worden stil gelegd wanneer cellen
zich gaan ontwikkelen. In hoofdstuk 7 hebben we laten zien dat het verlengen van Id1
expressie in voorlopercellen, met behulp van retrovirussen, ervoor zorgt dat de
ontwikkeling van de eosinofiele granulocyt geremd wordt terwijl die van de neutrofiele
granulocyt wordt verbeterd. Bekend is dat activering van PKB ervoor zorgt dat één van
zijn substraten (FOXO3a) geremd wordt. In hoofdstuk 8 laten we zien dat FOXO3a op
zijn beurt de expressie van Id1 kan remmen. Dit betekent dus dat remming van PKB
activering resulteert in activering van FOXO3a wat uiteindelijk leidt tot de remming van
Id1. Deze remming is noodzakelijk om de ontwikkeling van de eosinofiele granulocyt
mogelijk te maken. Wanneer PKB aangezet wordt, gebeurt het omgekeerde en wordt Id1
niet meer geremd en kunnen neutrofiele granulocyten zich ontwikkelen. De rol van Id1 in
de ontwikkeling van granulocyten lijkt redelijk specifiek. Vervroegde expressie van Id2,
een transcriptie factor die sterk lijkt op Id1, blijkt namelijk in tegenstelling tot Id1 de
ontwikkeling van beide soorten granulocyten te verbeteren (hoofdstuk 7). De resultaten
beschreven in dit proefschrift hebben er toe bijgedragen dat onze kennis met betrekking
tot de regulatie van de ontwikkeling van granulocyten sterk is toegenomen. Er zal echter
nog veel onderzoek gedaan moeten worden, hetgeen noodzakelijk is, om de ontwikkeling
van bloedcellen volledig te begrijpen om in de toekomst nieuwe therapieën te kunnen
ontwikkelen tegen ziektes als bijvoorbeeld leukemie. Uit ons onderzoek blijkt dat
verschillende signaaltransductie routes en transcriptiefactoren een rol spelen in de
regulatie van granulocyt differentiatie. Een belangrijke rol lijkt weggelegd voor PKB.
Aangezien zowel de groeifactoren IL-5 als G-CSF PKB kunnen activeren, moeten we in
de nabije toekomst gaan onderzoeken hoe in het beenmerg PKB activering geremd wordt
om de ontwikkeling van de eosinofiele granulocyt mogelijk te maken en welke signalen
daarbij betrokken zijn. Verder is het van belang om te onderzoeken of er naast de regulatie
Id1 en p38 nog meer eiwitten door PKB gereguleerd worden die nodig zijn voor de
ontwikkeling van granulocyten.
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problemen, schrijven van een stamcel-tel-programma, en de hulp bij het maken van de
foto’s. Deon, ook jij bedankt voor alle hulp met de FACS. Lei, bedankt voor het helpen
herkennen van “vreemde” cellen in mijn kweken. Lisa, jouw Italiaanse temperament
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houdt het lab levendig. Dank je wel voor alle discussies. Corneli, HELP de FACS doet
raar!! Zelfs tijdens je vakanties was je niet veilig. Dank je wel dat je toch elke keer weer
bereid bent om te helpen. Bart, bedankt voor alle gesprekken als ik weer eens beneden aan
het sorten was en ik wens je heel veel succes de komende tijd in de kliniek. Alex en Henk,
jullie ook bedankt voor de gezelligheid en interesse laatste maanden. Caroline, misschien
moeten we toch ergens samen een vakantiebaantje als FACS-operator gaan zoeken.
Volgens mij waren we best een goed team (zeker als we telefonische hulplijnen mogen
gebruiken). Trouwens de klaterende alpenbeekjes en sneeuw hielpen erg goed. Willem, als
een soort van pleeg-AIO zou je tijdelijk bij ons wat proeven komen doen. Al pesten we je
er nog wel eens mee, maar ik denk dat je toch wel echt bij ons bent gaan horen. Rolf, de
eerste 1,5 jaar heb ik onder jouw begeleiding gewerkt. In die korte periode heb ik toch
heel veel van je geleerd op het gebied van moleculaire biologie. Uiteraard wil ik ook alle
ex-collega’s, die ik nog niet genoemd heb, bedanken voor de gezelligheid en discussies:
Sandra, Madelon, Annelien, Mike, Niels, Pascale, Jacqueline, Dianne, Andy, Paula en
Ramon,. Ook wil ik bij deze graag Pauline en Marieke bedanken voor de hulp met mijn
manuscript en het lezen van mijn Nederlandse samenvatting. Ik heb de afgelopen jaren erg
veel tijd doorgebracht op het (oude) C1-lab. Ik wil daarom graag mijn C1 collega’s
bedanken voor de vele gezellige gesprekken, werkdiscussies en cellen. Ik wil ook graag
alle medewerkers van de afdeling verloskunde van het St. Elisabeth ziekenhuis in Tilburg
en van het Wilhelmina Kinder Ziekenhuis in Utrecht bedanken voor hun inzet. Zonder
jullie hulp had ik dit onderzoek niet kunnen doen. Ook wil ik alle mede-navelstrengbloed-
en beenmerggebruikers bedanken voor de vele keren dat ze aan ons gedacht hebben de
afgelopen maanden als ze wat over hadden. Dat heeft mij enorm geholpen.
Uiteraard wil ik ook alle mensen in mijn omgeving bedanken die me de afgelopen jaren
gesteund hebben en bij wie ik altijd terecht kon tijdens moeilijke periodes.
En dan natuurlijk Ronald, mijn andere paranimf. Sinds we beide uit huis zijn is onze
relatie eigenlijk alleen maar beter geworden. Juist daarom ben ik enorm blij dat je straks
als paranimf naast mij zult staan. Ik vond het ook erg dapper dat jij en Lianne een poging
gedaan hebben, om gewapend met een woordenboek, mijn eerste artikel te lezen, al
kwamen jullie dan niet verder dan de eerste drie regels.
Pap en mam, jullie hebben me altijd gesteund en gemotiveerd. Toen ik een jaar of tien
was, kreeg ik zelfs al mijn eerste microscoop van jullie. Al hebben jullie vast ook niet
voorzien dat ik later hele dagen cellen zou gaan bekijken. Dank jullie wel voor alles.
                                                                                                                Curriculum Vitae
173
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